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Abstract 
Despite current progress in early detection and anticancer treatments, 
chemotherapy resistance and cancer relapse remain as major obstacles for an 
effective cancer therapy. Increasing evidence suggests that tumour heterogeneity is 
driven by a population of cancer stem cells that possess enhanced capacity for self-
renewal, tumourigenesis, and survival. While current radio- and/or chemotherapies 
are effective in killing proliferating and differentiated cancer cells, they remain 
inefficient in eliminating cancer stem cells, thereby leading to tumour regrowth and 
relapse in cancer patients. A novel targeting strategy capable of killing cancer stem 
cells could effectively eliminate tumours from their roots, thus limiting their 
capacity for regrowth. Among chemoresistance pathways innately present in cancer 
stem cells, the overexpression of a key member of the inhibitor of apoptosis 
proteins, survivin, constitutes one of the most utilized targets for targeted cancer 
therapies. Indeed, a survivin inhibitor YM-155 is currently being tested in clinical 
trials. In this study, we demonstrated the use of a novel anti-survivin siRNA 
delivery method to colon cancer stem cells, and investigated the role of autophagy 
in chemoresistance. 
For the delivery of survivin siRNA to cancer stem cells, the siRNA was conjugated 
to the cancer stem cell-targeting EpCAM RNA aptamer. The aptamer-siRNA 
chimera showed specific binding to EpCAM-expressing cancer cells and displayed 
efficient survivin silencing in HT-29 cells in vitro by approximately 66.3%. The 
combinatorial treatment of survivin knockdown with 5-fluorouracil or oxaliplatin 
led to enhanced efficacy in supressing self-renewal of cancer stem cells by 2.71- 
and 2.91- folds, respectively. Additionally, the combined survivin knockdown and 
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5-fluorouracil treatment significantly reduced the tumourigenic potential of HT-29 
cells in immunodeficient mice (Chapter 3). 
To facilitate the in vivo delivery of the chimera to tumours, a terminal 20-kDa PEG 
was conjugated at an optimized position within the aptamer-siRNA chimera that 
led to an improved tumour delivery and retention. After confirming specific 
survivin targeting in vivo, a treatment strategy with PEGylated chimera and 5-
fluorouracil was developed for in vivo treatment using a mouse xenograft colorectal 
cancer model. The EpCAM aptamer-survivin chimera-mediated in vivo knockdown 
of survivin resulted in enhanced sensitivity of cancer stem cells to 5-fluorouracil as 
evident by significant 4-fold reduction in self-renewal of treated colorectal cancer 
stem cells s and ~3-fold increase in apoptosis. In addition, in vivo treatment of mice 
with the EpCAM aptamer-survivin chimera and 5-fluorouracil led to slower tumour 
growth rate and an improved overall survival during early stages of the treatment 
(Chapter 4). Furthermore, the chimera did not elicit in vitro or in vivo innate 
immune response, indicating that the observed survivin knockdown and tumour 
growth suppression was not immune-mediated, and that the chimera can be 
considered safe for future clinical applications (Chapter 4). 
In the final part of this thesis, autophagy as a mechanism underlying drug resistance 
in colon cancer stem cells was studied. Autophagy is a conserved cellular process 
with the ability to recycle damaged proteins and organelles. It is induced under a 
wide variety of stresses, including DNA-damaging drugs, and is associated with 
drug resistance and survival. The drug 5-fluorouracil was found to enhance 
autophagic flux in HT-29 cells by approximately 3-folds, suggesting that the 
inability of 5-fluorouracil in killing cancer stem cells was autophagy-related. 
Additionally, autophagy was found to be an essential survival component for cancer 
 
 
x 
 
stem cells as evident by the 2-fold reduction of self-renewal in HT-29 cells when 
treated with the autophagy inhibitor 3-MA and 5-fluorouracil simultaneously. To 
verify the results obtained from 3-MA treatment, an alternative approach of 
inhibiting autophagy was used by knocking down ATG5, an essential protein for 
autophagosome formation. Following ATG5 knockdown, the self-renewal of HT-
29 cells was significantly reduced by ~12-fold. Moreover, the combination of 5-
fluorouracil with ATG5 knockdown further reduced HT-29 self-renewal by ~39-
fold, further suggesting the critical role of autophagy for cancer stem cell survival 
and drug resistance. 
Finally, the role of survivin with autophagy-related drug-resistance was explored. 
It was found that the knockdown of survivin led to the enhanced autophagic flux. 
While survivin knockdown by itself had no adverse effects on colon cancer stem 
cells, it was suggested that enhanced autophagy activity induced by survivin 
knockdown may have played a role in protecting colon cancer stem cells. 
Surprisingly, survivin knockdown 24 hours prior to 5-fluorouracil treatment 
inhibited autophagy-induction, thereby enabling 5-fluorouracil to eliminate cancer 
stem cells through the inhibition of autophagy-mediated survival (Chapter 5). 
The results from this thesis highlights three main points for targeting cancer stem 
cells: Firstly, cancer stem cell-targeting aptamers are powerful tools for the delivery 
of therapeutic siRNA, circumventing the many challenges that faces in vivo siRNA 
delivery. Additionally, the combination of survivin knockdown and drug treatment 
proved effective in killing cancer stem cells in human colorectal cancer cells. 
Secondly, targeting survivin alone is not sufficient to kill cancer stem cells. On the 
contrary, survivin knockdown induced autophagic flux that potentially enhanced 
survival. Therefore, chemotherapy drugs need to be added in order to effectively 
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kill cancer stem cells. And thirdly, when studying novel anticancer treatment, it is 
critical to examine their effects on autophagy, and determine if the induced 
autophagic flux promotes survival. Further experimentations based on the results 
from this study might lead to accelerated progress in understanding the role of 
autophagy in cancer stem cells, and thereby develop new strategies that either target 
autophagy specifically, or develop a novel strategy that does not induce autophagy-
mediated survival for cancer cells. Moreover, as traditional anticancer therapies and 
the inhibition of survivin both induce autophagy, it is critical to monitor autophagy 
when testing new anticancer therapies.  
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Chapter 1 
Introduction and literature review 
This chapter was adapted from the following published articles: 
1. Al.Shamaileh H, Xiang D, Wang T, Yin W, Duan W, Shigdar S. Stem-Cell-
Specific Aptamers for Targeted Cancer Therapy, Aptamers: Tools for 
Nanotherapy and Molecular Imaging. Singapore: Pan Stanford publishing. 
2016;113-138 
2. Wang T, Shigdar S, Al.Shamaileh H, Gantier MP, Yin W, Xiang D, Wang 
L, Zhou SF, Hou Y, Wang P, Zhang W, Pu C, Duan W. 2016. Challenges 
and opportunities for siRNA-based cancer treatment, Cancer Lett. [ahead of 
print] 
3. Wang T, Shigdar S, Gantier M, Hou Y, Wang L, Li Y, Al.Shamaileh H, Yin 
W, Zhou S, Zhao X, Duan W. Cancer stem cell targeted therapy: progress 
amid controversies, Oncotarget. 2015;6(42):44191-206. 
4. Xiang D, Shigdar S, Qiao G, Zhou SF, Li Y, Wei MQ, Qiao L, 
Al.Shamaileh H, Zhu Y, Zheng C, Pu C, Duan W. Aptamer-mediated 
cancer gene therapy, Curr. Gene Ther. 2015;15(2):109-19. 
 
1.1. Cancer stem cell model 
1.1.1. Introduction 
During the first half of the twentieth century, the longstanding clonal evolution 
model of cancer, which postulates that all cancer cells in a given tumour have equal 
capacity for tumourigenesis, was contradicted by the newly emergent cancer stem 
cell model [1]. Contrary to the clonal evolution model, the cancer stem cell model 
suggests that only a specific subset of cells have the capacity to drive to initiate 
tumours to maintain growth (Figure 1-1) [1]. In 1937, Furth and Khan demonstrated 
that single cells extracted from a mouse tumour were capable of forming new 
tumours when they were transplanted into a different mouse, resembling the stem 
cell function of creating new cell progeny [2]. Such cells were found in both 
leukemias and solid tumours, and although their frequencies were found to be 
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variably low, they were sufficiently capable of forming new tumours with similar 
morphological heterogeneity as their parent tumours [3-5]. Additionally, the 
emergence of new technologies, such as cell radiolabeling and autoradiography 
enabled the tracking of cells throughout their differentiation, leading to additional 
support for the cancer stem cell model [6]. The accumulating evidence of cancer 
stem cells has decisively led to a formal and an early definition: a malignant stem 
cell population with a proliferative capacity and a limited differentiation capacity, 
and a population of differentiated cells that are the progeny of the malignant stem 
cell population [7]. However, support for the cancer stem cell model began to 
decline in the 1970s with the discovery of mutations in oncogenes and tumour-
suppressor genes, leading to the prevalence of the clonal evolution model of cancer 
[8]. Nevertheless, advances in stem cell research and the development of new 
research strategies, such as fluorescence-activated cell sorting (FACS) and lineage 
tracing, have revived and strongly supported the cancer stem cell model in 
leukemias and solid tumours. 
 
Figure 1-1. Evolution of cancer models. (a) The clonal evolution model driven 
by accumulating mutations and selection fitness, in which all cells are derived from 
a single cell and are divided into subpopulations. (b) The cancer stem cell model in 
which tumour cells follow a hierarchical organization and the cancer stem cells 
driving tumourigenesis. (Adapted from [9]) 
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Studies on leukemic stem cells have not only supported the cancer stem cell model, 
but have also been an accepted model for the cancer stem cell hypothesis [1]. It was 
found that CD34+CD38- cells in acute myeloid leukemia (AML) were capable of 
initiating leukemia in mice, and the frequency of these cells were found to be in the 
order of one per million tumour cells [10-12]. Furthermore, the work on human 
leukemic stem cells has addressed some concerns over the methodologies used for 
identifying cancer stem cells. Firstly, the stem cell hierarchy of hematopoiesis aided 
in the characterization of leukemic cancer stem cells [13, 14]. Secondly, the 
microenvironment plays a significant role in both normal stem cells and cancer 
stem cells, whereas studies on leukemic stem cells offered flexibility in 
environment adaptation due to their necessity to travel throughout the body [15]. 
And finally, the use of leukemic cells does not require proteolytic enzymes for 
dissociation, thereby minimizing experimental intervention. In solid tumours, 
cancer stem cells are best identified by the gold standard assay of 
xenotransplantation, which measures the tumourigenic potential of cells when 
injected into a mouse model. However, this may not accurately portray their fate in 
their original environment as the tumour cells are introduced into a foreign 
environment. Fortunately, compelling results from three independent laboratories 
have demonstrated strong evidence that further supports the cancer stem cell model 
[16, 17]. Through the use of lineage tracing techniques and clonal analysis, the 
existence of cancer stem cells in solid tumours was demonstrated by following the 
fates of individually marked mouse tumour cells throughout their tumourigenesis 
in their native environment, using tumour models including glioma, skin, and 
intestinal tumours [12, 18-20]. Parada and colleagues used the nestin-ΔTK-IRES-
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GFP transgene, which was previously used to trace quiescent neural stem cells, and 
identified a subpopulation of cells within the mouse glioma tumours that were a 
source of entirely new progenies [19]. Furthermore, Clevers and colleagues 
demonstrated that intestinal adenoma could be initiated and maintained by single 
intestinal stem cells via introduction of a gene which allowed for the identification 
of cells and their progenies upon activation by tamoxifen [18]. Finally, Blanpain 
and colleagues showed that the generation of cellular hierarchy was dependent on 
the stage of tumour growth and the progression from benign tumour to cancer, 
which was also accompanied by an expansion of the cancer stem cells [20]. These 
studies also demonstrated that a subpopulation of tumour cells with self-renewal 
properties are responsible for the tumourigenesis in these models, which strongly 
supported the cancer stem cell hypothesis. In addition, they also show that the 
stemness in cancer stem cells is a fluid state dependent on the stage of tumour 
development, environment, and genetic phenotype. 
In regards to the role of cancer stem cells in the development of human solid 
tumours, an auto-transplantation study dating back some 50 years ago used cancer 
cell suspensions from several solid tumours and injected them into either thigh of 
the same patient [21]. This revealed that tumour growth only occurred after 
inoculation of at least 106 cells, and demonstrated the existence of functional 
heterogeneity and proliferative ability of cells within a tumour mass. A modern 
approach using molecular markings, such as green fluorescence protein-lentiviral 
vectors, was used to visualize the contribution of individual cells from patient-
derived colon cancer sample in tumour formation in mice [22]. As a result, the 
study identified a functionally heterogeneous population of tumour cells, and only 
a particular subgroup in primary human colon cancer possessed self-renewal, 
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tumour initiation and metastasis formation [22, 23]. Although the specific origins 
of tumour growth is yet to be determined, these studies do highlight the roles of 
cancer stem cells in tumourigenesis, drug-resistance, and relapse in patients. 
Therefore, it is evident that targeting the cancer stem cell population may have a 
significant impact on the overall treatment efficacy and prognosis of cancer 
patients. 
In the view of the clonal evolution model, tumour heterogeneity is defined as a 
combination of cell populations originating as a result of various genetic and 
epigenetic backgrounds, which can directly influence their competitiveness for 
growth and expansion, and has been used to explain the variable responses to 
treatment and prognosis in patients [24, 25]. From this definition, cancer cells with 
a selective advantage of chemoresistance can survive anticancer treatments and 
later cause relapse. On the other hand, the cancer stem cell model offers a more 
‘static’ model in which only the cancer stem cells possess the ability to initiate and 
drive tumour growth, but this definition restricts the tumour heterogeneity model 
to identical cancer stem cells creating identical progenies within the tumour. In 
2011, three studies brought both cancer stem cells and clonal evolution models 
closer together with the observation that non-cancer stem cells were capable of 
dedifferentiating back to cancer stem cells (Figure 1-2) [26-28]. Weinberg and 
colleagues demonstrated that non-cancer stem cells acquire self-renewal potential 
through oncogenic transformation [26]. Additionally, non-cancer stem cells in 
basal breast cancers were shown to transform into a cancer stem cell-like state and 
was dependant on ZEB1, a regulator associated with the epithelial-mesenchymal 
transition [27]. Similarly, Dick and colleagues used xenotransplantation and DNA 
copy number alteration profiling to investigate the role of clonal evolution and 
 
 
6 
 
cancer stem cells hierarchy in BCR-ABL1 lymphoblastic leukemia-initiating cells 
and demonstrated that leukemic stem cells were subjected to clonal evolution [29]. 
Therefore, a new consensus has emerged in which tumour heterogeneity of 
leukemia can be attributed to the differences and genetic diversity inherent in 
leukemia stem cell. These recent discoveries highlight the importance of 
developing anticancer therapies that not only target cancer stem cells, but also their 
progeny and the bulk cancer cells altogether to prevent their dedifferentiation back 
to cancer stem cells. 
 
Figure 1-2. Plasticity of the cancer stem cell model. Progenitor cells and 
differentiated cells are capable of re-acquiring self-renewal potential. (Adapted 
from [9]) 
 
1.1.2. Cancer stem cells markers and association with stemness and survival  
In addition to identifying cancer stem cells by their functional properties, as well 
as tracking their tumourigenesis as mentioned earlier [17-19], cell surface proteins 
have also been used for the enrichment and prospective isolation of cancer stem 
cells. For instance, cells with CD44+CD24-/low in breast, prostate, and ovarian 
cancers showed high self-renewal represented by high sphere formation and 
tumour-initiation capacities at low cell densities [31-34]. Similarly, 
EpCAM+CD44+CD166+ cells displayed enhanced stem cell characteristics and 
high tumour-initiating capacities in xenograft models which recapitulated the 
parent tumour [35-37]. CD133 is another cell surface marker that has been 
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associated with a wide range of cancer types that includes breast, colon, glioma, 
liver, lung, melanoma, ovarian, pancreatic, and prostate [38]. To date, several 
markers have been identified in various cancer types that are associated with stem 
cell properties and have been tested for targeted treatments (Table 1-1) [38-40]. 
However, the majority of these markers have been primarily identified from cell 
line-based studies. Therefore, in a clinical setting, confirmation of such surface 
markers is necessary. 
Table 1-1. Cancer stem cell markers in solid tumours. 
Cancer type Marker expression Reference 
Breast CD44+/CD24-/low, CD133+, EpCAM+, 
CD133+/CXCR4+ 
[31, 41-43] 
Colon CD44+/CD166+/EpCAM+, CD44+/CD24+, 
CD133+/CD24+ 
[37, 44, 45] 
Brain CD133+ [46, 47] 
Liver CD133+/CD90+/CD44+/OV6+/EpCAM+ [48] 
Lung CD133+/ ALDH-1+ [49] 
Ovarian CD133+/ALDH-1+ [50] 
Pancreatic CD44+/CD24+/EpCAM+, CD133+, CXCR4+/CD133+ [51-54] 
Prostate CD133+, CD44+/integrin α2β1+/CD133+, CD44+, 
CD133+/Trop-2+ 
[55-58] 
 
The overexpression of these markers has been linked to signalling pathways 
associated with stemness, cell proliferation, chemoresistance, and survival. For 
example, CD44 plays an important role in cell-cell and cell-extracellular matrix 
communications and is also linked to pathways essential for self-renewal and stem 
cell maintenance, including the stem cell genes BMI-1 and Oct-3/4 [33]. EpCAM, 
a transmembrane protein, has also been found to be crucial for cell-cell adhesion 
while its intracellular domain contributes to transcription factor complexes that 
promote the expression of the stem cell-associated genes Klf4, Oct4, Nanog and 
Myc [59]. CD133, on the other hand, has been under debate as a cancer stem cell 
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marker as both CD133+ and CD133- cells equally showed capacities for 
tumourigenicity. Furthermore, its functional role in stemness is not as clearly 
defined as that of CD44 and EpCAM [60]. However, it was later revealed that the 
AC133 epitope of the CD133 marker served as a more reliable marker due to its 
loss during differentiation [61, 62], and was also found to be more highly expressed 
in leukemic stem cells by 1,000-fold compared to normal healthy cells [63, 64]. 
Additionally, it was also linked to an increased expression of survival proteins 
involved in the Akt/PKB and Bcl-2 pathways, which contributed to 
chemoresistance to drugs such as doxorubicin and 5-fluorouracil [65]. The 
overexpression of certain cell markers in cancer stem cells and their association 
with stemness, proliferation, and survival, suggests a viable strategy of targeting 
cancer stem cells via their surface marker proteins. 
1.1.3. Chemoresistance of cancer stem cells 
In the traditional view of cancer, a portion of the tumour cell population acquires 
genetic variation that confer drug resistance [66]. These cells possess a selective 
advantage of chemoresistance for survival and proliferation, thus causing relapse 
and the prevalence of chemoresistant clones. However, the cancer stem cells are 
often inherently chemoresistant, thus surviving anticancer therapy and mediating 
tumour regrowth [67]. Current traditional anticancer treatments are successful in 
killing the bulk cancer cells, but they are often not able to eliminate the cancer stem 
cell population. The cancer stem cells that survive traditional treatments would give 
rise to new tumours, which may become more malignant, fast spreading, and 
resistant to treatments [68]. Therefore, targeting cancer stem cells and effectively 
eliminating them would lead to an effective clinical outcome. In colon cancer, the 
cancer stem cells were shown to be resistant to 5-fluorouracil, oxaliplatin and 
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irinotecan-based treatments [69]. Consequently, these chemotherapeutic drugs 
caused an enrichment of cancer stem cells with high tumourigenic potential in 
xenograft models [69-71]. In breast cancer, residual tumour cells that survive 
anticancer treatment were enriched for cells of high tumourigenic potential. It is 
suggested that the breast cancer stem cells were resistant to docetaxel or 
doxorubicin with cyclophosphamide treatments, which led to the enrichment of the 
CD44+CD24-/low cell population [72, 73]. Cancer stem cells in glioblastoma 
multiforme were also resistant to radiotherapy and enriched for the CD133+ cell 
population [74]. Such resistance to anticancer treatments has been attributed to 
many factors, including their predominant quiescence, enhanced DNA repair 
capacity, elevated ABC-transporter expression, and overexpression of 
antiapoptotic proteins [66, 75-80]. Indeed, both CD44 and EpCAM markers were 
reported to be associated with signalling pathways, such as PI3K/E2F1 and wnt/β-
catenin that lead to the expression of the antiapoptotic protein BIRC5 (survivin) 
[59, 81]. In addition, an increasing body of evidence supports the role of autophagy 
as a survival mechanism of cancer stem cells in response to stress induced by 
anticancer treatments [82-84]. 
It should be noted that the elimination of non-cancer stem cells by traditional 
chemotherapy may tip the balance between non-cancer stem cells and cancer stem 
cells, allowing for further tumour expansion with potentially more aggressive 
malignancy and higher self-renewal capacity [62, 63, 85-88]. Indeed, treatment of 
colon cancer cells resulted in autocrine production of IL-4 that provided protection 
for CD133+ cancer stem cells from apoptosis [71]. Similar phenomenon has been 
observed with the exposure of human medullary thyroid carcinoma to 5-
fluorouracil which increased the subset of CD133+ tumour-initiating cells [89].  
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1.1.3.1. Mechanisms of chemoresistance  
Chemoresistance of cancer stem cells has been associated with different pathways, 
including the active extrusion of drugs via the ABC-transporters, up-regulation of 
anti-apoptotic proteins, increased DNA repair capacities, alterations in cell cycle 
kinetics, microenvironmental influences, and autophagy [75, 82-84, 90, 91]. 
1.1.3.1.1 ABC transporters 
ABC transporters are transmembrane proteins that utilize ATP to actively extrude 
substrates, such as dyes or drugs, out of the cells [88], thus decreasing the 
intracellular accumulation of drugs and representing one of the most common 
mechanisms associated with multi-drug resistance in cancer stem cells [92]. The 
ATP transporters have been used for the identification of cancer stem cells by their 
abilities to extrude the Hoechst dye, which is now known as side population assays 
(SP) [93, 94]. However, this technique has become less favorable as the drug efflux 
characteristic is also commonly associated with non-cancer stem cells [95], but it 
is still considered as viable supplementary data in cancer stem cell studies. Among 
the 48 known ABC transporter proteins, ABCB1 (P-gp, MDR1), ABCG2 
(BCRP1), ABCC11 (MRP8) and ABCB5 are strongly associated with cancer stem 
cells [90, 96]. Additionally, expression levels of ABC transporter proteins correlate 
with increased drug resistance and poor prognosis in cancer patients [97, 98]. As a 
result, ABC transporter proteins have become one of the targets of anticancer 
treatment to overcome chemoresistance in cancer patients. 
1.1.3.1.2. Aldehyde dehydrogenase activity 
Aldehyde dehydrogenase (ALDH) is an intracellular enzyme that participates in 
oxidizing (detoxification) of exogenously and endogenously generated aldehydes 
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[99-102]. ALDH plays an important role in controlling differentiation pathways, 
self-protection of stem cells and confer resistance to alkylating agents [92, 103, 
104], and can also confer drug resistance to anticancer drugs by metabolic 
inactivation, which was found to contribute to cancer recurrences [105-108]. 
Additionally, it is also reported that the ALDH activity by reactive oxygen species 
(ROS) may protect against cell death [109]. ALDH activity assays has been widely 
used as a method for identifying and tracking cancer stem cells. It has also been 
used in combination with specific cell surface markers to identify cancer stem cells 
in colon cancer [110-112]. In addition, expression of ALDH1 isoform in breast and 
ovarian cancer is associated with tumour invasion and metastases, correlating with 
poor clinical outcomes [113, 114]. 
1.1.3.1.3. Signalling pathways  
A number of signalling pathways has been shown to be associated with 
chemoresistance in multiple cancer types [51, 86, 115]. Such pathways include the 
Sonic hedgehog (SHH) in glioblastoma multiforme cancer stem cells [116, 117], 
and Notch signalling which has been shown to be associated with tumour 
development, metastasis, and self-renewal [118, 119]. McAuliffe and colleagues 
demonstrated that overexpression of Notch 3 has led to cancer stem cell expansion 
and increased chemoresistance in ovarian cancer [120], and the inhibition of Notch 
signalling using J-secretase inhibitors or siRNA knockdown increased cancer stem 
cell sensitivity to platinum-based therapeutics. The combination of cisplatin with 
J-secretase inhibitors was shown to target both cancer stem cell and bulk cancer 
cells as evident from the cell cycle arrest at G2/M phase and apoptosis. 
Although targeting such signalling pathways is clinically attractive for enhancing 
anticancer treatments, it remains a challenging task as these pathways are not 
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exclusively expressed in cancer stem cells, and they are crucial for the homeostasis 
of normal and healthy cells. Therefore, targeting such signalling pathways 
potentially risks severe irreversible impact on healthy tissues [121], and it is 
therefore important to develop new therapies that focuses on cancer stem cell-
related signalling pathways while avoiding healthy cells. Furthermore, 
dysregulation of signalling pathway does not necessarily define cancer stem cell in 
all tumours, as with the case with the Wnt signalling pathway in colon cancer, in 
which Wnt signalling is not only an intrinsic feature in cancer stem cells, but is also 
regulated by external factors and can be enhanced in differentiated tumour cells  
[122]. It is also worth noting that if a cancer stem cell subclone developed resistance 
to a specific signalling pathway inhibition, then it may run the risk of developing 
resistance to new combination treatments specifically targeted to cancer stem cells 
signalling pathways [123].  
1.1.3.1.4. Carcinoma associated fibroblasts (CAFs) 
The tumour microenvironment plays an important role in tumour development and 
drug transport [124, 125]. The fibroblasts within the tumour microenvironment can 
provide a key niche for developing drug resistance for tumours [75]. Indeed, 
carcinoma associated fibroblasts (CAFs) are found to enhance tumour formation in 
xenograft models with colon and breast carcinoma cells [126, 127].  In addition, 
CAFs are found to express growth factors, chemokines, and extracellular matrix 
(ECM) related proteins, including hepatocyte growth factor (HGF), chemokine (C-
X-C) ligand 12 (CXCL12), tenascin C, and periostin, that could influence 
chemoresistance and tumour metastasis [75, 128-131]. For example, HGF was 
found to be associated with the progression of drug resistant cancer cells by 
dedifferentiating non-cancer stem cells to cancer stem cells in colon cancer [122], 
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as well as inducing cancer stem cell-associated markers such as CD49b, CD49f, 
CD44, and Sox9 [132]. Additionally, CXCL12 was found to upregulate the 
expansion of drug-resistant cells by increasing activities of the cancer stem cell-
like microenvironment [129]. Furthermore, the CAFs potentially facilitates multi-
drug resistance against chemotherapeutic drugs through efflux mechanisms [75].  
Further studies are required in order to validate these findings in a clinical setting. 
1.1.3.1.5 Antiapoptotic proteins 
The inhibitor of apoptosis (IAP) family comprises of 8 human homologues and has 
been associated with the regulation of apoptosis in different types of cancers [133]. 
Amongst them, survivin and XIAP, have received more attention in recent years 
with more than 30 anticancer preparations reaching clinical trials [134, 135]. 
Survivin, which also acts as a cytoprotective molecule, participates in at least three 
homeostatic networks: mitosis control, regulation of apoptosis, and cellular stress 
response (Figure 1-2) [136]. Survivin’s antiapoptotic effect acts through 
interactions with other protein partners, particularly XIAP, rather than direct 
inhibition of caspase pathways [136]. 
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Figure 1-3. Multiple functions of the survivin protein. 
 
The survivin-XIAP complex suppresses apoptosis through promoting increased 
XIAP stability against degradation, activating multiple signalling pathways and 
synergistically inhibiting caspase-3 and -9 [136]. In addition, survivin can also 
inhibit apoptosis through the influence on a very important pro-apoptosis molecule 
in the apoptosis pathway, SMAC, either sequestering it away from XIAP or 
preventing its release from the mitochondria [137]. A major attraction point for 
survivin is that its expression is developmentally regulated and expressed at low 
levels, or absent, in terminally differentiated cells, whereas its expression is 
significantly higher in human cancers, especially when undergoing chemo- or 
radio- therapies [136-139]. Furthermore, survivin is more closely associated with 
stem cells and is absent in terminally differentiated cells [140]. Although the human 
genome encodes 8 known IAP family proteins, only survivin is found to crosstalk 
with the Wnt/β-catenin signalling pathway by interacting directly with β-catenin 
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[141]. Global gene expression analysis of human embryonic stem cells (hES) has 
revealed that genetic ablation of survivin induced apoptosis in hES cells in both in 
vitro and in vivo settings [142, 143]. As a result, in combination with stem cell 
associated genes, Hiwi and hTERT, survivin has been proposed to be an important 
stem-cell associated gene. The co-expression of all of these three genes 
demonstrated an increased risk of tumour-related death in soft-tissue sarcoma 
patients [139]. 
1.1.3.1.6. Autophagy 
Cancer stem cells can also use alternative energy sources through the activation of 
catabolic processes that maintain metabolic homeostasis and cell viability. One 
such mechanism is autophagy [82-84, 144]. When induced, autophagosomes are 
formed while enclosing proteins and organelles, and subsequently fuse with the 
lysosome for degradation for a source of energy and amino acids [82-84, 144, 145]. 
It was demonstrated that autophagy inhibition blocked ex vivo invasion of breast 
cancer progenitor cells in autologous breast stroma, and also resulted in suppressing 
spheroids and xenograft tumour formation in vivo [146]. Furthermore, autophagic 
flux was significantly higher in mammospheres in comparison with control breast 
cancer cells [146], and it was also associated with ALDH1 subpopulation of NST 
breast cancer [147]. Several other cancer entities demonstrated that autophagy is 
essential for progenitor cell maintenance and tumourigenicity [147-152]. It has 
been recently shown that the cytoprotective effect by autophagy in cancer stem cells 
is important for therapy resistance in multiple cancer types, including 
melanoma [153], prostate cancer [154], and anaplastic lymphoma kinase (ALK)-
positive non-small-cell lung cancer [155]. It was also demonstrated that blocking 
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autophagy could overcome therapy resistance in prostate and pancreatic cell lines 
[156-158]. 
Following the discovery of autophagy’s role in cancer, the anti-malaria drug 
chloroquine/hydroxychloroquine has entered clinical trials as an anti-cancer 
therapeutic approach to overcome autophagy-mediated resistance to sensitize cells 
of small cell lung cancer to treatment (NCT01575782). It is also used in 
combination with Gemcitabine/Abraxane for the treatment of ductal pancreatic 
adenocarcinoma (NCT01506973), and with VELCADE and Cyclophosphamide 
for relapsed and refractory multiple myeloma (NCT01438177). Indeed, 
chloroquine/hydroxychloroquine interferes with the autolysosomal degradation 
which blocks autophagy at its late stages, and also interferes with E-cadherin 
endocytosis and blocks the epithelial to mesenchymal transition (EMT) [159]. 
1.1.3.2. Chemoresistance in colon cancer 
According to estimates by the national cancer institute’s SEER database, the 5-year 
relative survival rate of patients diagnosed with colon cancer is dependent on its 
stage [160]. The estimates for patients with stage I cancer has the highest survival 
rate of 92%. Patients with stage IIA and stage IIB are 87% and 63%, respectively. 
Patients with stage IIIA cancer have an 89% relative survival rate, while patients 
with stage IIIB cancers have 69% survival rate and those with stage IIIC have 53%. 
Patients with the metastatic stage of the cancer (stage IV) tend to have a poorer 
outlook with a relative survival rate of about 11%. 5-fluorouracil in combination 
with leucovorin is considered the cornerstone of colon cancer treatments, and is 
also used in combination with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), or 
both (FOLFOXFIRI) [161]. The addition of a vascular endothelial growth factor 
inhibitor (bevacizumab) or an epidermal growth factor inhibitor (e.g., cetuximab or 
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panitumumab) has also been used but with the requirement that the tumour have a 
wild-type RAS gene. These treatment combinations represent the contemporary 
standard therapy and have been reported to extend the median survival among 
patients with metastatic cancer to almost 30 months [162, 163]. Additionally, an 
oral drug known as TAS-102 showed promising results in patients' overall survival, 
especially in patients who failed to benefit from fluoropyrimidines-based 
treatments [164, 165]. 
However, despite significant progress in colon cancer treatment, a high proportion 
of patients still fall victim to relapse and metastasis originating from residual 
malignancies not evident at the time of surgery [166, 167]. Additionally, anticancer 
treatments by either chemotherapy or radiotherapy has had limited success due to 
the development of therapeutic resistance in cancer cells [168, 169], leading to drug 
failures in 90% of metastatic cancers [170]. Colon cancer stem cells have been 
demonstrated to be resistant to chemotherapy, and have also been reported to 
produce soluble factors that enhance the survival of non-resistant tumour cells 
[171-174]. Indeed, this was demonstrated with growth media, conditioned by 
oxaliplatin-resistant cells, in stimulating colon cancer cell growth [174]. 
Furthermore, high ALDH enzyme activity was found to be resistant to 
cyclophosphamide (CPA) [70], further supporting the development of 
chemoresistance observed in colon cancer cells. 
Colon cancer cells were also found to express high ABCB5, and it was 
demonstrated that ABCB5 expression identified resistant colon cancer cells and 
contributed to resistance towards 5-fluorouracil in xenotransplantation studies [69]. 
Moreover, ABCB5 knockdown in human colon cancer cells by stable short hairpin 
RNA (shRNA) resulted in 5-fluorouracil-mediated apoptosis, providing further 
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evidence of chemoresistance of colon cancer towards 5-fluorouracil. It is also 
suggested that slow cell cycling and overexpression of antiapoptotic proteins 
contribute to chemotherapy resistance [175]. Spheroid cultures confirmed this 
hypothesis as they were found to be resistant to oxaliplatin, 5-fluorouracil, and 
TRAIL-induced cell death [71]. Despite the contribution of slow cell cycling to 
chemotherapy resistance, TRAIL sensitivity is not dependent on the cell cycle. 
Therefore, it is believed that resistance to cell death may in part be due to expression 
of antiapoptotic proteins, which was confirmed when Interleukin 4 (IL-4)-treated 
colon cancer spheroid cultures resulted in downregulation of three antiapoptotic 
proteins: cFLIP, PED, and Bcl-xL [71]. Moreover, autocrine production of IL-4 in 
both in vitro and in vivo settings mediated resistance of colon cancer cells to 
chemotherapy, while sensitivity towards chemotherapeutic drugs was enhanced 
with IL-4 neutralizing antibody or the blockage of IL-4Rα receptor [71]. These 
results also suggested that an autocrine production of IL-4 could mediate apoptosis 
protection through the upregulation of antiapoptotic proteins [176]. It was later 
revealed that the IL-4/STAT-6 pathway was involved in the regulation of MDM2, 
P53, and survivin [177]. 
1.1.4. Strategies in targeting cancer stem cells 
According to the cancer stem cell model, the cancer population are organized in a 
hierarchical arrangement where the cancer stem cells are at the top and are 
responsible for maintaining tumour growth and its progression through self-
renewal and indefinite proliferation [178]. Targeting cancer stem cells is a desirable 
therapeutic approach in overcoming current limitations in anticancer treatments, 
and therefore there are two aspects that need to be taken in consideration. Firstly, 
cancer stem cells are characterized by intrinsic (innate) or acquired drug resistance 
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[179]. Secondly, the tumour microenvironment plays a pivotal role in the behaviour 
of cancer stem cells as the surrounding microenvironment can contribute to 
plasticity [180], as well as providing a key niche for developing drug resistance 
[75]. Current targeted therapies mainly target these two properties by targeting 
relevant molecules or pathways, which includes various receptors, oncogenic 
derivatives, adhesion molecules, antibody-accessible surface components, 
signalling intermediates, survival pathway elements, chromatin modifiers, and 
metabolic targets [120, 181-187]. These findings have been employed in several 
therapeutic strategies. 
1.1.4.1. “Destemming” cancer stem cells 
With increasing evidence suggesting that normal stem cells and cancer stem cells 
share many similarities in terms of self-renewal and differentiation pathways, 
several of these pathways were studied extensively and taken into consideration for 
targeted treatments [188, 189]. “Destemming” cancer stem cells aims at either 
inhibiting self-renewal or by promoting their differentiation, thus exhausting the 
dormant cancer stem cells [190]. The outcome of this strategy is to generate more 
of the bulk cancer cells and reduce the population of cancer stem cells, thus 
combating drug resistance. 
Some of the most exploited signalling pathways involved in self-renewal of cancer 
stem cells include the Wnt/β-catenin, Hedgehog (HHG), and Notch signalling 
pathways [188, 191], and they have been tested for feasibility as potential 
anticancer targets in both in vitro and in vivo settings. Amongst them, the Notch 
signalling pathway was an attractive target partly because of its role in regulating 
cancer stem cell fate in many types of cancers, including both leukemias and solid 
tumours [184]. Indeed, several Notch inhibitors such as γ-secretase inhibitors and 
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monoclonal antibodies have been evaluated with promising results [184, 192, 193]. 
However, the first trial using the γ-secretase inhibitor (MK-0752) in patients with 
T-ALL or acute myeloid leukaemia was discontinued due to severe diarrhoea [194]. 
The drug did show promising reduction in mediastinal mass by 45% at 28 days in 
one T-ALL patient. Unfortunately, the cancer progressed by 56 days. Despite that, 
current studies are aiming to determine the maximum tolerated dose of the drug. 
Alternatively, promoting signalling pathways involved in cancer stem cell 
differentiation, such as the bone morphogenic protein (BMP) and Oncostatin M 
(OSM), has also produced encouraging results. Lombardo and colleagues observed 
an increase in terminal differentiation, apoptosis, and enhanced chemosensitivity 
through the promotion of the BMP signalling pathway in colon cancer stem cells 
by using BMP4, which is a natural ligand of MBP receptor [195]. Other studies 
demonstrated the sensitization of cancer stem cells to chemotherapeutic drugs 
through the activation of OSM signalling in breast cancers [196, 197]. These results 
indicate that combinatorial treatment of signal transduction targeting and 
conventional chemotherapy may aid in eliminating cancer stem cells. However, it 
should be taken into account that normal stem cells share these signalling pathways 
as well, and therefore any alteration may cause irreversible damages and cause 
harm to the patient. Furthermore, these pathways regulate and interact with many 
other pathways, making it an extreme necessity to evaluate the potential toxicity 
and side effects of targeting signalling pathways [198]. 
Current methods in targeting signalling pathway mainly depend on activating or 
inhibiting the critical receptors of the corresponding signalling pathway with 
endogenous ligands or cytokines. However, Wurdak and colleagues demonstrated 
that using RNAi-mediated destemming can achieve similar results [199]. By using 
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a genome-wide RNA interference screen, they identified a function of 
transformation/transcription domain-associated protein (TRRAP) in being critical 
for the regulation of cancer stem cell differentiation. By silencing TRRAP with 
small interfering RNA (siRNA), a substantial differentiation was observed in cells 
derived from multiple glioblastoma multiforme patients [199]. 
1.1.4.2. Targeting the cancer stem cell microenvironment (niche) 
The cancer stem cell microenvironment (niche) is a discrete location in the tissue 
where the cancer stem cells are regulated by their surrounding environment [200]. 
Cancer cells exist in a complicated ecosystem along with various endothelial, 
hematopoietic, stromal fibroblast and other types of cells, allowing the cancer cells 
to be heavily influenced and supported by the surrounding microenvironment. For 
instance, metabolic changes in the surrounding environment, such as hypoxia or 
nutrient fluctuations, may initiate pro-survival pressure and further drive their 
malignancy as well as contribute to the heterogeneity of the tumour population. 
Furthermore, it has been observed that cancer stem cells’ reactions to drugs differ 
between in vitro and in vivo settings, suggesting that the microenvironment plays a 
major role in cancer stem cell response to treatments [201]. Moreover, it was 
discovered that interaction between cancer stem cells and their microenvironment 
may contribute to epithelial mesenchymal transition (EMT), conferring aggressive 
behaviour and altering their sensitivity to chemotherapeutic drugs [202, 203]. 
Despite the appeal to target the cancer stem cell microenvironment, the relationship 
between the cancer stem cells and their microenvironments remains largely unclear. 
Moreover, cancer stem cells may share similar microenvironments with normal 
stem cells. Therefore, there exists a risk of potential side effects associated with 
this method of treatment [204]. 
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1.1.4.3. Targeting cancer stem cells via specific cell surface markers 
Targeting relevant genes or pathways in cancer stem cells while sparing the 
surrounding healthy cells, particularly those that share the targeted genes and 
pathways, is particularly important as it may limit undesired side effects. To 
accomplish this, targeting cell surface markers that are commonly overexpressed 
in cancer stem cells represent a viable treatment strategy, and several surface 
marker proteins have been identified to be associated with a variety of cancer stem 
cells (Table 1.1). Unfortunately, the currently discovered markers are not 
exclusively expressed by cancer stem cells and are shared by other tissues, thus 
potentially endangering them if these markers are targeted. As Clevers suggested 
“The markers that have been used so far to define cancer stem cells constitute 
unlikely candidates for antibody therapy given that they are usually broadly 
expressed in healthy tissue” [205]. Furthermore, targeted delivery of drugs to cells 
necessitates the need for internalization through the cell membrane while avoiding 
or limiting the active efflux of the ABC transporter proteins. Additionally, cancer 
stem cells may avoid cell death as they have rapid DNA repair capacity and are 
predominantly dormant, making them less sensitive to traditional anticancer drugs 
that specifically affect rapidly-proliferating cells. Although traditional anticancer 
drugs can be successful in eliminating the bulk cancer cells, they remain inefficient 
in eliminating cancer stem cells [206]. Therefore, a comprehensive strategy is 
required for anti-cancer stem cell therapy. 
1.1.5. Common obstacles in cancer stem cells-targeted therapy 
An optimal design for targeted cancer stem cell therapy requires overcoming 
certain obstacles (Figure 1-3). Amongst them is to ensure the drug is guided to the 
target tumour and promote its accumulation. Furthermore, it is essential to limit the 
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drug’s exposure to normal stem cells and the healthy surrounding tissues that share 
the expression of signalling pathways or proteins of the targeted cancer stem cell, 
thus limiting the side effects associated with the drug. This can be achieved by 
exploiting a widely utilised phenomenon in cancer research: The permeability and 
retention effect (EPR) [207]. The EPR effect utilises the differences in the 
vasculature’s organization between normal and tumour tissues, which allows 
particles with a size between 10 nm and 200 nm (> 50 kDa in the case of 
macromolecules), to achieve preferential accumulation in tumours by 5 – 7 folds 
after systemic administration [208-210]. Once successfully accumulated in the 
target tumour and internalised by the cells, it is imperative to evade the active efflux 
by the ABC transporter proteins, but since they can only extrude micro-molecules, 
it does not appear to be a problem for nanoparticles. However, it is worth noting 
that the ABC transporter proteins can rapidly pump out traditional 
chemotherapeutic drugs from the cytoplasm regardless whether or not they had 
been loaded into nanoparticles. RNAi-based strategies present a promising method 
to overcome obstacles posed by the ABC transporters, as well as the obstacles by 
antiapoptotic proteins, by silencing the expression of the relevant genes [211, 212]. 
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Figure 1-4. Obstacles for cancer stem cell targeted therapies and their 
suggested solutions. 
 
In regards to the antiapoptosis pathways, the most utilised proapoptotic strategies 
include targeting the death receptors [213], IAP family protein [214], and Bcl-2 
family proteins [215]. Both IAP and Bcl-2 showed promise for nucleotide-based 
therapy, especially with RNAi-based therapeutics. Survivin, a member of the IAP, 
has been demonstrated as a suitable anticancer target not only because of its 
overexpression in cancer and its role in inhibiting apoptosis [136], but also its close 
association with stem cells and  its near absence in terminally differentiated cells  
[140]. It is however undeniable that there are concerns regarding the safety of using 
anti-survivin targeted therapies, especially in consideration that healthy tissues 
have low, yet essential levels of survivin expression [216]. Additionally, survivin 
has been reported to be involved in regulating the proliferation of hematopoietic 
progenitor cells, its expression is essential for steady-state haematopoiesis and 
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proper erythroid differentiation [217]. Nevertheless, it may not present a significant 
problem. It was reported that survivin addiction mechanism was specifically shown 
in tumours, and the existence of qualitative differences of survivin strictly appeared 
in transformed cells rather than normal tissues [218]. 
YM-155 is a small molecule survivin suppressant that has been studied in multiple 
phase I and II trials. Satoh and colleagues tested the drug on patients with advanced 
refractory solid tumours and observed adverse reactions including urine 
microalbumin and increased urinary protein [219]. However, these were indicative 
of early renal impairment and normal renal parameters were recovered without 
severe renopathy. Decreases in hemoglobin/anemia were frequently observed at 
higher doses of YM-155, but the cause remains unidentified. Fevers were also 
observed and remain under investigation. The majority of the discontinuation of 
this study was due to disease progression, but only one case was discontinued due 
to adverse event, which was later judged to be unrelated to YM-155. Lewis and 
colleagues reported in a phase II study that good tolerability for YM-155 in 
chemotherapy naive patients with unresectable stage III or IV malignant melanoma 
was demonstrated [220]. However, one patient developed reversible acute renal 
failure, and only two patients had a partial response and the efficacy endpoint of 
two responses out of 29 patients was not met. Giaccone and colleagues tested the 
drug on patients with advanced non–small-cell lung cancer, and achieved two 
partial responses with a median progression-free survival (PFS) of 1.7 months 
[221]. Cheson and colleagues tested the drug on patients with refractory diffuse 
large B-cell lymphoma and observed one patient had complete remission and an 
additional response from two patients with a median progression-free survival of 
58 days [222]. From these clinical trials, YM-155 was shown to have a well-
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tolerated response from patients, and the adverse reactions caused by the drug can 
be well-controlled. However, the drug itself has had limited single-agent activity 
and it is suggested to be included in a combination treatment.  
Another significant obstacle to cancer stem cell-targeted therapy is the slow cell 
cycling. As previously noted, both inhibition of self-renewal and promotion of 
differentiation lead to the exhaustion of cancer stem cells, and these can be achieved 
by using endogenous ligands, RNAi-based strategies, or cytokines, though the use 
of cytokines have limited selectivity and may act on many cell types. The final 
obstacle is to address the plasticity of cancer stem cells. As previously mentioned, 
cancer stem cells display plasticity properties in which non-cancer stem cells can 
dedifferentiate to cancer stem cells [1, 223]. Therefore, it is more beneficial to 
target the both cancer stem cells and the bulk cancer cells. 
1.2. RNA interference (RNAi) 
1.2.1. Introduction 
RNA interference (RNAi) is a conserved mechanism found within most eukaryotic 
cells in which the introduction of double-stranded RNA triggers a series of 
biochemical reactions leading to sequence-specific suppression of a corresponding 
gene sequence. Following its first report in 1998 [224], RNAi has received huge 
attention and enthusiasm in many research fields due to its powerful loss-of-
function property and its potential in numerous therapeutic applications. 
Cancer has been a dynamic research area for RNAi-based therapy and represents 
more than half of the currently conducting RNAi clinical trials [225]. Of RNAi 
tools available, short hairpin RNA (shRNA) and small interfering RNA (siRNA) 
have been widely used, and they each provide their own advantages. Although 
shRNA has a longer-lasting RNAi effect, siRNA has manageable administration 
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due to its transient effect and lack of genome integration, and can be synthesized in 
vitro with high affinity and efficiency, making it pharmaceutically attractive. 
Indeed, siRNAs has been employed in the majority of the current clinical trials 
[226]. However, siRNA-based therapies face many obstacles, particularly in its 
application for in vivo delivery which has been slow and raised some doubts about 
its applicability. However, key concerns have been addressed with 
recommendations in order to make siRNA-based cancer therapy a viable part of 
oncology care. 
1.2.2. siRNA for targeted anticancer therapy 
The strategy for using siRNA for anticancer treatment is to target a gene expression 
critical for tumour growth or drug resistance. The target gene should also correlate 
with a reliable marker that can be used to assess the biological and clinical response, 
as well as be expressed in the target tumours. Although cell line-based studies 
identified a number of important targets for siRNA-based therapies, such as 
GATA2 and BRCA1 [227, 228], genome-wide RNAi screens in animal model 
using primary tumour samples can be more reliable as it better mimics human 
physiology [229, 230]. Additionally, since tumours are progressive diseases with 
multiple genetic abnormalities, simultaneous inhibition of multiple genes, rather 
than a single gene, represents a better strategy [231]. In regards to targeting cancer 
stem cells, it has become widely accepted that cancer stem cell-targeted therapies 
does provide a promising opportunity to target tumour cells responsible for drug 
resistance and recurrences [232]. 
Despite the challenges, in vivo delivery of siRNA still remains as a promising and 
rapidly advancing frontier in biomedicine and drug development today, as evident 
by countless efforts of specific and non-specific delivery methods to a variety of 
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human ailments. Furthermore, promising clinical data by Alnylam has resulted in 
a significant increase in its market capitalisation from US $290M to US $6B in only 
three years [233]. Despite some renewed investor interest and over optimisms 
surrounding the field of RNAi therapies [234], it is very likely the first approved 
siRNA therapeutics may soon become available. 
1.2.3. Caveats of RNAi in therapeutics 
1.2.3.1. Chemical modifications 
Chemical modifications of siRNAs can enhance their stability in physiological 
conditions and overcome immunogenic reactions, a safety concern associated with 
oligonucleotide-based treatments [235]. The only approved nucleic acid-based 
drugs - Fomivirsen (AON) and Macugen (aptamer) – are modified in the 2’-OH 
position of the sugar with a 2’-fluoro substitute [236, 237]. It should be noted that 
although chemical modifications can increase stability and safety, it may interfere 
with the RNAi function of gene silencing. This is especially true when chemical 
modifications interrupt the Dicer recognition sites, which is located 8-bp from the 
5’ end of the guide strand [238, 239]. Unless experimentally tested, it is difficult to 
predict the impact of modification on gene silencing efficiency. For example, the 
2’-O-Me modification has previously showed reduced siRNA activity [240], yet 
the same modification on other siRNAs could increase the gene silencing efficacy 
by up to 500-fold [241]. Therefore, the impact of chemical modifications on siRNA 
activity needs to be experimentally tested for stability and gene silencing efficacy 
for each individual siRNA. 
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1.2.3.2. The EPR effect, distribution, and tumoural penetration 
Systemic administration of siRNA therapeutics is essential for anticancer 
treatments. However, the relative small size (~13 kDa) and anionic surface 
properties make siRNAs susceptible to elimination by serum degradation and renal 
filtration, making it difficult to accumulate in tumours and penetrate individual 
tumour cells. Fortunately, the EPR effect has greatly encouraged and raised 
enthusiasm for the development of siRNA for cancer therapies [225]. Due to the 
high permeability and a lack of an intact lymphatic system in tumour vessels, 
nanoparticles (NPs) with a size between 10 nm and 200 nm – the thresholds for 
kidney filtration and reticuloendothelial system, respectively – can preferentially 
aggregate in the tumour area [242, 243]. This is the reason why NPs between 50 
nm and 200 nm have been popular in clinical trials, as well as the reason why almost 
all of the effective siRNA delivery systems seen in recent years target tumours or 
organs displaying the EPR effect [244]. 
However, various formulations of siRNA-NPs showed poor clinical translations, 
insufficient tumour accumulation in preclinical studies, and high accumulation in 
normal organs such as the liver, intestines, and spleen [225]. In addition, the intra-
tumoural distribution is a critical factor that needs attention for siRNA-based 
therapeutics as poor intra-tumoural distribution would translate into poor siRNA 
efficacy in the tumour tissue [245, 246]. Indeed, patchy RNAi effect characterized 
by inconsistent tumoural distribution patterns of gene silencing has been observed 
[247]. These findings demonstrate that accumulation of siRNA therapeutics is not 
sufficient on its own, but requires stronger penetration and efficient distribution 
within the targeted tumours. 
 
 
30 
 
The majority of the NPs currently being tested consists of pools of particles with 
different sizes, shapes, and components. The uneven formulations of NPs may 
produce uneven distribution and tumoural penetration. To overcome the uniformity 
obstacle faced by liposome or polymer-based delivery systems, aptamer and 
peptide-based delivery methods show great promise [248, 249]. Particularly with 
aptamers, which was first demonstrated by Giangrande’s group in 2006 [248]. 
Being entirely made up of oligonucleotide, its manufacturing can be done in vitro 
with highly uniform particles and minimal batch-to-batch variation. In addition, the 
aptamer-based siRNA delivery system can be readily modified chemically, thus 
providing endless possibilities for easy physical and chemical manipulation. 
1.2.3.3. Intracellular Trafficking and Endosomal Escape 
The capacity of siRNAs to gain access to their target mRNAs is another 
fundamental concern for RNAi therapeutics. Once internalized, siRNAs need to 
escape the endosome to survive lysosome degradation [250]. The requirement for 
endosome escape may not be as high compared with antisense oligonucleotides 
(AON), as siRNAs can be reused in the endogenous RNAi machinery. However, 
the gene silencing capacity could significantly increase if more siRNAs escape the 
endosome. Endocytosis related-studies is arguably one of the most complicated 
topics in current biomedical research, and increasing the gene silencing efficiency 
of the escaped siRNA sequences seems like a practical alternative strategy. One 
example is when Rossi and colleagues demonstrated that using Dicer substrate 
siRNA (27-mer), as opposed to a 21-mer siRNA, can increase gene silencing 
efficacy by 100-fold, which as a result allowed for a significant reduction of siRNA 
from 10 nM to 0.5 nM in order to achieve comparable gene silencing efficiency 
[251]. 
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1.2.3.4. Side effects associated with siRNAs 
As an exogenous oligonucleotide with similar properties as viral dsRNA, siRNAs 
are susceptible to elicit the innate immune system through the Toll-like receptors 
(TLR) [252], and it has been reported that TLRs, such as TLR3, TLR7 and TLR8, 
are involved in recognising siRNAs [253, 254]. Triggering the immune response 
presents an obstacle for siRNA-based therapies due to toxicities associated with 
excessive cytokines release. However, it is reported that TLR recognition of 
siRNAs is sequence dependent, particularly the UG dinucleotides and the 5’-UGU-
3’ motif [255]. Therefore, siRNA-mediated immune response can be limited 
through careful design of the siRNA sequence. Another safety issue concerned with 
siRNA-based therapies is the off-target effects, which may result in unanticipated 
biological consequences. Off-target effects can be provoked either by the immune 
response through the universal post-transcriptional gene suppression [256], or by 
siRNA-induced miRNA-like effects because of the shared RNAi machinery and 
structural similarities. 
The off-target gene silencing by siRNA administration emphasises the importance 
of applying improved RNAi assessment methods. Indeed, stringent standards need 
to be introduced to siRNA design, and equally important, the design of negative 
controls as well. Currently, scrambled siRNAs, which are random permutation 
sequences, remain as the most commonly used negative controls for siRNA-based 
studies. Although scrambled siRNAs are often described as non-targeting siRNAs 
in a given study, the imperfect nature of this control may allow a possibility of 
inducing off-target gene silencing [257]. To address this problem, point mutation 
in the siRNA of interest stands as a potential solution [258]. This type of control 
can be achieved by introducing limited point mutations (2-nt for example) on the 
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siRNA guide strand, which preserves the identical miRNA seed sequence, allowing 
for the preservation of its sequence specific immunogenicity and miRNA-like off-
target effects. Furthermore, the 5’ complementary DNA ends (5’RACE) assay can 
be used to further provide solid evidence for siRNA-induced sequence specific 
gene silencing. Unfortunately, to this date, 5’RACE assay is not often used in many 
of the reported early-phase siRNA-based cancer clinical trials [225]. 
1.3. Aptamers  
1.3.1. Introduction 
In 1991, two independent studies introduced a new concept of high-affinity ligands 
composed of single-strand nucleic acids which became known today as “aptamers” 
[259, 260]. The name “aptamer” is derived from the Latin – Aptus (fitting), and 
from Greek – Meros (particle). These single-stranded oligonucleotide structures, 
whether RNA or DNA, comprise of specific sequences that fold into complex 
secondary and tertiary structures, which mediate specific target binding mainly 
through structural compatibility, and from a combination of aromatic rings 
stacking, van der Waals forces, and hydrogen bonding [261]. Additionally, 
aptamers can be developed in vitro by a selection process known as SELEX 
(Systematic Evolution of Ligands by Exponential enrichment). The process of 
SELEX involves iterative rounds of binding reactions between an oligonucleotide 
library of random sequences and the desired target molecule, followed by extraction 
of the target-bound oligonucleotides, and then amplification of the selected 
oligonucleotides in preparation for the subsequent round of selection. This method 
of selection makes it possible to develop aptamers capable of binding to a wide 
variety of targets ranging from proteins, cells, complex molecules, and even metal 
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ions [262-265], thus enabling them to become valuable tools in many research 
areas. 
Both aptamers and monoclonal antibodies bind to their targets with high affinity 
and specificity, and both of them have advantages over the other. However, recent 
advances in SELEX may place aptamers in a more favourable view over antibodies 
[262-266]. In vitro production of aptamers allows the procedure to be versatile and 
removes any complication imposed by physiological conditions (e.g. target purity, 
clearance… etc.). Additionally, aptamers can be chemically synthesized to improve 
their stability and binding efficiency [267-270], and unlike antibodies, the in vitro 
production of aptamers eliminates batch-to-batch variations [271]. With nucleic 
acid bases being the building block of aptamers, their ability to fold back to their 
natural forms after denaturation makes them structurally stable with a longer shelf 
life than antibodies [272]. Furthermore, their lack of peptide components and small 
size in comparison to antibodies gives them more potential at avoiding host 
immunogenicity and toxicity [273]. The most significant advantage of aptamer-
mediated drug delivery is the superior tumour penetration ability. Furthermore, 
aptamers can undergo receptor-mediated endocytosis upon binding to their targeted 
cells, while reducing systemic toxicity often associated with nonspecific 
chemotherapeutic drugs [274-277].  
1.3.2. Aptamers as anticancer drugs 
Solely as a binding ligand, aptamers can be effective therapeutic drugs by 
interrupting catalytic sites on enzymes, ligand recognition sites in receptors, or 
induce loss-of-function conformational changes [278, 279]. The first aptamer 
approved for clinical trial in cancer treatment is the anti-nucleolin AS1411 [280]. 
In in vivo xenografts, the AS1411 aptamer resulted in cytostasis and induction of 
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cell death, as well as enhanced antitumour activity when combined with 
gemcitabine [281]. Based on promising in vitro results from GROs and in vivo 
results of AS1411 in antitumour activity, the AS1411 was selected for phase I 
clinical trials and became the first nucleic acid-based aptamer tested for the 
treatment of cancer in humans, and has been tested in 17 patients with advanced 
solid tumours with promising results [280-285]. Alternatively, aptamers offer a 
variety of drug delivering strategies (Figure 1-3), such as flexibility in allowing for 
additional functionalization either by direct conjugation to chemotherapeutic 
agents such as doxorubicin or RNAi-inducing agents (siRNA, miRNA, shRNA), or 
conjugation onto drug-loaded NPs, thus broadening the application of aptamers in 
targeted therapies [286]. 
 
Figure 1-5. Various applications of aptamers for specific drug delivery. 
 
Targeted therapy aims to improve treatment response in patients and overall 
survival. Most conventional NP-drug complexes rely on the EPR effect to achieve 
preferential accumulation in tumours by utilising the differences in the 
vasculature’s organization between normal and tumoural tissues [208]. However, 
the efficacy of this passive targeting system is limited by poor tumour penetration 
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and drug uptake [287, 288], whereas an active targeting system promises superior 
tumoural penetration and improved drug uptake by the targeted cells [274-276]. 
Therefore, great interest has shifted towards the development of molecular binding 
ligands that specifically target tumour cells. For anticancer drug delivery purposes, 
aptamers have favourable properties over antibodies, including low or lack of 
immunogenicity [289, 290] while antibodies are generally immunogenic [291-
293].  Furthermore, due to the relative small size of aptamers, aptamers displayed 
superior tumour penetration than antibodies, for example, in the case of CD133 
aptamer where it showed improved penetration of tumour spheres and retention for 
a minimum of 24 hours [294, 295]. In contrast, the antibody counterpart (AC133) 
was not capable of penetrating the tumours spheres even at 300-fold higher 
concentration than the aptamer [295]. 
Despite the advantages of aptamers, they also face limitations in in vivo 
applications. Aptamers are vulnerable to enzymatic degradation by exo- and/or 
endo-nucleases, and are also susceptible to short circulatory half-life. Introducing 
chemical modifications in the backbone or side chains of the aptamer can alleviate 
these limitations, as well as incorporating unnatural nucleotide bases (e.g. locked 
nucleic acids) and capping the aptamer ends, thus minimizing the susceptibility to 
nuclease degradation [286, 296, 297]. Blood residence time is also an obstacle for 
aptamers as they are susceptible to renal filtration due to being smaller than the 
renal filtration threshold of 40 kDa [297].  To increase the circulatory half-life, 
aptamers can be conjugated to polyethylene glycol (PEG) to increase the overall 
size, but this may compromise it tumoural penetration efficacy and should be 
experimentally tested [296, 298]. It should be noted that similar to siRNAs, 
chemical modifications to aptamers may sacrifice its binding ability and therefore 
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requires careful modifications and experimentations to maintain their binding 
efficacy. 
1.3.3. Aptamers for the delivery of siRNA 
A key obstacle for RNAi-based therapies is in vivo delivery method [299, 300]. 
Several methods for siRNA delivery has been used with a variety of small 
molecule, lipids, peptides, and proteins. For instance, cholesterol-labelled siRNA 
demonstrated effective non-specific cellular uptake in culture and in mouse models 
[301]; or Shchiffelers and colleagues demonstrated in vivo siRNA delivery to 
tumour neovalsulature using PEGylated polyethyleneimine and an integrin-binding 
RGD peptide [302]. The emergence of nucleic acid aptamers provided a non-
protein based binding ligand with potential applications for siRNA delivery to 
tumour cells with superior penetration and cellular uptake [295, 303, 304]. 
Aptamer-mediated delivery of siRNA can be used to target critical genes for growth 
and drug-resistance. Indeed, aptamers have been used to deliver siRNA which 
resulted in reduced gene expression similar to that observed with oligofectamine 
delivery [305]. With properties such as low immunogenicity, specific targeting, 
superior penetration and cellular uptake, aptamer as siRNA delivery may become 
a powerful tool for anticancer treatment.   
1.4. Role of autophagy in chemoresistance 
Autophagy is a conserved cellular process that maintains homeostasis and recycles 
damaged proteins and organelles [82-84, 144, 145]. It’s involvement in cancer 
ranges from protection against malignant transformation and carcinogenesis of 
healthy cells, to being a critical survival factor for tumours cells under stressful 
situations, such as nutrient depravation, hypoxia, absence of growth factors, and 
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anticancer treatments (Figure 1-6) [306-310]. A growing body of evidence suggest 
the involvement of autophagy in different types of cancer stem cells, including in 
breast, pancreatic, and colon cancers [83, 147, 311, 312]. Although autophagy plays 
a critical role in cancer stem cell survival, chemoresistance, differentiation and 
tumourigenicity [313, 314], the relationship between autophagy and cancer stem 
cells remains largely not fully understood. 
 
Figure 1-6. Various outcomes of autophagy in response to stresses. 
1.4.1. Impact of autophagy on cancer cells 
When cancer cells are exposed to stressful conditions, autophagy is induced to 
maintain homeostasis in response to the changing conditions through reduced 
growth and increased catabolic lysis of excessive or unnecessary proteins and 
organelles [310]. However, autophagy has also demonstrated an opposite role by 
promoting cell death either by enhancing apoptosis or mediating ‘autophagic cell 
death’ [310]. Although the molecular mechanism of autophagy in both healthy and 
cancer cells have not been fully elucidated, various signalling pathways have been 
shown to be associated with autophagy regulation [315, 316]. Both the 
phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) and 
AMP-activated protein kinase (AMPK) have shown to be a central conduit in 
autophagy regulation, where the activation of mTOR is associated with the class I 
PI3K/Akt pathway, and can be inhibited by AMPK and p53 [317, 318]. Upon 
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mTOR activation, a complex of autophagy proteins are phosphorylated resulting in 
a negative effect on autophagy [319, 320]. However, inhibition by AMPK can 
suppress mTORC1 to stimulate autophagy through TSC1/2 phosphorylation [321, 
322]. It should also be noted that several other tumour suppressor genes, such as 
p53, PTEN,TSC1/TSC2, and tumour-associated genes, such as p21, AKT, have 
roles in stimulation or inhibition of autophagy, respectively [315, 320]. In addition 
to metabolic stress that can induce autophagy, such as endoplasmic reticulum (ER) 
stress, hypoxia, oxidative stress, expression of aggregate-prone proteins, and 
glucose deprivation [323], various anticancer drugs and targeted therapies can 
induce autophagy by inhibiting the PI3K/Akt/mTOR axis or through the alteration 
of genetic/epigenetic phenotypes of cancer cells, often resulting in a pro-survival 
behavior [324-326].  
A number of evidences suggest that autophagy has a contradictory role for cancer 
cells following anticancer treatments [310]. On one hand, autophagy can act as a 
pro-survival mechanism for cancer cells when treated with anticancer drugs, thus 
inhibiting autophagy in this scenario can sensitize the drug-resistant cancer cells 
and promote cell death. In contrast, autophagy may promote autophagic cell death, 
a form of physiological cell death which is contradictory to type I programmed cell 
death (apoptosis). 
1.4.1.2. Autophagy as a pro-survival mechanism 
Studies show that resistance to traditional cancer therapies can be enhanced via 
induced autophagy in various tumour cells [327, 328]. Furthermore, inhibition of 
autophagy has augmented the cytotoxic effect of several anticancer drugs in 
preclinical models [329-331]. Several pharmacological compounds and strategies 
have demonstrated to inhibit autophagy in both in vitro and in vivo settings, most 
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notable the antimalarial drug chloroquine (CQ) and its derivative 
hydroxychloroquine (HCQ), have been used as autophagy inhibitors in vivo in 
clinical trials, and have also been approved by the FDA [332, 333]. Both CQ and 
HCQ have been investigated in preclinical and clinical trials, with HCQ being 
safely dose escalated in cancer patients [334]. 
For colon cancer, 5-fluorouracil in combination with other drugs, such as 
oxaliplatin and irinotecan are the cornerstone treatment for the disease. Studies 
show that inhibition of autophagy enhances the anticancer effects of 
chemotherapeutic drugs and some targeted therapies [335, 336]. It was also 
demonstrated that mitogen-activated protein kinase 14 (MAPK14)/p38α has a role 
in chemoresistance against 5-fluorouracil and irinotecan by triggering pro-survival 
autophagy and protecting the cells from the cytotoxic effects of the drugs [337, 
338]. Furthermore, CQ treatment significantly enhanced the cytotoxic effect of 5-
fluorouracil and inhibited tumour growth in vitro and in vivo [339, 340]. Currently, 
the combination of FOLFOX/bevacizumab with HCQ is being investigated [310]. 
In addition to pharmacologic inhibition of autophagy, gene silencing of autophagy 
related genes has been developed to further study the role of autophagy in cancer 
biology and survival [341-345]. 
1.4.1.3. Autophagy as a pro-cell death mechanism 
Contrary to survival, emerging evidence support that autophagy may mediate cell 
death, especially in cells with defective or hard to induce apoptosis. Xiong and 
colleagues found that 5-fluorouracil can induce autophagic cell death and decreased 
proliferation in PUMA- or Bax-deficient human colon cancer cells [346]. Similarly, 
an HDAC inhibitor (Suberoylanilide hydroxamic) induced autophagic cell death in 
tamoxifen-resistant MCF-7 breast cancer cells and significantly reduced tumour 
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growth in vitro and in vivo [347]. Cell proliferation of cisplatin-resistant urothelial 
cancer cells were inhibited by NVP-BEZ235 through induced autophagy and cell 
cycle arrest rather than inducing apoptotic cell death [348]. These findings indicate 
that autophagic cell death can be used as an alternative mechanism to target cancer 
cells that fail to undergo apoptosis. Indeed, a derivative of the anticancer peptide 
LL-37 (FK-16), can induce caspase-independent apoptosis and autophagic cell 
death in colon cancer cells [349]. Similarly, ursolic acid have been show to promote 
cancer cell death by inducing Atg5-dependent autophagy [350]. In a GBM cell line, 
the mTOR inhibitor RAD001 potentiates autophagic cell death induced by 
temozolomide [351]. 
It is suggested that autophagy can act as an alternative process for cell death when 
apoptosis is inhibited, and it is also recognized that autophagy can precede caspase-
dependent apoptosis [352, 353]. Therefore, induction of autophagy may equally 
provide new strategies in designing new and novel anticancer treatments. 
1.4.2. Role of autophagy in cancer stem cells 
As previously mentioned, autophagy is involved in maintaining metabolic 
homeostasis and viability in cancer stem cells. Additionally, it has been reported 
that cancer stem cells can use autophagy as mechanism of chemoresistance [308, 
354, 355]. In colon cancer, Wu and colleagues demonstrated that Cdx1 expression 
in p53mutant colon cancer stem cells were resistant to paclitaxel treatment [83]. 
Paclitaxel was found to upregulate Cdx1 expression followed by autophagy 
activation in CD44+CD24+Cdx1+ cell population. In contrast, the p53WT colon 
cancer cells were more sensitive to paclitaxel through apoptosis-associated 
signalling pathways [83]. They later demonstrated that paclitaxel-induced Cdx1 
upregulation increases caspace-3, Bcl-2, and autophagy, which suggests that Cdx1-
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Bcl-2/Cas-3 pathway is involved in the activation of autophagy in colon cancer 
stem cells and plays a key role for survival. Another study by Yang and colleagues 
showed that oxaliplatin treatment induced autophagy in colon cancer stem cells and 
resulted in increased chemoresistance and stemness maintenance [312]. 
Furthermore, the autophagy induction by oxaliplatin treatment and the hypoxic and 
ischemic conditions protected colon cancer stem cells from apoptosis, especially in 
CD44+ colon cancer cells, and maintained tumourigenicity.  
When treated with chemotherapeutic drugs, both autophagic and apoptotic 
pathways are activated [356], raising speculations that autophagy may play a 
critical role in cancer biology [357]. One interesting intersection between the two 
pathways is the survivin protein, and the current trend suggests that survivin 
inhibition induces autophagic flux [358-361]. Furthermore, it was revealed that 
Autophagy Protein 5 (ATG5) translocates into the nucleus in response to DNA-
damaging drugs and physically interacts with survivin, interrupting survivin’s role 
in cell division and leading to chromosome misalignment and segregation defects 
[362]. Furthermore, it was later demonstrated that YM-155, a survivin suppressant, 
can modulate autophagy instead of caspase-3-dependent apoptosis and induce 
autophagic cell death [358]. In prostate cancer cells, YM-155 induced autophagy 
as a pro-apoptotic role, and ectopic expression of survivin attenuated the effects of 
YM-155 and apoptosis [359]. Currently, autophagy is generally viewed as a pro-
survival mechanism for the bulk cancer cells and cancer stem cells alike, and the 
pro-death autophagy observed in YM-155-treated cells does not necessarily reflect 
on all cell types or stress types. 
Survivin expression may play a key role in tipping the balance between cell death 
and survival when cells undergo induced autophagy. Moreover, while inhibiting 
 
 
42 
 
the antiapoptotic function of survivin is a desirable therapeutic target, the 
unintended inhibition of survivin’s other function in cell division may pose 
significant risks through the enrichment of highly diverse and dangerous aneuploid 
cells [363, 364], thus it may be ideal to not completely inhibit survivin but rather 
target a more specific function of survival. 
1.5. Conclusion 
As more evidence continually support the cancer stem cell model and their roles in 
maintaining tumourigenesis and drug resistance, the need for novel therapeutics 
and strategies to target the cancer stem cell population increases. Indeed, targeting 
the cancer stem cell to overcome drug resistance is a desired target for anticancer 
treatments. Recent evidence also suggests that the clonal evolution and cancer stem 
cell models are not mutually exclusive, but rather they may rely on each other to 
maintain the tumour progression, necessitating the need to not only target the 
cancer stem cells, but the bulk cancer cells as well. 
The emergence of aptamers as binding ligands possess attractive properties for 
clinical applications, from relative ease of production to convenient biological 
properties. One application of interest is the specific delivery of drug to cancer stem 
cells, either by direct conjugation with drugs or by chemical conjugation onto 
nanoparticles. In addition, mechanism of cancer stem cell drug resistance remains 
an important topic for anticancer research, allowing for the development of new 
strategies to improve therapeutic outcomes. The emergence of autophagy as a key 
player in cancer therapy has sparked interests into further understanding this 
mechanism, particularly with its dual role in response to various chemotherapeutic 
drugs by inducing either a pro-survival or pro-death responses. Further studies in 
anti-cancer stem cell treatments could facilitate a deeper understanding of drug 
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resistance and could potentially lead to development of new and novel anticancer 
therapies. 
1.6. Hypothesis and aims of the study 
1.6.1 Hypothesis 
The following are thesis hypothesis: 
1. Aptamers can efficiently deliver siRNA to colon cancer stem cells and 
silence the gene expression of the antiapoptotic protein survivin and 
overcome chemoresistance in both in vitro and in vivo settings. 
2. Targeting survivin expression in colon cancer stem cells with siRNA can 
reduce the autophagy-mediated survival. 
1.6.2. Study aims 
The specific aims of this thesis are: 
1. To evaluate the aptamer-siRNA system in targeting cancer stem cells in 
vitro and in vivo using xenograft colon tumour-bearing NOD/SCID mice. 
To investigate the role of autophagy in chemoresistance and its association with 
survivin expression. 
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Chapter 2 
Materials and methods 
2.1. Ethics Statement 
All animal protocols used in this research have been approved by the Deakin 
University Animal Welfare committee. 
2.2. Materials and equipment 
2.2.1. Chemicals and reagents 
10 × PCR loading buffer (Takara, Cat No: A260) 
10% Neutral buffered formalin (Sigma, Cat No: HT5014-ICS) 
2-Mercaptoethanol (Merck, Cat No: 8.05740.0250) 
4% Metaphor Agarose gel (Lonza, Cat No: 50535) 
40 μm cell Strainers (BD Falcon, Cat No: 352340) 
8-chamber coverglass slides (Lab-Tek, Cat No: 155409) 
Acetic acid (Merck, Cat No: 1.00063.2500) 
Acrylamide (Bio-Rad, Cat No: 161-0156) 
Agar (Merck, Cat No: 1.01614.1000) 
Agarose powder (Bio-Rad, Cat No: 161-3105) 
Ammonium Persulphate (Bio-Rad, Cat No: 161-0700) 
ApopTag Red In Situ Apoptosis Detection Kit (Millipore, Cat No: SK-4105) 
B27 (Gibco, Cat No: 10889-038) 
Bisbenzimide Hoechst 33342 (Sigma, Cat No: 14533) 
Bovine serum albumin (BSA, Sigma, Cat No: A4503) 
Bromophenol Blue (Bio-Rad, Cat No: 161-0404) 
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Chloroform (Sigma, Cat No: 366927) 
Collagenase II (Sigma, Cat No: C6885) 
Costar Ultralow attachment surface 6-well plates (Corning, Cat No: 3471) 
DAPI (Sigma, Cat No: D9642) 
DBL™ Fluorouracil Injection BP (Solution for injection) 
DBL™ Oxaliplatin Concentrate 
DEPC-treated water (Santa Cruz, Cat No: sc-204391A) 
Dimethyl Sulfoxide (DMSO, Merck, Cat No: 1.02952.1000) 
DMEM medium (Invitrogen, Cat No: 12800-017) 
DMEM/F-12 media (Invitrogen, Cat No: 12500-096) 
DNase I (Epicentre, Cat No: PSZ-10226) 
Doxorubicin (Sigma, Cat No: 44583) 
DPX (Sigma, Cat No: 317616) 
EcoRI Takara, Cat No: 1040A 
Epidermal growth factor (EGF, Sapphire Bioscience, Cat No: 701-02360) 
Ethanol (Merck, Cat No: 1434543) 
Ethylenediaminetetraacetic acid (EDTA, Scharlau, Cat No: AC0965) 
Ex Taq DNA Polymerase (Katara, Cat No: RR001A), 
Fast SYBR Green Master Mix (Invitrogen, Cat No: 4385612) 
Fibroblast growth factor (FGF, Sapphire Bioscience, Cat No: 701-23300) 
Foetal bovine serum (FBS, Invitro Technologies, Cat No: A50111-5039) 
GelStar (Lonza, Cat No: 50535) 
GeneAmp Fast PCR Master Mix (Applied biosystems, Cat No: 4359187) 
GeneRacer RNA adaptor (Invitrogen, Cat No: 46-0243) 
Giesma (Sigma, GS500) 
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Glucose (Sigma, Cat No: 50-99-7) 
Glutamax (Life Technologies, Cat No: 35050-061) 
Glycerol (Ajax Finechem, Cat No: 0810081) 
Glycine (MP Biomedical, Cat No: 808831) 
Goat serum (Abcam, Cat No: ab7481) 
Ham’s F12 medium (Invitrogen, Australia, Cat No: 11765-054) 
HCL (Merck, Cat No: K37835117 737) 
HEPES (Applichem, Cat No: A3724, 0100) 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Cat No: 
4368814) 
Insulin (Sigma, Cat No: 19278) 
Isopropyl alcohol (Fluka, Cat No: 59304) 
Kanamycin (Sigma, Cat No: K4378) 
KCl (Sigma, Cat No: P9541) 
Ligase buffer (Invitrogen, Cat No: 46-0226) 
Lipofectamine 2000 (Life Technologies, Cat No: 11668-030) 
Low melt agarose powder (Bio-Rad, Cat No: 161-3113) 
LysoTraker Green (Life technologies, Cat No: L-7526) 
Matrigel™ Basement Membrane Matrix (BD Biosciences, Cat No: 354234) 
Methanol (Merck, Cat No: 6.10158.2511) 
MgCl2 (Ajax Finechem, Cat No: A296) 
Mouse IFN-Ƴ (Gibco, Cat No: PMC4031). 
Mouse IFN-α ELISA kit (PBL Interferon Source, Cat No: 42120-1) 
Mouse TNF-α ELISA kit (BD Biosciences, Cat No: 560478) 
Thiazolyl Blue Tetrazolium Bromide (MTT) (Sigma, Cat No: M5655) 
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Mussel glycogen (Roche, Cat No: 10901393001) 
MxPro software (Agilent Technologies). 
N-[1-(2,3-Dioleoyloxy)propyl]-N,N,Ntrimethylammonium methylsulfate 
(DOTAP) (Roche, Cat No: 1811177) 
Na2HPO4 (Riedel-de Haen, Cat No: 30435 ) 
NaCl (Merck, Cat No: K37303004) 
NaHCO3 (Sigma, Cat No: 30435) 
One Shot® TOP10 chemically competent E.coli (Life technologies, Cat No: 
C4040-10) 
OptEIA (Human TNF ELISA Set) ELISA sets (BD Biosciences, Cat No: 555212 
and 558874) 
Opti-MEM reduced serum medium (Gibco, Cat No: 31985) 
Penicillin /Streptomycin (InvitrogenTM, Australia, Cat No: 15070-063) 
Phenol:Chloroform (Invitrogen, Cat No: 46-0374) 
Phosphate saline buffer (PBS, Medicago, Cat No: 09-7400-100) 
Pierce High Sensitivity Streptavidin HRP conjugate (Thermo Scientific, Cat No: 
21140) 
Platinum Taq DNA Polymerase High Fidelity kit (Invitrogen, Cat No: 11304-011) 
Poly I:C (InvivoGen, Cat No: PIC-34-08) 
Propidium iodide (Sigma, Cat No: P4864) 
Protease inhibitor cocktails (Roche, Cat No: 11697498001). 
QIAprep spin miniprep kit (Qiagen, Cat No: 27106) 
Quanta Blu fluorogenic Peroxidase substrate system (Thermo scientific, Cat No: 
15169) 
RNaseOut (Invitrogen, Cat No: 51535) 
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RPMI 1640 plus l-glutamine medium (Invitrogen Life Technologies, Cat No: 
11875) 
S.N.A.P. column (Invitrogen, Cat No: 46-0261) 
S.O.C medium (Invitrogen, Cat No: 15544-034) 
S.O.M medium (Invitrogen, Cat No: 15544-034) 
Salmon sperm DNA (Sigma, Cat No: D1626) 
Scott’s tap water substitute (Amber Scientific, Cat No: 111226) 
Skim milk powder (Diploma, Cat No 28510001) 
Sodium dodecyl sulfate (SDS, Medicago, Cat No: 09-2026-1000) 
Stripping buffer (Thermo Scientifics, Cat No: 21059) 
Super Signal West Dura substrate (Thermo Sciences, Cat No: 34075) 
SuperBlock Blocking buffer (Thermo Scientific, Cat No: 37537) 
T4 RNA ligase (Invitrogen, Cat No: 46-2141) 
TdT enzyme (Millipore, Cat No: 90418) 
TEMED (Invitrogen, Cat No: 15524-010) 
Tetramethyl benzidine substrate (Sigma-Aldrich, Cat No: T0440) 
TOPO TA Cloning vector pCR 4-TOPO vector (Invitrogen, Cat No: K4575-02) 
Transfer RNA (Sigma, Cat No: R8508) 
Tris Base (Sigma, Cat No: T6066) 
Triton X-100 (Merck, Cat No: 1.08603.2500) 
Trizol (Invitrogen, Cat No: 15596-026) 
Trypan Blue (Sigma, Cat No: T8154) 
Trypsin-EDTA (Gibco, Australia, Cat No: 15400-054) 
Tryptone (Sigma, Cat No: T7293) 
Tween 20 (MP Biomedicals, Cat No: Tween201) 
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VECTASHIELD® Mounting medium (Vector Laboratories, Cat No: H-1000) 
Yeast extract (Fluka, Cat No: 92144) 
All solvents were of analytical grade, unless stated otherwise, and were used 
without further purification. 
2.2.2. Equipment, services, and consumables 
0.22 mm syringe driven filter (Millipore, Cat No: SLGP033RS) 
15 mL centrifuge tube (Corning, Cat No: 430791) 
5 ml polystyrene round bottom tube with strainer (BD Falcon, Cat No: 352235) 
ABX Micros ESV60 haematology analysing system (Horiba Medical) 
Australian Genome Research Facility (AGRF) 
BD FACSDiva software (v6.0) 
BD ultrafine insulin syringe (BD, Cat No: 326769) 
CellBank Australia 
Cellstar 24 well plates (Greiner Bio One, Cat No: 662160) 
Cellstar 6-well plate (Greiner Bio One, Cat No: 657160) 
Cellstar 96-well plates (Greiner Bio One, Cat No: 657185) 
Cellstar Cell culture dish (Greiner Bio One, Cat No: 664160) 
CLC MIAN WORKBWENCH software 7.0.3 (Qiagen). 
Electrical homogenizer (Glas-Col, S/N CTM0500082) 
FACS Canto II flow cytometer (Becton Dickinson) 
FACSAria II flow cytometer (BD Biosciences) 
Flowjo 7.6.1 (Tree star) 
Fluostar OPTIMA plate reader (BMG Labtech) 
FluoView FV10i confocal microscope (Olympus , Japan) 
FrameStrip 8 Clear Tubes & Caps (Integrated Sciences, Cat No: 4ti-0751) 
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Graphpad 6.0 (Prism) 
HERA cell 150i CO2 incubator (Thermo Scientific) 
Hitachi CT15RE Bench-top Refrigerated Centrifuge (Japan, Cat No: 90560701) 
Image-Pro software (Media Cybernetics) 
ImageQuant LAS-4000 Chemiluminescence & Fluorescence Imaging System 
(Fujitsu Life Sciences) 
LAS-4000 Imaging software (GE Healthcare Life Sciences). 
Living Image Software V2.50 (Xenogen) Electrical homogenizer (Glas-Col) 
Milli-Q® Advantage A10 Water System (Millipore) 
Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, 170-3931) 
NC membrane (Whatman, Cat No: 10401196) 
Olympus SC20 camera (B & B Microscopes, USA) 
Orbital Shaking Incubator (Ratex, Cat No: OM15) 
PCR thermal cycler (Takara, Dice mini) 
Petri Dish (Global Science, Cat No: 031604-000110) 
pH metre (HANNA, Cat No: pH211) 
Poly-l-lysine coated glass slides (Sigma, Cat No: S9027-1PAK) 
PowerPac 300 Basic Power Supply (Bio-Rad, 164-5050). 
PVDF membrane (Thermo Scientific, Cat No: 77010) 
qRT-PCR machine (Agilent Technologies, Stratagene Mx 3000P) 
Semi-Micro Analytical Balances (A&D, Cat No: GR-200) 
Spectrophotometers and Fluorospectrometers (Thermo Scientific, NanoDrop 
2000c) 
TaKaRa PCR Thermal Cycler Dice™ mini (Cat No: TP100) 
T75 flask (CELLSTAR, Cat No: 658170). 
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TECNIPLAST SealsafeTM Individually Ventilated Cages (UK) 
The limiting dilution formula on the website of Walter and Eliza Hall Institute of 
Medical Research (http://bioinf.wehi.edu.au/software/elda/index.html). 
UV Trans-illuminator (Scientifix, M-20) 
VICTOR TM X5 Plate Reader (PerkinElmer Life and Analytical Sciences) 
Xenogen IVIS Lumina II imaging system (Caliper life sciences) 
Zetasizer Nano ZS Particle Characterisation System from Malver Instruments 
(Malvern, UK) 
2.2.3. Cells used in this study 
HT-29 (human colorectal adenocarcinoma, ATCC® HTB38™), HCT-116 (human 
colorectal carcinoma, ATCC® CCL-247™), MCF-7 (human breast 
adenocarcinoma, ATCC® HTB22™), U118MG (human glioblastoma, ATCC ® 
HTB-15™) cell line, and HEK-293T (human embryonic kidney, ATCC ® CRL-
11268™) cell lines were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). Acquired doxorubicin resistance MCF-7 (MCF-7/Adr) 
cells were induced from MCF-7 cells exposed to 300 nM doxorubicin for 20 
passages and maintained in 300 nM doxorubicin in every other passage. The 
abovementioned cells were cultured in DMEM media (Invitrogen, Australia) 
supplemented with 10% fetal bovine serum (FBS, Hyclone, Canada), 50 U/L 
penicillin and streptomycin (Invitrogen, Australia), and 1x Glutamax (Life 
Technologies). Cultures were kept in a humidified atmosphere with 5% CO2 at 37 
°C. For subculturing the adherent cells, the culture medium was removed, followed 
by a gentle rinse with sterilized phosphate buffer saline (PBS) 2 – 3 times, then the 
monolayer was detached from the surface of the flasks with 0.05% trypsin-EDTA 
(Invitrogen, Australia) at 37 °C. Complete medium with 10% fetal bovine serum 
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was used to deactivate the trypsin, then cells were collected and centrifuged at room 
temperature at 1,000x g, followed by resuspension with appropriate buffer or 
medium. 
2.2.4. Animals used in this study 
All animals were acquired from the Animal Resources Centre (Perth, Australia) 
and were allowed to acclimate for 1 week as per the guidelines set by the Deakin 
University Animal Ethics Committee. NOD/SCID female mice aged 6 – 8 weeks 
were used for HT-29, U118MG, and MCF-7/Adr xenograft establishment. The 
mice were housed under pathogen-free conditions in TECNIPLAST SealsafeTM 
Individually Ventilated Cages in groups of two to five per cage, which were placed 
in a temperature-controlled room (25 ± 1 °C) with a 12-hour light-dark cycle. Mice 
were fed ad libitum with a standard diet. Beddings, cages and water were 
autoclaved at 121 °C for 30 minutes while the fodder was sterilized by ultraviolet 
irradiation prior to each use. To establish xenograft tumours, single cell 
preparations were suspended with Matrigel (BD Biosciences) at 1:1 ratio with 
serum-free medium. Cells were injected into the left flank of each mouse with a 0.1 
mL syringe and 30-gauge needle. Tumour size was monitored daily after 
implantation and approximate tumour volume (mm3) was calculated as (Length x 
Width2)/2, where length and width are determined as the longest and shortest axis 
in millimeters, respectively. 
Female BALB/c mice aged eight weeks were used for immune response analysis. 
The mice were housed in a temperature-controlled room (25 ± 1 °C) with a 12-hour 
light-dark cycle and fed ad libitum with a standard diet. 
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2.2.5. Aptamer-siRNA chimeras used in this study 
Aptamers were synthesised by IBA GmbH followed by HPLC purification. 2’-F 
represents 2’-fluoropyrimidine modified nucleotides while “m” indicates 2’-O-
methyl modification. 
EpCAM targeting aptamer: 5’- A (2’-F-C) G (2’-F-U) A (2’-F-U) (2’-F-C) (2’-F-
C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) G (2’-F-U) - 
fluorophore-3’ (fluorescence: FITC). 
Chimeras were synthesised by Thermo Scientific or IBA GmbH or BioSpring 
followed by HPCL purification. 2’-F represents 2’-fluoropyrimidine modified 
nucleotides while “m” indicates 2’-O-methyl modification. 
Long strand (obtained from IBA GmbH): 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U) (2’-
F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) G 
(2’-F-U) AA (2’-F-C) (2’-F-U) (2’-F-U) G A A(2’-F-U) G (2’-F-U) A G A G A 
(2’-F-U) G (2’-F-C) G G (2’-F-U) G G (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-
U) -3’ (WD-49) 
Control Long strand 8 (obtained from IBA GmbH): 5’- A (2’-F-C) G (2’-F-U) 
A(2’-F-U) (2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-
C) G (2’-F-C) G (2’-F-U) X X C U U G A A U G mU A mG A mG A A G A G 
mG U mG G mU CmC mUmU -3’ (XX: HEGL) (WD-34Ep27 Guide-control) 
Short strand 1 (obtained from IBA GmbH): 5’- Dy647 - G G A C C A C C G C A 
U C U C U A C A U U C A dA dG -3’ (WD-53) 
Short strand 2 (obtained from BioSpring): 5’ – Cy5- G G A C C A C C G C A U C 
U C U A C A U U C A dA dG-PEG (20 KDa) -3’ (PEG terminally linked to aptamer 
via C6-Amino) (WD-66) 
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Short strand 3 (obtained from BioSpring): 5’ – PEG (20 KDa)- FITC - G G A C C 
A C C G C A U C U C U A C A U U C A dA dG-Biotin -3’ (PEG terminally linked 
to aptamer via C6-Amino) (WD-64) 
2.2.6. Antibodies used in this study 
Mouse anti-human Survivin antibody (Santa Cruz, Cat No: SC-17779). 
Mouse anti-human β-actin antibody (Sigma, Cat No: A5441) 
Mouse anti-human LC3 antibody (Nanotools, Cat No: 0231-100/LC3-5F10) 
Mouse anti-human SQSTM1/p62 (Abcam, Cat No: ab56416) 
Goat anti-mouse secondary antibody (Thermo Fisher, Cat No: 31430) 
Goat anti-mouse lgG pre-coated wells (Sapphire Bioscience, Cat No: 600-11050) 
Goat anti-rabbit HRP-conjugated Ab (Pierce, Cat No: 31460) 
PE conjugated mouse anti-human CD133 antibody (MACS Miltenyi Biotec, Cat 
No: AC141) 
PE conjugated mouse anti-human CD24 antibody (BD Biosciences, Cat No: 
555428) 
Percp.cy5.5 conjugated mouse anti-human CD44 antibody (BD Biosciences, Cat 
No: 560531) 
FITC conjugated mouse anti-human EpCAM antibody (BD Biosciences, Cat No: 
347197) 
Percp.cy5.5 conjugated mouse anti-human CD44 antibody (BD Biosciences, Cat 
No: 560531) 
FITC conjugated mouse anti-human EpCAM antibody (BD Biosciences, Cat No: 
347197) 
Rabbit polyclonal anti-human IFN Alpha (PBL Biomedical, Cat No: 31130-1) 
Rabbit anti-human ATG5 antibody (Cell signaling, Cat No: 2630) 
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Monoclonal Anti-FITC antibody (mouse IgG1 isotype) (Sigma, Cat No: F5636) 
Rhodamine conjugated anti-digoxigenin antibody (Millipore, Cat No: 90429) 
2.2.7. siRNA sequences 
siRNAs were synthesised by Thermo Scientific and Integrated DNA 
Technologies (IDT) followed by HPCL purification. The guide strands of survivin 
siRNA and ATG5 siRNA are 5’-UGUAGAGAUGCGGUGGUCCTT-3’ and 5’-
AAACCAAUUGGAUAAUGCCTT-3’, respectively. 
2.3. Methods 
2.3.1. Aptamer-siRNA chimera preparation 
Both the long and short strands of the chimera were synthesized by TriLink 
BioTechnologies, Inc, followed by HPLC purification. The molecular weights of 
the long strand and short strand are 14,692 and 28,432 g/mol, respectively. The 
strands were delivered in lyophilized forms and were suspended in buffer 
containing 300 mM KCl, 30 mM HEPES, and 10 mM MgCl2 at pH 7.4. For 
chimera folding, both strands were mixed at equal molar amounts, followed by a 
denaturation step at 95 °C for 5 minutes and a cooling down period to room 
temperature. The structural integrity of the chimera was confirmed with a 4% 
Metaphor agarose gel. The secondary structure of the chimera was predicted using 
the CLC MAIN WORKBENCH software (Qiagen). 
2.3.2. In vitro Dicer digestion assay 
One microgram of the chimera was digested using the recombinant Dicer enzyme 
kit (Genlantis) in a 10 μL reaction mix for 12 hours at 37 °C following the 
manufacturer's recommendations. The reaction was halted by adding Dicer Stop 
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solution, followed by resolving the digests on a 4% Metaphor Agarose gel (Lonza) 
and stained with 1:10,000 diluted GelStar (Lonza) before visualization using the 
LAS-4000 Imaging System (GE Healthcare Life Sciences). Relative quantification 
was conducted using the the LAS-4000 Imaging software (GE Healthcare Life 
Sciences). The Dicer digested chimera was compared with a 21-bp siRNA. 
2.3.3. MTT assay 
The response of cells to chemotherapeutic drugs were determined by the MTT (3-
(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide) assay. The 
assay measures the mitochondrial conversion of MTT to formazan which can be 
detected by a change of optical density at 570 nm. HT-29 cells were plated at a 
density of 2 x 103 cells per well in 100 μL complete DMEM medium in 96-well 
plates. The cells were exposed to a series of drug concentrations (5-fluorouracil: 2, 
4, 8, 15, 40, 77, 115, 150, and 200 μM) (oxaliplatin: 0.5, 1, 2, 5, 10, 15, 20, 30, and 
40 μM) for 48 hours at 37 °C in a humidified atmosphere with 5% CO2. The MTT 
solution (5 mg/mL; Sigma) was later added (20 μL) into each well and incubated 
for 4 hours. After incubation, the reaction was stopped by removing the medium 
from each well followed by the addition of 150 μL of solubilization reagent 
Dimethyl Sulfoxide (DMSO, Merck). The absorbance of each well was measured 
at 570 nm using a VICTOR X5 Plate Reader (PerkinElmer Life and Analytical 
Sciences). The inhibitory concentration 50 (IC50), which is defined as the required 
dosage that inhibits 50% of cell growth, was calculated by plotting the survival rate 
of each drug concentration (compared to saline control) against the natural 
logarithm of the drug concentration. 
 
 
57 
 
2.3.4. Protein extraction and western blot assays. 
Cells from adherent culture were collected either by trypsinization or by scraping 
method and transferred into either a 1.5 or 15 mL tube. The cells were washed twice 
with 1x PBS by centrifugation at 1,000x g for 5 minutes and the pellet was 
suspended in Lysis buffer (20 mM Tris HCL pH 7.5, 135 mM NaCl, 1.5 mM 
MgCl2, 1 mM EDTA, 1% Triton X-100, 10% Glycerol, and 1x protease inhibitor 
cocktails (Roche)) at a ratio of 0.2 mL/1 x 106 cells. Following 10 minutes of 
incubation on ice, the lysates were centrifuged at 21,500x g at 4 °C for 30 minutes. 
The supernatant was then collected and used for western blot analysis with the 
remainder stored in -80 °C for long term storage. Total proteins from mice tumours 
were extracted and washed with PBS, followed by mincing in a Petri dish. The 
minced pieces were then briefly homogenized with an electrical homogenizer 
(Glas-Col) in 1x PBS at a weight ratio of 1:3 (tissue:PBS). After washing with PBS, 
the pellets were mixed with the lysis buffer and subjected to the same total protein 
extraction procedure described for adherent cell culture. Lysates were separated 
with SDS-PAGE gels and the proteins were transferred onto a nitrocellulose 
membrane (Whatman) or PVDF membrane (Thermo Scientific). Following 
sufficient blocking with 5% skim milk (4 hours at room temperature or overnight 
at 4°C), primary antibodies were incubated according to the manufacturers’ 
suggestions. Specific mouse anti-human antibodies to Survivin (Santa Cruz), 
MDR1 (Santa Cruz), LC3 (Nanotools), p62 (Abcam), ATG5 (Cell Signaling), and 
β-actin (Sigma) were detected using goat anti-mouse antibody (Sigma) and 
visualized using the Super Signal West Dura substrate (Thermo Sciences). Relative 
quantification was conducted using a LAS-4000 Imaging System (GE Healthcare 
Life Sciences) with β-actin as an internal control. 
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2.3.5. RNA extraction, reverse transcription, and qPCR 
Total RNA was extracted using Trizol (Invitrogen) according to the manufacturer’s 
protocol. Approximately 5 – 10 x 106 of adherent cells were collected via 
trypsinization and then washed 2 – 3 times with ice cold 1x PBS. The cells were 
then suspended with 1.0 mL of Trizol reagent and vortexed for 15 seconds followed 
by incubation at room temperature for 5 minutes. Following the incubation, 0.2 mL 
of chloroform was added to the homogenized mixture and was shaken vigorously 
for 30 seconds prior to incubation at room temperature for 3 minutes. The mixture 
was centrifuged at 12,000 x g at 4 °C and the upper aqueous phase was carefully 
collected into a new 1.5 mL Eppendorf tube, in which the RNA was precipitated 
with 0.5 mL of isopropyl alcohol at room temperature for 10 minutes. The RNA 
pellet was air dried for 5 – 10 minutes at room temperature and dissolved in 10 – 
20 μL DEPC-treated water. The RNA was quantified using the Nanodrop and later 
used for reverse transcription with the remainder stored at -80 °C for long term 
storage. When extracting total RNA from tissues, the tissues were subjected to the 
same mechanical mincing and homogenization step described for protein extraction 
(section 2.3.4). One microgram of the extracted total RNA was used in a 20 μL 
reverse transcription reaction using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) and following the manufacturer’s 
instructions. The cDNA product was stored at -20 °C. 
2.3.6. Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) assay 
Fast SYBR Green Master Mix (Invitrogen) and Stratagene Mx3000P system 
(Agilent Technologies) were used to carry out qRT-PCR assays, and all primers 
used in this study had a melting temperature of approximately 58 °C to meet the 
optimum working condition of the PCR Master Mix. In a single reaction mix, 2 μL 
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of cDNA was mixed with 10 μL master mix, 1 μL of each forward and reverse 
primer (final concentration was 200 nM), and the reaction mix was completed to 
20 μL with H2O. The anneal/extension temperatures was set to 60 °C for 30 seconds 
and fluorescence was detected at 72 °C to minimize primer dimers. GAPDH was 
used as an internal control. Data analysis was performed with MxPro software 
(Agilent Technologies). 
The amplification efficiency of the primers was determined by performing qRT-
PCR reactions with serial dilutions of the cDNA (1-fold, 2-fold, 4-fold to 20-fold 
dilution). The amplification efficiency was calculated with the equation: E=10(-
1/slope) -1, where E is the efficiency of the reaction and slope represents the slope 
of CT value plotted against the log of the input template amount. An amplification 
efficiency between the values 0.8 and 1.2 was considered acceptable. The relative 
quantification was calculated with the Pfaffi method using the following equation: 
Fold change= (Ep-target gene) ΔCt-target / (Ep-GAPDH) ΔCt-GAPDH, where Ep 
(Pfaffi efficiency) equals E+1, ΔCt is the difference of Ct between compared 
samples. Table 2-1 shows the primers used for qRT-PCR. 
Table 2-1. Primers used for qRT-PCR  
Gene Primer sequence Amplicon (bp) 
GAPDH (Human) F 5’-GAAATCCCATCACCATCTTCCAGG-3’ 
R 5’-GAGCCCCAGCCTTCTCCATG-3’ 
120 
Survivin (Human) F 5’-GAACTGGCCCTTCTTGGAG-3’ 
R 5’-AAGTCTGGCTCGTTCTCAGT-3’ 
93 
GAPDH (Mouse) F 5’-GGAAGCCCATCACCATCTTCCAGG-3’ 
R 5’- GGCCCCGGCCTTCTCCATG-3’ 
120 
IFIT1 (Mouse) F 5’-CTGAGGAGTTCTGCTCTGCT-3’ 
R 5’-ACCTGGTCACCATCAGCATT-3’ 
86 
 
 
 
60 
 
2.3.7. Flow cytometry analyses 
For cell surface marker analysis, adherent cell culture was trypsinized to prepare 
single cell suspension. The cells were washed with PBS containing 0.1% BSA and 
stained with PE-labeled human-specific CD133 antibody (MACS Miltenyi Biotec) 
and FITC-labeled human-specific EpCAM antibody (BD Biosciences) for 30 
minutes at 4 °C. After thorough washing with PBS, the population of cells defined 
by EpCAM+/CD133+ were analyzed using FACS Canto II (Becton Dickinson). A 
minimum of 10,000 events were analyzed for each sample from three independent 
experiments. 
2.3.8. Confocal microscopy 
Cells were seeded at a density of 8 x 103 cells/well in an 8-chamber slide (Lab-Tek) 
and incubated at 37 °C 5% CO2 for 24 hours. EpCAM-negative HEK293T was used 
as a negative control. Following medium aspiration, the cells were incubated with 
blocking buffer (PBS supplemented with 5 mM MgCl2, 0.1 mg⁄mL tRNA, 0.1 
mg⁄mL salmon sperm DNA, and 5% FBS) at 37 °C for 15 minutes, then washed 2 
– 3 times prior to incubation with 100 nM of chimera for 30 minutes at 37 °C. The 
cells were counterstained with 3 μg/mL Hoechst 33342 (Sigma) in the final 15 
minutes of incubation. The solution was removed and the cells were washed gently 
and thoroughly prior to visualization with FluoView FV10i confocal microscope 
(Olympus, Japan). 
2.3.9. In vitro tumoursphere formation assay and ex vivo limiting dilution 
combined with tumorigenicity assay (LDA) 
The tumoursphere assay was performed in accordance with previously reported 
protocols [365]. HT-29 cells were plated at 6 x 104 cells/mL with three different 
treatment groups: Saline, 20 nM chimera, and 20 nM control chimera. After 48 
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hours of treatment, the cells were collected by trypsinization and resuspended as 
single cells in DMEM/F12 (Invitrogen) serum-free media supplemented with 100 
units/mL B27 (Gibco), 10 μg/mL Insulin (Sigma), 20 ng/mL EGF (Sapphire 
Bioscience), and 20 ng/mL bFGF (Sapphire Bioscience). Single cell suspension 
was confirmed by cell counting in a haemocytometer with over 90% single cells 
which was considered acceptable. The cells were plated into a round-bottom 96-
well ultralow attachment plates (Corning) at a density of 1, 5, 20, and 50 cells/well, 
or at 8 x 103 cells/well into a flat-bottom 6-well ultralow attachment plates 
(Corning). Upon plating, the cells were treated with 2 – 5 μM 5-fluorouracil or 50 
nM oxaliplatin and incubated at 37 °C for 5 – 7 days. Tumoursphere formation in 
96-well plates were recorded after incubation and the frequency was calculated 
using the limiting dilution software package (ELDA) on the website of Walter and 
Eliza Hall Institute of Medical Research 
(http://bioinf.wehi.edu.au/software/elda/index.html) [366]. The tumoursphere 
formation from 6-well plates were calculated according with the formula: F = 
Number of forming tumorspheres / Number of single cells plated, where F is the 
tumoursphere formation frequency [365]. Only spheres with a size larger than 50 
μm in diameter were counted. 
For ex vivo limiting dilution assay, HT-29 cells were seeded at 6 x 104 cells/mL and 
treated with 20 nM of each chimera and control chimera for 48 hours, then treated 
with 2 μM of 5-fluorouracil for 5 days. The treatment groups were the following: 
Saline, 2-fluorouracil, chimera, mixture of chimera and 5-fluorouracil, and mixture 
of control chimera and 5-fluorouracil. Each group contains 3 subgroups (n = 4). 
After incubation, single cell suspension preparation was injected subcutaneously 
(s.c.) into female NOD/SCID mice at three cell densities (5 x 104, 1 x 104, and 1 x 
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104) in serum-free DMEM/Matrigel (1:1 ratio). Tumour diameters were measured 
using a digital caliper every day post inoculation and tumour volume was calculated 
with the formula: Volume = Length × Width2/2 (V=LW2/2). The survival rate of 
mice was also recorded. 
2.3.10. TUNEL assay 
TUNEL assay was performed with cell suspensions prepared from adherent cell 
culture and tissue dissociation. The cell suspensions were prepared and washed 
with 1x PBS, then fixed with 1% paraformaldehyde in PBS for 10 minutes at room 
temperature or overnight at 4 °C. The cells were spread on a glass slide followed 
by thorough washing with 1x PBS. A pre-cooled mixture having a molar ratio of 
ethanol to acetic acid of 2:1 was used to post-fix for 5 minutes at -20°C in a coplin 
jar, and then resuspended in 1x PBS followed by washing in two changes of 1x 
PBS for 2 minutes each. The excess liquid was gently aspirated dry and blot-dried, 
then equilibration buffer was applied directly on the fixed cells and incubated for 1 
minute at room temperature. The cells were incubated with 55 μL/5 cm2 of working 
strength TdT enzyme at 37 °C for 1 hour, and the reaction halted by washing with 
stop/wash buffer at room temperature for 10 minutes, followed by washing with 1x 
PBS. The cells were incubated with rhodamine-conjugated anti-digoxigenin 
antibody (1:50) at room temperature in a darkened humidified chamber for 30 
minutes. After incubation with the antibody, the cells were washed thoroughly with 
1x PBS followed by a counterstaining with mounting medium (Vectashield, Vector 
Laboratories, Burlingame, CA) containing 0.5-1 μg/mL DAPI. The slides were 
visualized with Fluoview FV10i laser scanning confocal microscope (Olympus, 
NSW, Australia). 
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2.3.11. Determining the particle sizes of non-PEGylated and PEGylated 
chimeras 
Ten microliters of each chimera and PEGylated chimera (25 μM) was diluted with 
990 μL PBS. The vesicle size was measured using a Zetasizer Nano ZS Particle 
Characterisation System (Malvern, UK) following the manufacturer’s instruction. 
2.3.12. Biodistribution assay 
HT-29 tumour-bearing NOD/SCID mice with 150 mm3 tumour volume were 
injected with 2 nmol of biotinylated chimera via tail vein injection (n = 3). After 6 
hours of post injection, the following organs were collected: tumour, stomach, 
intestines, heart, liver, kidney, spleen, kidneys, and brain. The tissues were washed 
with pre-chilled physiological saline to remove any excess blood, and then blot-
dried with filter paper and weighed on aluminium foil. The tissues were 
homogenized in 1x PBS (tissue:PBS, 1:3) with an electric homogenizer, and the 
homogenate was centrifuged at 10,000x g at 4 °C for 10 minutes followed by 
collection of the supernatants. The homogenates were stored in -80 °C and the 
chimera concentration was quantified by ELISA. 
2.3.13. RNA-ELISA assay 
The assay was performed on 96-well plates recoated with goat anti-mouse lgG 
(Sapphire Bioscience), in which 50 μL of 10 μg/mL anti-FITC antibody (Sigma) in 
washing buffer composed of 1x PBS, 0.1 mg/ml tRNA, and 1 mg/ml BSA were 
added for one-hour incubation at room temperature. The antibodies were aspirated 
and the wells were thoroughly washed, followed by blocking with 50 μL of 1x 
SuperBlock Blocking buffer (Thermo Scientific) at room temperature for 1 hour. 
Following incubation, the wells were washed 3 times (3 minutes each wash). The 
homogenized tissues were added into each well (100 μL/well) and left to incubate 
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for 1 hour at room temperature. After thorough washing, 50 μL of 1:5000 diluted 
Pierce High Sensitivity Streptavidin HRP conjugate (Thermo Scientific) was added 
into each well to bind to the biotinylated chimera. After 1 hour of incubation at 
room temperature, the wells were thoroughly washed and the bound chimera was 
detected with a Quanta Blu fluorogenic Peroxidase substrate system (Thermo 
scientific) by measuring at a wavelength of 325/420 nm using VICTOR X5 Plate 
Reader (PerkinElmer Life and Analytical Sciences). 
2.3.14. Establishing standard curves of chimera in tissues 
The standard curves of chimera in tissues were established with homogenized 
tissues containing a series of chimera concentration. For each organ, 100 μg was 
placed in a 15 mL centrifuge tube with 1x PBS (tissue: PBS weight ratio at 1:3) and 
then homogenized with an electrical homogenizer (Glas-Col). The tissue 
homogenate was centrifuged at 21,000x g for 10 minutes at 4 °C and the 
supernatant aspirated into another tube. Serially diluted chimera was prepared with 
the tissue homogenates (2.5 x 103, 1.25 x 103, 6.25 x 102, 3.13 x 102, 1.56 x 102, 
7.81 x 10, 3.91 x 10, 1.95 x 10, 9.77, 4.88, 1.22 ng/mL) and were added into the 
FITC antibody-coated plates. The OD values of each concentration of chimera was 
measured as described in 2.3.10. Calibration curves were constructed by plotting 
the OD values against the chimera concentrations and the linear regression formula 
was used for quantification. The linear regression formula: Y = aX + b, where Y is 
the OD value of the chimera and X is the chimera concentration (log values were 
applied on both X and Y). 
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2.3.15. 5’RACE assay 
Tumour-bearing NOD/SCID mice (60 mm3 tumour volume) were injected with 2 
nmols of chimera. Twenty four hours following the injection, the tumours were 
collected and homogenized as previously described for RNA extraction (section 
2.3.5). The total extracted RNAs were subjected to 5’RACE assay. Table 2-2 shows 
the GeneRacer adaptor and primers used for this assay. 
Table 2-2. GeneRacer adaptor and primers used in the 5’RACE assay 
GeneRacer adaptor 5'-CGACUGGAGCACGAGGACACUGACAUGG 
ACUGAAGGAGUAGAAA-3' 
5' RACE Primer 5'-CGACTGGAGCACGAGGACACTGA-3' 
Survivin primer 5’-CGCACTTTCTCCGCAGTTTCCTCAA-3’ 
Nested 5’RACE Primer 5'-GGACACTGACATGGACTGAAGGAGTA-3' 
Nested survivin Primer 5’-GCCAAGTCTGGCTCGTTCTCAGT-3’ 
M13 primer Forward 5’-GTAAAACGACGGCCAG-3’ 
M13 primer Reverse 5’-CAGGAAACAGCTATGAC-3’ 
 
2.3.16. Ligating RNA oligo to total RNA 
The total RNA was ligated to a GeneRacer RNA adaptor (Invitrogen) using the 
manufacturer’s protocol. Firstly, 3.5 μg of total RNA was added to the kit-provided 
tube containing the pre-aliquoted RNA oligo (0.25 μg). Following a gentle and brief 
mixing and centrifugation, the tubes were sealed tightly and incubated at 65 °C for 
5 minutes to disrupt the RNA secondary structures. The samples were then chilled 
on ice for 2 minutes and centrifuged briefly again in preparation for mixing with 
10x ligase buffer (1 μL), 10 mM ATP (1 μL), 40 U/μL RNaseOut (1 μL), and 5 
U/μL T4 RNA ligase (1 μL), and incubated at 37 °C for 1 hour. Following the 
incubation, the ligated RNA was precipitated with a solution of 90 μL DEPC-
treated water and 100 μL 1:1 saturated phenol: chloroform (supplied) and mixed 
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vigorously for 30 seconds, and later centrifuged at 12,500x g for 5 minutes at room 
temperature. The top aqueous phase was aspirated and transferred to a new tube, 
followed by the addition of 2 μL of 10 mg/mL mussel glycogen and 10 μL of 3 M 
sodium acetate (pH 5.2) to the aspirated aqueous phase and mixed gently.  The 
mixture was placed in dry ice for 10 minutes and 220 μL of 95% alcohol was added 
and vortexed briefly. The mixture was centrifuged at 12,500x g for 20 minutes at 4 
°C to discard the supernatant and the pellet washed with 500 μL 70% alcohol. The 
mixture was centrifuged again at 12,500x g for 2 minutes at 4 °C. This process was 
repeated twice. Finally, the supernatant was removed and the RNA pellet was air-
dried for 2 minutes at room temperature, followed by resuspension in 10 μL DEPC-
treated water. The extracted RNA was quantified using Nanodrop, and its integrity 
and ligation were verified using agarose gel electrophoresis (2%). 
2.3.17. Amplifying 5’cDNA ends 
The ligated RNA product from the 5’RACE assay was reverse transcribed to cDNA 
using High Capacity cDNA Reverse Transcription kit (Applied Biosystems) as 
previously described (section 2.3.5). The end of 5’cDNA was amplified using 
Platinum Taq DNA Polymerase High Fidelity kit (Invitrogen) following the 
manufacturer’s instruction. 5’RACE primer and gene specific survivin primer were 
added at the concentration of 600 nM and 200 nM, respectively, in a 50 μL PCR 
reaction mix. To increase specificity of the PCR reaction, touchdown PCR was 
applied with the following reaction conditions: 94 °C for 2 minutes; 94 °C for 30 
seconds and 72 °C for 2 minutes for 5 cycles; 94 °C for 30 seconds and 70 °C for 
2 minutes for 5 cycles; 94 °C for 30 seconds, 65 °C for 30 seconds and 68 °C for 2 
minutes for 20 cycles; 68 °C for 10 minutes for 1 cycle. The reaction was stopped 
at 4 °C. 
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Nested PCR was performed to enhance the resolution of band separation for the 
touchdown PCR products. Nested PCR reactions used Platinum Taq DNA 
Polymerase High Fidelity kit (Invitrogen) with equal concentration of 5’ RACE 
nested primer and survivin nested primer (200 nM). The reaction conditions were 
as follows: 94 °C for 2 minutes; 94 °C for 30 seconds and 65 °C for 30 seconds and 
68 °C for 2 minutes for 30 cycles; 68 °C for 10 minutes for 1 cycle. The reaction 
was stopped at 4 °C. 
2.3.18. Gel-Purification of PCR products 
Ten micrograms of amplified DNA were loaded and separated in a 1% low melt 
agarose gel (Bio-Rad). The target band was excised with a razor blade under UV 
light and transferred to a S.N.A.P. column (Invitrogen), then placed in a sterile 
microcentrifuge tube. The tube was centrifuged at 12,500x g at room temperature 
and the recovered DNA was collected and quantified using Nanodrop. 
2.3.19. Transforming competent E.coli cells 
Transformation was done using the TOPO TA Cloning vector pCR 4-TOPO vector 
(Invitrogen). Fifty nanograms of freshly recovered DNA was mixed with 20 mM 
NaCl, 10 mM MgCl2, and 1 μL of vector to a total volume of 6 μL. The mixture 
was gently mixed and incubated at room temperature for 5 minutes, then 2 μL of 
the mixture was added into a vial of One Shot TOP10 competent E.coli cell 
(Invitrogen). The mixture was gently mixed and incubated on ice for 15 min, 
followed by a heat-shock step by placing the mixture in a water bath at 42°C for 30 
seconds (without shaking) then cooling down on ice. Pre-warmed S.O.M. medium 
(250 μL) was added to the cells, after which they were shaken horizontally at 200 
rpm. at 37 °C for 1 hour. Following the incubation, an appropriate volume of cells 
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(10 – 50 μL) were spread on a pre-warmed LB plates containing 100 μg/mL of 
ampicillin and incubated overnight at 37 °C. 
2.3.20. Colony amplification 
Single colonies were picked with a sterile loop and seeded into 3 mL of 2YT 
medium and incubated overnight at 37°C while shaken at 200 rpm. Concurrently, 
cells from the same colonies were added into a PCR reaction mix to confirm the 
insertion of the expected 5’DNA sequence. The PCR reaction mix contained Ex 
Taq DNA Polymerase (Katara), 50 mM dNTP mix and 200 nM M13 primers to be 
subjected to the conditions of 94 °C for 10 minutes; 94 °C for 1 minute, 55 °C for 
1 minute and 72 °C for 1 minute for 25 cycles; 72 °C for 10 minutes for 1 cycle. 
The reaction was stopped at 4 °C. The PCR product was separated in a 1% agarose 
gel (Bio-Rad). The insertion of the expected DNA sequence was further confirmed 
with the use of restriction enzyme digestion with EcoRI enzyme (Katara). 
2.3.21. Plasmid purification and DNA sequencing 
Plasmid DNA purification was done with the QIAprep spin miniprep kit (Qiagen) 
in accordance with the manufacturer’s instructions. The purified plasmid DNA was 
quantified using Nanodrop and verified by PCR with 5’RACE nested primer and 
Survivin nested primer. The presence of 141-bp (approximate) band in gel 
electrophoresis indicates a successful cloning of the insert. The recombinant 
plasmids (200 ng – 800 ng) were mixed with M13 reverse primer (10 pmol) and 
were sent to the Australian Genome Research Facility (AGRF) for sequencing. 
2.3.22. In vivo treatment 
HT-29 xenograft models were established in NOD/SCID mice for in vivo 
treatments with chimera and/or 5-fluorouracil. 
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2.3.22.1. Tumour measurement and survival rate 
HT-29 cells were inculcated subcutaneously into NOD/SCID mice. When the 
tumours reached 60 mm3 in volume, they were randomly assigned to five groups 
(n = 5 in each group): Saline, 5-fluorouracil-only, chimera-only, combination of 
chimera and 5-fluorouracil, and combination of control chimera and 5-fluorouracil. 
The tumour-bearing mice received tail-vein injections on days 1, 3, 5, 7, 8, and 9. 
Specifically, the 5-fluorouracil treatment group received 5% glucose injection on 
day 1 and 30 mg/kg of 5-fluorouracil on days 3, 5, 7, 8, and 9. Mice with chimera 
treatments received 2 nmol/mouse on days 1, 3, and 5 and PBS on day 7, while the 
combination treatment of chimera and 5-fluorouracil, and the combination of 
control chimera and 5-fluorouracil groups received 2 nmol/mouse of chimera or 
control chimera on day 1, followed by a combined treatment of either of the 
chimeras with 5-fluorouracil on days 3 and 5, and 5-fluorouracil on days 7, 8, and 
9. Mice weights and tumour dimensions were monitored every other day as 
described in section 2.3.9., and the survival of the mice were also observed. The 
endpoints set for the experiments were defined by rapid weight loss by 20%, tumour 
diameter exceeding 15 mm, other health deteriorations impacting on the welfare of 
the animal, and experiment duration limit set by the Deakin University Animal 
Ethics Committee. 
2.3.22.2. Treatment strategy for in vivo limiting dilution xenotransplantation 
and tumoursphere assay 
HT-29 tumour bearing mice were prepared and treated as previously described in 
section 2.3.21.1. The 5-fluorouracil treatment groups received 5% glucose injection 
on day 1 and 30 mg/kg of 5-fluorouracil on days 3, 5, and 7. Mice with chimera 
treatments received 2 nmol of chimera on days 1, 3, and 5 and PBS on day 7, while 
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mixture of chimera and 5-fluorouracil and control mixture of chimera and 5-
fluorouracil groups received 2 nmol/mouse of chimera or control chimera on day 
1, followed by a combined treatment of chimera and 5-fluorouracil on days 3 and 
5, and 5-fluorouracil on day 7. The tumours were collected after 48 hours of the 
last injection and dissociated into single cell suspensions to be used for in vitro 
limiting dilution tumoursphere assay and xenotransplantation. Viable single cell 
suspensions dissociated from each tumour were inoculated into three sub-groups of 
mice using cell doses of 1 x 105, 1 x 104, 1 x 103, and 1 x 102 per mouse (n = 4 per 
sub group). Tumour growth and mice weights were monitored daily for a total 
duration of four months. The cancer stem cells frequency was measured using the 
limiting dilution software package on the website of Walter and Eliza Hall Institute 
of Medical Research (http://bioinf.wehi.edu.au/software/elda/index.html) [366]. 
2.3.23. Tumour dissociation 
All procedures were performed using sterile techniques. Tumours collected from 
xenografts models were washed thoroughly with Hank’s buffer containing 1% 
penicillin/streptomycin to remove excess blood and any extraneous material. The 
tumours were placed in a sterile petri dish and minced into smaller pieces 
(approximately 2 – 4 mm3) with a scalpel. The chopped tissues were collected into 
a 50 mL centrifuge tube in Hank’s buffer and rinsed 3 times, then resuspended in 
dissociation medium (1x DMEM, 20% FBS, 2% penicillin/streptomycin, 100 
units/mL B27, 10 μg/mL Insulin, 20 ng/mL EGF, 20 ng/mL bFGF, and 50 U/mL 
collagenase II (Sigma)). The dissociation medium was used on the chopped 
tumours at a ratio of 6 ml per gram of tumour and incubated at 37 °C overnight on 
a rotating orbit mixer incubator at 60 rpm. Cells were collected after incubation and 
centrifuged at 1,000x g for 5 minutes. The pellets were resuspended and washed 
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with 1x PBS twice (centrifugation at 500x g) to remove any residual debris. The 
cell viability was determined by Trypan blue staining. 
2.3.24 Complete blood count assay 
To evaluate the general toxicity of the chimera, blood from BALB/c mice were 
collected and whole blood counts were analyzed by an ABX Micros ESV60 
haematology analysing system (Horiba Medical). Blood smears were obtained for 
each animal to obtain a relative white cell count adapted from the Fonio method for 
platelet counting [367, 368]. Slides were stained with Giesma and an area of the 
blood smear was selected where the red cells bordered each other without 
overlapping, with consecutive fields chosen to eliminate bias. The total number of 
white cells per 1,500 red cells were counted (n = 3 for each slide) and compared for 
each group. 
2.3.25. Innate immune response assay 
For in vivo assay, BALB/c mice aged eight weeks were randomly divided into 4 
groups (n = 6, 3 females and 3 males. Mice in the chimera and control chimera 
groups were each injected with 2 nmols of either chimera or control chimera. 200 
ng/mouse of Poly I:C (InvivoGen) and equal volume of PBD were used as positive 
and negative controls, respectively. At 4 hours and 24 hours time points, 200 μL of 
blood were collected from each mouse, and the blood was allowed to coagulate at 
25 °C for 30 minutes before centrifugations at 17,000x g for 10 minutes for serum 
collection. Levels of mouse IFN-α and TNF-α in the serum were determined with 
mouse IFN-α (PBL Biomedical Laboratories) and mouse TNF-α (Rahman et al.) 
ELISA kits according to the manufacturer’s instruction. For IFIT1 expression 
assay, total RNA collected from mouse livers and lungs after 24 hours of treatment, 
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and IFIT1 expression was determined by qRT-PCR with GAPDH as internal 
control. 
Fir in vitro human peripheral blood mononuclear cells (PBMCs) assay, PBMCs 
were prepared from freshly donated adult blood. The full blood was collected in 
heparin-treated tubes, and subjected to Ficoll-Paque plus (17-1440-02; GE 
Healthcare) gradient purification following the manufacturer’s guidelines. The 
isolated cells were plated in a 96-well plate at 2 x 105 cells/well in RPMI 1640 plus 
lx glutamine medium (11875; Invitrogen Life Technologies) complemented with 
1x antibiotic/antimycotic (15204064; Invitrogen Life Technologies) and 10% FBS 
(complete RPMI 1640), followed by incubation for 4 hours at 37°C in a 5% CO2 
atmosphere prior to treatment with 750 nM chimera, either duplexed with DOTAP 
or without, or with a known immunostimulatory single stranded RNA control (B-
406-AS). The cells were incubated overnight and supernatants were assayed for 
human INF-α and TNF-α levels. Human IFN-α in culture supernatants was 
quantified by sandwich ELISA using mouse monoclonal (0.5 μg/ml, 21112-1; PBL 
Biomedical) and rabbit polyclonal Abs (0.5 μg/ml, 31130-1; PBL Biomedical). A 
secondary goat anti-rabbit HRP-conjugated antibody (0.8 μg/ml, 31460; Pierce) 
was used for detection. Human TNF-α was measured using the OptEIA ELISA sets 
(555212 and 558874, respectively; BD Biosciences). In both IFN and TNF-α 
ELISAs, tetramethyl benzidine substrate (T0440; Sigma-Aldrich) was used for 
quantification of the cytokines on the Fluostar OPTIMA (BMG Labtech) plate 
reader. 
2.3.26. ATG5 siRNAs transfection 
Twenty-four hours prior to siRNA transfection, cells were plated in a 6-well cell 
culture plate at a density of 6 x 104 cells/well in 2 mL/well DMEM medium without 
 
 
73 
 
antibiotics. ATG5 siRNA (20 nM) was gently diluted in 250 μL of Opti-MEM 
reduced serum medium. In parallel, 10 μL of Lipofectamine 2000 was diluted in 
250 μL Opti-MEM medium. Following a 5 minute incubation at room temperature, 
the diluted siRNA and Lipofectamine 2000 were mixed gently and incubated for 
20 minutes at room temperature, followed by the addition of 500 μL of complexes 
to each well (containing cells and 1.5 mL full DMEM medium). The plate was 
mixed gently by rocking back and forth and the cells were incubated in a humidified 
atmosphere containing 5% CO2 at 37 °C for 72 hours prior to testing for ATG5 
expression levels with western blot analysis. 
2.3.27 Data analysis 
All statistical analyses were performed using GraphPad Prism 6. Statistical analysis 
between two experimental groups were calculated with unpaired t test, while 
comparisons with >2 experimental groups was analyzed with ANOVA. Survival 
data was analyzed with the Mantel–Cox log-rank test. Unless specified, all results 
were averaged from triplicates and values were reported as means ± SD. A p value 
of less than 0.05 was considered statistically significant. 
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Chapter 3 
EpCAM aptamer-siRNA chimera and its function in 
targeting colon cancer stem cells 
This chapter was adapted from the following published article: 
1. Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou SF, Khasraw M, 
Ward A, Wang L, Wei MQ, Al.Shamaileh H, Chen L, She X, Lin J, Kong 
L, Shigdar S, and Duan W. EpCAM Aptamer-mediated Survivin Silencing 
Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. 
Theranostics 5, 1456-1472, (2015). 
Part of the results presented in this Chapter was derived from the work performed 
in collaboration with other members of the laboratory. 
 
3.1. Introduction 
Current approaches in treating cancer patients include chemo- and radio-therapies, 
but their lack of specificity often results in increased side effects with limited 
therapeutic efficacy [369, 370]. The dose-limiting toxicity associated with free 
drugs in a clinical setting limits the opportunity to treat patients at a planned dose 
or to start a new treatment cycle, thereby underlying the limitations of 
chemotherapy [371, 372]. The cancer stem cell model describes the tumour 
heterogeneity as a hierarchical organization, placing the cells with the ability to 
extensively proliferate, self-renew, and differentiate to generate tumours at the top 
of the hierarchy. Thus, cancer stem cells are regarded as ‘roots of cancer’ as they 
are defined by their ability to form new tumors with histological resemblance to the 
parent tumour when transplanted into immunodeficient mice [373, 374]. The 
failure in cancer treatment remains largely attributed to our inability to eliminate 
cancer stem cells [9, 373], as they have been shown to be resistant to traditional 
anticancer treatments such as chemo- and radio-therapies [375-377]. Indeed, colon 
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cancer stem cells have been shown to be resistant to traditional anticancer drugs 
through various means, such as elevated expression of ABC transporters, active 
DNA-repair capacity, and overexpression of antiapoptotic proteins [66, 80]. As 
cancer stem cells are more drug resistant, aggressive, and invasive with higher 
metastatic potential than the terminally differentiated bulk cancer cells, they must 
be effectively targeted in order to improve the overall efficacy of anticancer 
treatments [373]. As an alternative to developing new chemotherapeutic drugs, 
which may cost approximately $800 million dollars and up to 10 years of 
development [378, 379], currently established drugs can be turned effective against 
cancer stem cells, either by targeted therapy to increase cellular uptake, or by 
increasing the cancer stem cells’ sensitivity to the drugs. 
Active targeting requires the guidance of therapeutic drugs to tumour cells and 
promote their uptake through receptor-mediated endocytosis [274-276], thereby 
improving the therapeutic efficacy whilst minimizing toxicity [380, 381]. Binding 
ligands such as peptide and proteins have been used for specific cell targeting [382-
384]. However, the tedious linkage of drugs with antibodies or proteins pose 
significant limitations. Aptamers, binding ligands also known as chemical 
antibodies, offer significant advantages over antibodies in terms of size, lower 
immunogenicity, stability, and ease of synthesis and modification [291, 292, 385, 
386]. As a guiding module for drugs, aptamers allow for improved delivery of 
therapeutic drugs to tumour cells and promote cellular uptake whilst limiting their 
exposure to healthy cells, thus minimizing the side effects associated with free 
drugs. 
This project aims to improve the efficiency of traditional chemotherapeutic drugs 
against colon cancer stem cells. Our laboratory has developed the first reported 
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RNA aptamers against the cancer stem cell markers EpCAM and CD133 [295, 
387]. Upon binding to cancer cells expressing these cancer stem cell markers, the 
aptamers were efficiently internalized via receptor-mediated endocytosis, allowing 
for the delivery of drugs capable of bypassing active efflux by the ATP-binding 
cassette transporters, or the delivery of siRNA without the use of nonspecific and 
complex lipid formulations. 5-fluorouracil and oxaliplatin are widely used drugs 
for the treatment of colon cancer and often recommended as the first line treatment. 
5-fluorouracil is a pyrimidine analogue and exerts its anticancer properties through 
3 active metabolites: fluorouridine triphosphate (FUTP), fluorodeoxy 
monophosphate (FdUMP), and fluorodeoxyuridine triphosphate (FdUTP). These 
metabolites disrupt RNA synthesis and the action of thymidylate synthase (TS) as 
well as incorporate into DNA [388-392], resulting in DNA strand breaks and cell 
death. Oxaliplatin is a platinum-based drug commonly used in combination with 5-
fluorouracil. It forms platinated intrastrand cross-links between adjacent guanine 
bases or guanine-adenine bases, causing cytotoxic lesions [393]. Despite some 
efficacy of these drugs against bulk cancer cells, they remain mostly ineffective 
against cancer stem cells as reported by others [394, 395] and also demonstrated in 
this study (Figure 3-1a). 
The focus of this chapter is to deliver siRNA to colon cancer stem cells in order to 
increase their sensitivity to traditional chemotherapeutic drugs. To accomplish this, 
an aptamer-mediated siRNA delivery system was developed by linking an EpCAM 
aptamer to survivin-specific siRNA. Theoretically, knocking down survivin protein 
expression would increase the cancer stem cells’ sensitivity towards 5-fluorouracil 
and oxaliplatin, thus improving the overall efficacy of the chemotherapeutic drugs 
(Figure 3-1b). Using the aptamer-siRNA chimera, the aptamer portion binds to the 
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cancer stem cell surface marker, leading to receptor-mediated endocytosis, and the 
release of the siRNA portion and subsequent integration into the endogenous RNA 
interference (RNAi) machinery of the host cell (Figure 3-1b). To verify the 
successful eradication of cancer stem cells, assays that measure self-renewal and 
tumourigenicity was used in both in vitro and ex vivo settings, and in vivo as well 
in chapter 4. Self-renewal was evaluated by the cell’s ability to form sphere-like 
growth (tumourspheres) in serum-free low-adherent culture, and tumourigenicity 
was evaluated by the cells’ ability to form tumours in immunodeficient mice. The 
aim of this chapter is to evaluate the aptamer-siRNA chimera developed in our 
laboratory as a promising tool in targeting colon cancer stem cells in vitro. 
 
Figure 3-1. Schematic illustration of targeting cancer stem cells with aptamer-
siRNA chimera delivery. (a) Traditional cancer chemotherapy primarily targets 
the bulk cancer cells, but spares  the cancer stem cells, resulting in tumour regrowth 
and relapse in cancer patients. (b) An alternative therapeutic strategy by targeting 
the cancer stem cells with aptamers for the delivery of siRNA. I, the aptamer-
siRNA chimera binds to the surface target molecule; II, undergoes receptor-
mediated endocytosis; III; recognition by the Dicer enzyme; IV; release of siRNA 
duplex; V, formation of RISC; VI, specific gene silencing. 
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3.2. aptamer-siRNA chimera structure 
Despite the routine use of siRNAs as an experimental tool to supress target gene 
expression in cell culture, the in vivo use of siRNA remains a big challenge [396]. 
To achieve the desired RNAi effect in a clinical setting, a safe and effective in vivo 
delivery method is imperative. One of the various available delivery methods of 
recent years is the aptamer-mediated siRNA delivery method [248]. The aptamer-
siRNA chimera gives the advantage of a nucleotide-based drug that obviates the 
need for complex lipid-based formulations [290]. Moreover, it may cause little or 
no adaptive immunogenicity [290]. As a result of its first introduction in 2006 
[248], the aptamer-siRNA chimeras have been comprehensively studied for the 
treatment of various diseases such as cancer and HIV infection [397-399]. Our 
laboratory was the first to develop an RNA aptamer that could specifically target 
the cancer stem cell surface marker epithelial cell adhesion molecule (EpCAM) 
[387], which upon binding to cells, undergoes receptor-mediated endocytosis. 
Thus, the EpCAM aptamer provides a promising tool for delivering siRNA 
specifically to EpCAM-positive cancer stem cells (Figure 3-1b).  
The aptamer-siRNA chimera used in this study was designed by linking the 
EpCAM aptamer with a survivin-specific siRNA sequence. The siRNA used was 
derived from a previously published 21-mer which was confirmed to have a high 
knockdown efficiency [400]. Additionally, the siRNA was confirmed to have a 
robust silencing efficiency in a wide range of cell lines including HT-29, MCF-
7/Adr, T47D, MDA-MB-231, and U118MG, in which more than 80% silencing 
efficiency was achieved at both the protein and mRNA levels using Western blot 
and qRT-PCR (data not shown). The aptamer used was shortened from the original 
19-nt [387] to an 18-nt RNA sequence to shorten the length and minimize 
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production costs (Figure 3-2). Based on the recent consensus that a 27-mer siRNA 
is a better Dicer substrate [251, 401], the original 21-mer siRNA was extended to a 
27-mer Dicer substrate complex for enhanced silencing efficiency. The 18-nt 
EpCAM aptamer was then linked to the 27-mer siRNA by designing a ‘long strand’ 
which consists of the siRNA guide strand and the 18-nt aptamer sequence (Figure 
3-3a), and a separate ‘short strand’ that make up the siRNA passenger strand 
(Figure 3-3b). Once annealed, both strands form a single oligonucleotide structure 
composed of a siRNA portion and an aptamer portion conjugated together with a 
2-nt AA linker (Figure 3-3c). The complete structure features a 2-nt overhang at 
the 3’ end of the long strand (UU-overhangs) and two DNA residues at the 3’ end 
of the short strand (Figure 3-3c). Such an asymmetric structure would facilitate its 
recognition by an endogenous Dicer enzyme to cleave the chimera from the 3’ end 
overhang of the long strand and result in the release of the expected 21-mer siRNA 
sequence [251] (Figure 3-3d). 
 
Figure 3-2. EpCAM-specific aptamer from 19 to 18 nucleotides in length. The 
secondary structures were predicted using CLC Main Workbench. 
 
To better control the potential off-target effects, an alternative chimera structure 
similar to the original version was designed with two point mutations in the guide 
strand. This new negative control chimera abolished the survivin silencing efficacy 
but retained the original aptamer and siRNA passenger sequences (Figure 3-3a & 
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c). This modification pattern was designed to control the potential immune 
response-associated gene suppression and EpCAM-binding side-effects. In 
addition, the “miRNA-like seed region”, located 2 – 7 bases from the 5’end of the 
guide strand, was retained in the chimera in order to control for miRNA-liked off-
target effects (Figure 3-3c). 
 
Figure 3-3. Schematic representation of the aptamer-siRNA chimera. (a) 
Secondary structure of the long strand consists of the siRNA guide strand 
covalently linked to the EpCAM aptamer via a 2-nt AA linker. All pyrimidines 
were 2’-fluoropyrimidines. In the negative control version of the long strand, 2 
point mutations were introduced as indicated. (b) The short strand makes up the 
passenger strand of the 27-mer survivin siRNA, and contains a 2-nt DNA residue 
at the 3’ end and a fluorophore (Dy647) at the 5’ end. The secondary structural 
predictions and Gibbs' free energy in (a) and (b) were generated or calculated using 
CLC Main Workbench. (c) A stable aptamer-siRNA chimera with Gibbs' free 
energy of -42.6 kcal/mol formed by annealing the long and short strands together. 
(d) The predicted 21-mer survivin siRNA after Dicer processing. 
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To confirm if the chimera was an efficient Dicer substrate, the chimera was 
incubated with recombinant human Dicer enzyme for 12 hours prior to loading on 
a 4% metaphor agarose gel. As shown in Figure 3-4, the chimera (labelled as 
Chimera 10), along with other variations of the chimera, showed efficient Dicer 
processing. With the use of a 27-mer siRNA with an asymmetric structure and an 
unmodified passenger strand, the chimera retained the predicted Dicer recognition 
site leading to the release of the 21 bp siRNA duplex [238]. 
 
Figure 3-4. Dicer substrate capacity of chimera. In vitro Dicer processing was 
analyzed by incubating individual chimeras with recombinant human Dicer enzyme 
for 12 hours. Dicer cleavage and uncleaved control (No Dicer) were visualized after 
electrophoresis through a 4% Metaphor agarose gel. An siRNA was loaded as 
control to indicate the position of 21 bp. 
 
In general, an effective therapeutic application of the aptamer-siRNA chimera to 
target cancer stem cells requires several features, including potent silencing activity 
and specificity, enhanced in vivo stability and minimal immune induction [396, 
402, 403]. A total of 20 chimera formulations were engineered and studied, and 
only one was selected for further studies. The selected chimera displayed an 8.5 
hour half-life in 50% human serum (data not shown) and was an efficient Dicer 
substrate (Figure 3-4). Subsequent work further confirmed the chimera’s 
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knockdown potency at the concentration of 20 nM, without causing sequence-
specific innate immune response (Chapter 4). Therefore, this Chimera (#10) 
seemed to be safe for in vivo application. 
3.3. The expression of cancer stem cell marker in HT-29 cells and chimera 
binding specificity 
EpCAM and CD133 are established cancer stem cell markers for colon cancer [37, 
45]. Therefore, it is possible that culturing tumour cells in sphere-forming media 
would enrich for cells expressing these markers. Both FITC-labelled EpCAM and 
PE-labelled CD133 antibodies were incubated with HT-29 cells to evaluate the 
expression levels of EpCAM and CD133 and their enrichment in tumoursphere 
culture. The expression of EpCAM and CD133 on HT-29 cells accounted for 17.9% 
of the cells cultured under standard conditions (Figure 3-5a), and their expression 
levels increased to 71.4% of the population in HT-29 cultured in sphere-forming 
media for 7 days (Figure 3-5b). An increase in both EpCAM and CD133 surface 
markers indicates that a cell population in HT-29 cells was enriched in stem cell-
promoting media, suggesting an enrichment of cancer stem cells. 
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Figure 3-5. Cancer stem cell marker expression in HT-29 cells and chimera 
binding.  (a) Cells with EpCAM and CD133 expression in HT-29 cells account for 
17.9% of the population. (b) When grown in tumoursphere media, HT-29 cells with 
EpCAM and CD133 expression are enriched to 71.4% of the population. (c) 
Chimera binding on EpCAM-expressing cells. Cy5-labelled chimeras (red) was 
incubated with HT-29, HCT-116, and HEK293T cell lines for 30 minutes at 37 °C 
and visualized by laser scanning confocal microscopy. Cell nuclei were 
counterstained with Hoechst 33342. Scale bar = 20 μm. 
 
The binding of aptamers to their targets strictly depends on their three-dimensional 
structure and conformity to their target molecules [404]. Therefore, any 
modifications introduced to the aptamers or changes to the external environment 
may potentially influence their steric structures and limit or abolish their binding 
capacities [405]. Therefore, the binding ability of the chimera with chemically 
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modified aptamer and a linkage to the siRNA to human colorectal cancer cells 
(HT29) were studied using confocal microscopy.  Following 30 minutes of 
incubation at 37 °C, the chimera demonstrated specifically by binding to EpCAM-
expressing HT-29 and HCT-116 cells but not to the EpCAM-negative HEK-293T 
cells (Figure 3-5b). However, internalization of the chimera was initially not 
evident potentially due to the masking of fluorescence signal on the cell surface 
over the fluorescence signal of the internalized chimera. To obtain visual evidence 
of internalization, the surface fluorescence signal was quenched with 0.04% trypan 
blue, which therefore allowed for the detection of internalized chimera (Figure 3-
5b).  
Although tumour-directed siRNA delivery requires high specificity of the binding 
ligand, the binding affinity need not be of high affinity. As reported, high affinity 
binding ligands may not necessarily be advantageous in a clinical setting, especially 
when targeting proteins such as EpCAM [406]. This is in part due to the non-
exclusive expression of the EpCAM protein on tumour cells. EpCAM is also 
expressed at low levels in a number of normal epithelial cells, including 
gastrointestinal tract, bile ducts, and pancreas [407]. Consequently, using targeting 
agents with moderate affinity are more likely to deliver the payload preferentially 
to tumour cells overexpressing the target molecule, with limited or low amounts of 
the payload delivered to normal cells [406]. 
3.4. Determination of LC50 and sub-lethal doses of chemotherapeutic drugs 
Both 5-fluorouracil and oxaliplatin are commonly used chemotherapeutic drugs for 
the treatment of colon cancer. Despite their efficacy in eradicating the bulk cancer 
cells, they remain inefficient in killing cancer stem cells [394, 395]. To clearly 
evaluate the efficacy of chimera and drug combination treatment in targeting cancer 
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stem cells, an optimal concentration of the drugs needed to be identified where it 
can clearly demonstrate the efficacy of the combination treatment in eliminating 
cancer stem cells. Firstly, the LC50 of the drugs were determined by employing the 
MTT assay (Figure 3-6) in which HT-29 cells were exposed to a range of drug 
concentrations. The LC50 of 5-fluorouracil on HT-29 cells was determined to be 
6.06 ± 1.37 μM (Figure 3-4a), while the LC50 value for oxaliplatin was 1.19 ± 0.404 
μM (Figure 3-6b). Secondly, a range of drug concentrations – with the LC50 as the 
upper limit – was tested in subsequent tumoursphere assays to measure their effects 
on HT-29 self-renewal with or without co-treatment with chimera. Eventually, it 
was decided to use 2 μM of 5-fluorouracil and 50 nM of oxaliplatin in subsequent 
tumoursphere assays. 
 
Figure 3-6. Cytotoxic effects of 5-fluorouracil and oxaliplatin on HT-29 cells. 
Cytotoxic effects of 5-fluorouracil on HT-29 cells. (b) Cytotoxic effects of 
oxaliplatin on HT-29 cells. Data shown are mean ± SD, n = 3. p < 0.05. 
3.5.   In vitro survivin knockdown efficiency of the chimera   
To study the chimera’s efficacy in silencing survivin expression, total protein and 
RNA were extracted from HT-29 and HEK-293T cells after treatment with 20 nM 
of chimera or control chimera. Proteins and RNA levels were evaluated with 
Western blot and qRT-PCR analysis. As shown in Figure 3-7, the survivin protein 
was significantly reduced to 33.7 ± 13.8% after 48 hours of treatment with chimera 
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(Figure 3-7a). Similarly, survivin mRNA knockdown was also confirmed by qRT-
PCR assay as illustrated in Figure 3-7a, which was significantly reduced to 30.3 ± 
6.76% after 24 hours of treatment. In contrast, the chimera showed no effect in 
survivin expression in EpCAM-negative HEK-293T, demonstrating the survivin 
knockdown in cells is EpCAM-dependent (Figure 3-7b). 
 
Figure 3-7. Chimera selectively inhibits survivin expression in EpCAM-
positive cells. (a) Survivin protein and mRNA was significantly reduced in HT-29 
cells after 48 hours and 24 hours of incubation with 20 nM chimera, respectively. 
(b) Chimera failed to knockdown survivin in EpCAM-negative HEK-293T. Data 
shown are means ± SD, n = 3. *, p < 0.05; **, p < 0.005. 
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3.6. Reduction of self-renewal of HT-29 cells after combined treatment of 
chimera and chemotherapeutic drugs in vitro 
Having established that the chimera can efficiently target survivin expression in 
EpCAM-expressing cells, it is important to evaluate if this siRNA-delivery system 
can target cancer stem cells and increase their sensitivity to traditional 
chemotherapeutic drugs, such as 5-fluorouracil and oxaliplatin. For this purpose, it 
is critical to implement analysis based on the functional properties of cancer stem 
cells. While the phenotypic characteristics of cancer stem cells may vary depending 
on the type of cancer, tumour progression, and heterogeneity of a population, the 
capacities for self-renewal and sustainment of tumour growth remain the same, 
which are the most critical functional attributes of cancer stem cells [1, 86, 408-
412]. The gold standard for determination of the frequency of cancer stem cells is 
in vivo limiting dilution assay of xenograft tumour in mice, while the in vitro 
tumoursphere assay is a valid surrogate for the in vivo limiting dilution and can be 
used to measure self-renewal frequency as the assay conditions promote self-
renewal and eliminates terminally differentiated cells [171, 413]. 
To evaluate if the chimera-mediated survivin knockdown can sensitize the 
otherwise chemoresistant cancer stem cells to chemotherapeutic drugs such 5-
fluorouracil or oxaliplatin, the in vitro tumoursphere formation assay was used. 
After 48 hours of treatment with either 20 nM chimera or control chimera, single 
cell suspensions were collected and seeded at low cell densities (20 cells/well, 10 
cells/well, and 5 cells/well) on ultra-low attachment plates with or without 
chemotherapeutic drugs (2 μM 5-fluorouracil or 50 nM oxaliplatin). As shown in 
Table 3-1 and figure 3-8, there were no significant changes in tumoursphere 
formation when the cells were treated with chimera or control chimera in 
comparison with saline control. Similarly, cells that underwent chemotherapeutic 
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drug treatments without pre-treatment with chimera showed no significant 
reduction in tumourspheres. However, cells pre-treated with the chimera followed 
by treatments with either 2 μM 5-fluoruoracil or 50 nM oxaliplatin showed 
significant reduction in tumourspheres by approximately 3 and 2.7 fold, 
respectively (Table 3-1, figure 3-8). As a control, cells pre-treated with negative 
control chimera showed no changes in the capacity of tumoursphere formation after 
treatment with either 5-fluorouracil or oxaliplatin, similar to the saline-treated 
controls. These data demonstrate not only the efficacy of the chimera in sensitizing 
colon cancer stem cells to chemotherapeutic drugs, but also demonstrate the role of 
survivin in maintaining self-renewal. 
Table 3-1. Representative in vitro tumoursphere results. Self-renewal measured 
by the cell’s ability to form spheres in vitro. Data shown in final column are mean 
± SD, n = 3. p < 0.05. 
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Figure 3-8. Chimera and chemotherapeutic drugs reduce the self-renewal 
property of cancer stem cells. The formation of tumourspheres was monitored 
after 5 – 7 days of incubation in cancer stem cell media. Data shown are means ± 
SD, n = 3. ***, p < 0.001. 
3.7. Combined chimera and 5-fluorouracil treatment resulted in reduced 
tumour growth and elimination of cancer stem cells ex vivo 
To further determine if the combination treatment of chimera and 5-fluorouracil 
would influence the activity of cancer stem cells in terms of tumourigenicity in 
immunocompromised mice, HT-29 cells were treated in vitro with chimera or 
control chimera for 24 hours, followed by treatment with 2 μM 5-fluorouracil for 5 
days. The treated cells were then injected subcutaneously into the left flanks of 
NOD/SCID mice at three cell dosages of 5 × 104, 1 × 104 and 1 × 103 cells/mouse. 
Results from this assay indicate that mice injected with cells treated with chimera 
and 5-fluorouracil combinatorial treatment resulted in significant reduction in 
tumour formation capacity than mice injected with cells treated with 5-fluorouracil-
only, chimera-only, or control chimera combined with 5-fluorouracil (Table 3-2). 
Mice injected with 1 x 103 cells from the chimera and 5-fluorouracil combination 
treatment were the only group that did not form tumours. Furthermore, the mice 
injected with 1 x 104 and 5 x 104 cells/mouse of the same treatment group showed 
delayed tumour formation compared to cells treated with 5-fluorouracil-only, 
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chimera-only, or control chimera with 5-fluorouracil. These results indicate that 
EpCAM-directed delivery of survivin siRNA to HT-29 cells resulted in sensitizing 
cancer stem cells to 5-fluorouracil treatment, leading to reduced tumourigenicity. 
As shown in Figure 3-9, the tumour volume and mice survival was monitored for 
4 months or until the mice reached the designated animal ethics end point. In all 
cell dosages, both mice injected with saline control and chimera-only treatments 
showed similar tumour growth rates (Figure 3-9a). Similarly, mice received cells 
treated with 5-fluorouracil-only or chimera with 5-fluorouracil showed a slightly 
slower growth rate than those injected with saline- or chimera-only treated cells. 
The tumour growth rates also correlates with the survival rates of the mice, where 
the cells treated with chimera and 5-fluorouracil showed improved survival rates 
for mice injected with 1 x 104 and 5 x 104 cells, while mice injected with 1 x 103 
cells of the same treatment group did not reach any experimental end points (Figure 
3-9b). These results suggest that the combined treatment of chimera with 5-
fluorouracil successfully targeted cancer stem cells in vitro, evident by reduced 
self-renewal, suppressed tumour growth, prolonged tumour-free tendency, as well 
as extended survival. The improved efficacy in reducing the cancer stem cell 
functions of self-renewal and tumourigenicity was most likely due to the 
elimination of cancer stem cells when treated in vitro before xenotransplantation 
into immunodeficient mice. 
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Table 3-2. Ex vivo limiting dilution assay of single cell suspension after in vitro 
treatment. Tumourigenicity measured by the cells ability to form tumours 
subcutaneously in immunocompromised mice. 
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Figure 3-9. Chimera and 5-fluorouracil combination treatment reduces 
tumour growth and prolongs survival in ex vivo xenotransplantation. (a) 
Tumour growth of colon cancer cells that were transplanted with 5 × 104, 1 × 104, 
and 1 × 103 following treatment with various groups as indicated. (n = 3 – 4) error 
bars indicate SD. (b) Survival curves of NOD/SCID mice-bearing xenograft 
tumours treated as described (n=3 – 4). 
3.8. Conclusion 
Current strategies in treating cancer patients mainly focus on the elimination of the 
bulk cancer cells, which often fail as the survived cancer stem cells cause tumour 
recurrences due to their resistance to traditional therapies. The EpCAM cell surface 
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marker is a widely accepted cancer stem cell marker in a variety of solid tumours 
encompassing colon, breast, pancreas, liver, and prostate, with 800- to 1000-fold 
higher expression in tumour cells, while its expression remains low in normal 
epithelial tissues [295, 387, 414, 415]. In addition, its overexpression is closely 
correlated with cancer stem cells phenotype and properties [387, 415, 416], making 
EpCAM a viable target for cancer stem cell-targeted therapy. 
In this Chapter, an aptamer-siRNA chimera was used to specifically deliver siRNA 
to colon cancer stem cells by utilizing the aptamer’s specificity to EpCAM. The 
optimized modifications and structural design of the chimera showed successful 
binding efficacy and specificity, good Dicer substrate, and EpCAM-dependent 
survivin knockdown in vitro. In addition to EpCAM binding, the chimera 
undergoes receptor-mediated endocytosis and escape the endosome prior to 
lysosome degradation [417].  
Despite the efficacy of 5-fluorouracil and oxaliplatin in eliminating the bulk cancer 
cells, they remain ineffective in eradicating the cancer stem cell population [394, 
395]. The chimera was used to deliver survivin siRNA to HT-29 tumour cells 
expressing the EpCAM surface marker and demonstrated promising evidence of 
targeting the cancer stem cells. Upon chimera treatments and survivin knockdown, 
the protective mechanism of the survivin protein was compromised, leading to the 
enhanced efficacy of both 5-fluorouracil and oxaliplatin. To determine the 
chimera’s ability in targeting cancer stem cells, an in vitro tumoursphere assay was 
employed to provide an initial assessment. The tumoursphere formation assay 
measures self-renewal, a key functional property of cancer stem cells [171]. By 
seeding the HT-29 cells in ultralow attachment plates with serum-free medium 
supplemented with EGF, FGF, insulin, and B27, the more differentiated cells with 
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limited or no self-renewal underwent programmed cell death while cells with high 
capacities for self-renewal survived and grew into sphere-like cultures. This assay 
has been widely used to test various strategies, both conventional and novel, to 
determine their cytotoxic effect on putative cancer stem cells in vitro [418, 419]. 
Careful analysis at varying cell densities confirmed the ability of chimera treatment 
combined with either 5-fluorouracil or oxaliplatin in inhibiting tumoursphere 
formation capacity (Table 3-1). 
To further functionally assess the anticancer efficacy of the chimera and 5-
fluorouracil combination treatment, the gold standard analysis of cancer stem cells 
was carried out by xenotransplanting single cell suspension of tumour cells into 
immunodeficient mice in limiting dilution (ex vivo). Single cell preparations of 
tumour cells from different treatment groups and controls – prepared in vitro – were 
transplanted into the left flank of immunocompromised NOD/SCID mice. 
Consistent with the in vitro results obtained from the tumoursphere assays, the 
treatment of cells with chimera and 5-fluororuacil resulted in a significant reduction 
of tumour formation in mice with longer latency compared to cells the received 5-
fluorouracil-only, chimera only, and control chimera with 5-fluorouracil treatments 
(Table 3-1, Fig. 3-7a and b). Additionally, the chimera and 5-fluorouracil 
combination treatment prolonged the survival of tumour-bearing mice, indicating 
that the cancer stem cell population was effectively eliminated in vitro before 
xenotransplantation. 
In summary, the data obtained in this chapter provides evidence for a strategy of 
delivering siRNA to colon cancer stem cells. Following the delivery of siRNA, the 
innate chemoresistance of cancer stem cells was reversed, leading to sensitization 
to either 5-fluorouracil or oxaliplatin, and resulted in reduced self-renewal and 
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reduced tumourigenicity in vitro and ex vivo, paving the way for further assessment 
of this chimera for targeting colon cancer stem cells in vivo. 
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Chapter 4 
In vivo delivery of chimera and its impact on colon cancer 
stem cells 
This chapter was adapted from the following published article: 
1. Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou SF, Khasraw M, 
Ward A, Wang L, Wei MQ, Al.Shamaileh H, Chen L, She X, Lin J, Kong 
L, Shigdar S, and Duan W. EpCAM Aptamer-mediated Survivin Silencing 
Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. 
Theranostics 5, 1456-1472, (2015). 
Part of the results presented in this Chapter was derived from the work performed 
in collaboration with other members of the laboratory. 
 
4.1 Introduction 
The cancer stem cells in colon cancer are endowed with high capacities for self-
renewal and tumourigenesis [420-423]. Moreover, they are resistant to 
conventional anticancer treatments through various mechanisms including elevated 
drug efflux function, active DNA repair mechanisms, and increased signalling 
pathways that promote growth, drug resistance, and invasion. Therefore, cancer 
stem cells are responsible for tumour relapse, progression and regrowth [373, 375, 
424-427]. Consequently, developing new treatment strategies that are able to 
eliminate cancer stem cells may eventually lead to effective anticancer therapies 
[428-430]. Targeted cancer therapies using antibodies against the surface markers 
of cancer stem cells, such as DLL4, CD123, and CD133, have demonstrated 
promising therapeutic effects in a number of cancers, along with increasing 
commercial success [71, 410, 431, 432]. Aptamers have shown promising 
applications in targeted anticancer therapies [433-435], and as demonstrated in 
chapter 3, they showed potential in delivering siRNA to colon cancer stem cells. 
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In Chapter 3, the aptamer-siRNA chimera was used to target EpCAM-expressing 
cells, which led to its internalization and subsequent siRNA delivery. The efficacy 
of targeting cancer stem cells in both in vitro and ex vivo was confirmed by the 
impact of the combined chimera and 5-fluorouracil treatment on self-renewal and 
tumourigenicity of HT-29 cells. The focus of this chapter is to evaluate the 
chimera’s efficacy in an in vivo setting. To achieve preferential systemic 
distribution, the chimera was conjugated to a 20-kDa PEG to prolong the 
circulation half-life. HT-29 tumour-bearing NOD/SCID mice were established for 
in vivo treatments via intravenous tail-vein injections. The efficacy of the chimera 
in targeting cancer stem cells in vivo was evaluated by its effects on apoptosis, self-
renewal, tumourigenicity, and survival rates. Furthermore, the impact of the 
PEGylated chimera on the overall well-being of mice was also evaluated. 
4.2. Chimera PEGylation and tumour accumulation in vivo 
For in vivo applications, the performance of the chimera in regards to tumour 
localization and survivin targeting efficacy needed to be assessed. As the non-
PEGylated chimera showed poor blood residence time and poor tumour 
localization [417] (Figure 4-1), the chimera was engineered with a conjugation of 
a 20-kDa PEG to minimize the loss through renal filtration and to increase its 
circulation half-life. With the addition of the 20-kDa PEG molecule (Figure 4-1a), 
the chimera overall size increased from approximately 4.4 ± 1.6 nm to 15 ± 2.2 nm 
(Figure 4-1b), which exceeds the 10 nm renal filtration threshold [436]. To facilitate 
the biodistribution study of the PEGylated chimera in tumour-bearing NOD/SCID 
mice, chemical modifications were introduced to allow for in vivo live imaging 
through the use of Dy647 fluorescence label (Figure 4-1a). Additionally, the 
chimera was conjugated with biotin and FITC at the two ends of the chimera’s 
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siRNA passenger strand to enable accurate quantification in tissues through 
Enzyme-linked immunosorbent assay (ELISA) (Figure 4-1a). 
 
Figure 4-1. Schematic representation of PEGylated chimera and its 
comparison with non-PEGylated chimera in size and tumour accumulation 
efficacy. (a) The chimera was engineered with a 20-kDa polyethylene glycol (PEG) 
molecule – FITC to the 3’ end and a biotin or Dy647 to the 5’ end of the siRNA 
passenger strand. The negative control version of the chimera, two point mutations 
were introduced as illustrated in the figure. (b) Particle size comparison between 
PEGylated and non-PEGylated versions of the chimera. (c) The PEGylated chimera 
showed improved tumour accumulation efficacy in MCF-7/Adr tumours over the 
non-PEGylated chimera. Additionally, PEGylated chimera showed delayed 
appearance in EpCAM-negative U118MG tumours with low fluorescence intensity 
and shorter duration of accumulation. 
 
For in vivo imaging, 2 nmol/mouse of PEGylated chimera was injected 
intravenously via the tail vein of MCF-7/Adr tumour-bearing NOD/SCID mice. 
Live animal imaging showed a significant increase of PEGylated chimera in the 
tumours as evident from a 9.5-fold larger area under the fluorescence intensity 
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curve compared with the non-PEGylated chimera (Figure 4-1c). The fluorescence 
signal of the PEGylated chimera in the MCF-7/Adr xenograft tumour was detected 
10 minutes after tail vein injection and lasted for 24 hours, peaking at 6 hours after 
injection (Figure 4-2a & b). The tissues were then extracted and imaged to reveal 
that the chimera signal was stronger in the tumours than most of the other tissues, 
with the exception of the kidneys (Figure 4-2c). The accumulation of fluorescence 
signals in the kidneys after 24 hours is likely caused by non-specific renal 
elimination. Interestingly, when tested on EpCAM-negative U118MG tumours, 
faint PEGylated chimera fluorescence signal was detected four hours after 
intravenous tail vein injection, which lasted for approximately six hours before 
disappearing at the 10-hour time-point (Figure 4-3a & b). Imaging of the extracted 
tissues revealed that the kidneys, lungs, and liver showed higher accumulation of 
PEGylated chimera than that of the U118MG tumour (Figure 4-3c). 
In both tumour models (MCF-7/Adr and U118MG), the accumulation of 
PEGylated chimera in the spleen and heart were relatively lower than what was 
found in both tumours. Given that the heart and spleen have higher blood flow than 
tumours [437], it is unlikely that the blood flow alone resulted in the accumulation 
of the PEGylated chimera in the tumours. However, it is apparent that the enhanced 
permeability and retention (EPR) effect, which favours the accumulation of 
nanoparticles in tumours and tissues such as the lungs and liver [243, 438], played 
a major role for the accumulation of the PEGylated chimera. The contribution of 
the EPR effect on the enhanced tumour retention of the PEGylated chimera can be 
inferred from Figure 4-1c, where the PEGylated chimera had a 9.5-fold increase in 
MCF-7/Adr tumours compared to the non-PEGylated chimera, emphasizing the 
necessity of PEG to prolong blood circulation and take advantage of the increased 
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EPR effect in tumours. Additionally, EpCAM expression played a major role for 
chimera accumulation as the EpCAM-negative U118MG tumour showed late 
onset, low accumulation, and short retention time of the PEGylated chimera. These 
collective data suggest that while the EPR effect contributes to the chimera’s 
delivery to tumours, the chimera’s specificity to EpCAM expression ensures 
specific targeting of EpCAM-positive tumours with prolonged retention time. 
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Figure 4-2. Enhanced tumour binding and retention to EpCAM-positive 
MCF-7/Adr tumours. (a) Representative live imaging of PEGylated chimera in 
MCF-7/Adr tumour-bearing mice (60 mm3). Mice received 2 nmol/mouse 
injections of PEGylated chimera labelled with Dy647 fluorescence tag, followed 
by fluorescence imaging at the indicated time points. Log-scale heat map of photon 
flux applies to all panels. (b) Fluorescence time curve of the PEGylated chimera in 
MCF-7/Adr tumours determined by Living Imaging Software v2.50. (c) 
Representative images of extracted tissues 24 hours after a single injection of 2 
nmol/mouse of PEGylated chimera with Dy647 label. The Semi-quantification of 
the average fluorescence intensity was performed with Living Image Software 
V2.50 (Xenogen) with the units of photons/s/cm2/sr. Log-scale heat map of photon 
flux applies to all panels. p/s/cm2/sr: photons per second per cm2 per Ste radian. 
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Figure 4-3. Transient tumour binding and retention of PEGylated chimera in 
EpCAM-negative U118MG tumours. (a) Representative live imaging of 
PEGylated chimera in U118MG tumour-bearing mice (60 mm3). Mice received 2 
nmol/mouse injections of PEGylated chimera labelled with Dy647 fluorescence 
tag, followed by fluorescence imaging at the indicated time points. Log-scale heat 
map of photon flux applies to all panels. (b) Fluorescence time curve of the 
PEGylated chimera in U118MG tumours determined by Living Imaging Software 
v2.50. (c) Representative images of extracted tissues 10 hours after a single 
injection of 2 nmol/mouse of PEGylated chimera with Dy647 label. The Semi-
quantification of the average fluorescence intensity was performed with Living 
Image Software V2.50 (Xenogen) with the units of photons/s/cm2/sr. Log-scale 
heat map of photon flux applies to all panels. p/s/cm2/sr: photons per second per 
cm2 per Ste radian. 
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For a more accurate measurement of chimera biodistribution, a reliable absolute 
quantification method using the FITC and biotin modifications was used to 
facilitate an indirect ELISA-based quantification approach [439] (Figure 4-4). In 
this method, an anti-FITC antibody and the streptavidin-biotin binding relationship 
were exploited, as well as a fluorogenic peroxidase substrate system for high 
sensitivity quantification. In this assay, detection of fluorescence signals is strictly 
dependent on the number of chimeras with both FITC and biotin conjugation on 
both ends of the siRNA portion intact (Figure 4-4). Any breakage in the siRNA 
strand would result in abolished output signals. Therefore, only chimeras with 
intact siRNA portions can be detected, assuring high specificity measurements.    
Although the conjugation with FITC and biotin may alter the chimera’s overall 
structure, it is imperative to add the modifications in positions that do not 
compromise the chimera’s silencing efficacy. Computational structural analysis 
suggested that modifications on the 3’ end of the guide strand could significantly 
compromise the gene silencing capacity of the chimera. In addition, adding a 
modification on the guide strand would have resulted in high costs and low yield 
for synthesis. Given that the potential degradation site on the chimera was more 
likely to be in the siRNA portion and not the aptamer portion, conjugating both 
FITC and biotin on both sides of the siRNA passenger strand as illustrated in Figure 
4-1a was the most practical option. 
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Figure 4-4. Schematic representation of RNA-ELISA for the quantification of 
chimeras in tissues. Mouse anti-FITC antibody were loaded into 96-well plates 
that had been pre-coated with goat anti-mouse IgG. After one hour of incubation at 
room temperature, the wells were washed and blocked prior to loading tissue 
samples in the wells. After one hour incubation at room temperature and extensive 
washing, streptavidin-HRP conjugates were added to each well to bind to the 
chimera-conjugated biotin, emitting fluorescence intensities detectable by using a 
plate reader. 
4.2.1. Establishment of standard curves for chimera distribution in various 
tissues 
To quantify the chimera content in tissues using the RNA-ELISA system, 
homogenate preparations (tumour, heart, liver, spleen, lung, intestine, stomach, 
kidneys, and brain) were spiked with serial dilutions of chimera (2500 ng/mL, 1250 
ng/mL, 625 ng/mL, 300 ng/mL, 150 ng/mL, 75 ng/mL, 37.5 ng/mL, 18.8 ng/mL, 
9.38 ng/mL, 4.88 ng/mL, 2.44 ng/mL, and 1.22 ng/mL) to obtain standard curves 
for each tissue. The optical density of each dilution of each tissue was plotted 
against its respective chimera concentration (Figure 4-5). The correlation 
coefficients (R2) being greater than 0.900 suggested a good linear regression within 
the tested ranges (Fig. 4-5). 
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Figure 4-5. Standard curves of PEGylated chimera for in vivo quantification 
in various tissues. PEGylated chimera was serially diluted in tissue homogenates 
(2500 ng/mL, 1250 ng/mL, 625 ng/mL, 300 ng/mL, 150 ng/mL, 75 ng/mL, 37.5 
ng/mL, 18.8 ng/mL, 9.38 ng/mL, 4.88 ng/mL, 2.44 ng/mL, and 1.22 ng/mL). The 
absorbance values of each homogenate with different chimera concentration was 
measured via ELISA. Standard curves were constructed by plotting the absorbance 
values against its respective chimera concentration with the correlation coefficient 
displayed on each graph. 
4.2.2. Biodistribution of PEGylated chimera in HT-29 tumour bearing 
NOD/SCID mice 
Based on the previous live imaging results, the fluorescence in the tumour area 
peaked at 6 hours after injecting 2 nmols of chimera intravenously via the tail vein. 
To further confirm this finding, a single 2 nmol/mouse of PEGylated chimera was 
intravenously injected in HT-29 tumour-bearing mice. After 6 hours of injection, 
various tissues (tumour, heart, liver, spleen, lung, intestine, stomach, kidneys, 
brain, and eyes) were extracted and homogenized for chimera quantification using 
the RNA-ELISA method as previously illustrated in Figure 4-4. As shown in Figure 
4-6, the PEGylated chimera accumulated rapidly in the highly perfused organs, 
including the heart, liver, kidneys, spleen, and lungs. However, the tumour showed 
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high accumulation of the PEGylated chimera at approximately 5812.38 ng, which 
is equivalent to ~62 nM. Such concentration has been suggested to be sufficient to 
silence most target genes [440]. These data suggest that a single dose of 2 
nmol/mouse may have potential to achieve effective survivin silencing in HT-29 
xenografts. However, the complicated microenvironment of tumours and high 
turnover of tumour cells may compromise the overall efficacy of the chimera’s gene 
silencing efficacy. Therefore, in subsequent in vivo studies, a 3-day injection 
regimen of the PEGylated chimera was performed. Specifically, a dose of 2 
nmol/mouse were injected on days 1, 3, and 5. 
Interestingly, the PEGylated chimera also showed preferential accumulation in the 
intestine and lungs. Given that similar distribution pattern had been previously 
reported using different aptamers [273], it is likely that the PEGylated chimera was 
accumulated in these tissues non-specifically. As survivin expression in the 
intestine and lungs is undetectable or detected at low levels [441-446], the potential 
side effects to be associated with the chimera would most likely be restricted to the 
materials and make up the chimera, i.e. oligonucleotides and the chemical 
modifications. The possibility of toxicity in the intestine was studied and no 
noticeable pathological abnormalities were observed (see section 4.9). 
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Figure 4-6. Concentration of chimera in tissues after a single injection of 2 
nmol/mouse. HT-29 tumour-bearing mice (150 mm3) were injected with 2 nmol of 
PEGylated chimera. After 6 hours of injection, the tumour and other tissues were 
extracted and homogenized for chimera measurement. Data shown are mean ± SD, 
n = 3. ****, p < 0.0001. 
4.3. In vivo survivin gene silencing efficacy of PEGylated chimera 
After establishing favourable accumulation of PEGylated chimera in tumours in 
vivo, the in vivo survivin silencing capacity was tested. HT-29 tumour bearing mice 
with 60 mm3 tumour volumes were injected with 2 nmols of chimera intravenously 
via the tail vein, and total RNA were collected 48 hours after a single injection. 
Survivin expression levels were measured with qRT-PCR analysis. Although the 
non-PEGylated chimera showed significant in vitro survivin silencing (Figure 3-5), 
the PEGylated chimera showed partial in vivo survivin silencing (42.48% ± 17.24) 
at the mRNA level (Figure 4-8a). Additionally, the PEGylated chimera 
demonstrated specific survivin mRNA cleavage at the expected siRNA cut site 
evident by a 5’ rapid amplification of cDNA ends (5’RACE) PCR assay (Figure 4-
7). 
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To verify the chimera’s silencing mechanism operated through an Argonaute2 
(Ago2) mechanism of action, a 5’RACE-PCR assay was carried out (Figure 4-7). 
The purity of the total RNA was confirmed by measuring the ratio between their 
optical densities A260/A280, and only samples with a ratio between 1.80 and 2.00 
were selected for further analysis. Having confirmed the purity of the total RNA, a 
42-nt adaptor was ligated to the 5’ end of the total RNA at the expected siRNA cut 
site, followed by a reverse transcription to cDNA (Figure 4-7). The cDNA was then 
amplified by PCR using a GeneRacer 5’ primer and a survivin gene specific primer 
to generate DNA segments containing the expected siRNA cut site. To improve the 
specificity of the PCR reaction, a touchdown PCR [447] was used and generated a 
band with a molecular weight of ~800 bp (Figure 4-8b), which was close to the 
expected size of 726 bp (Figure 4-7).  However, the observed band had poor 
contrast along with close proximity to smears. To address this problem, nested 
primers were used for nested PCR using the amplicon generated from the 
touchdown PCR (Figure 4-7). The nested PCR generated a clear band with the 
expected size of 141 bp (Figure 4-7 & Figure 4-8c), which was then extracted from 
the agarose gel for purification. 
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Figure 4-7. Schematic representation of 5’ RACE-PCR assay. Forty-eight hours 
after chimera injection, total RNA was extracted from HT-29 tumour-bearing mice 
and quantified. GeneRacer adaptor RNA was ligated to the 5’ end of the cleaved 
mRNA and was later reverse transcribed to cDNA. The cDNA fragments were then 
amplified using a GeneRacer 5’ primer and a survivin gene specific primer. Further 
amplification using GeneRacer nested 5’ primer and survivin gene specific nested 
primer. Amplified fragments were then cloned into pCRTM4-TOPO vectors and 
transfected into E. coli cells in preparation for sequencing. 
 
The purified nested PCR product (~141 bp) was cloned into a cloning vector 
(pCRTM4-TOPO) and propagated in competent One Shot® E. coli cells (Figure 4-
7). The E. coli was cultured in an Ampicillin-selective LB plates to select for 
successfully transformed clones. To identify the successfully recombinant 
plasmids, plasmids from six random colonies were extracted and subjected to 
EcoRI digestion, which led to the cleavage of the plasmids at two sites surrounding 
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the insert and producing bands with the expected molecular weights of ~159 bp and 
~4000 bp, excluding colony #4 (Figure 4-8d). To further support the EcoRI 
digestion results, a PCR reaction using M13 primers was carried out using the same 
six colonies from which the plasmids were extracted. As shown in (Figure 4-8e), 
only the successfully transformed plasmids (colonies 1, 2, 3, 5, and 6) generated 
bands with the expected molecular weight of ~310 bp containing the 141 bp insert. 
To pinpoint the chimera target site on the survivin mRNA, the extracted plasmid 
DNA was sequenced using the M13 reverse primers. It was revealed that the RNA 
adaptor was ligated to survivin mRNA at the position with the sequence 3’-
UGUAGAGAUG-5’ (shown as 3’-CATCTCTACA-5’ on the amplified cDNA 
sequence (Figure 4-8f, survivin siRNA corresponding sequence)). This data 
strongly suggests that the survivin gene silencing function of the chimera was 
mediated by siRNA/Ago2 mechanism. 
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Figure 4-8: In vivo survivin knockdown and 5’ RACE-PCR verification. (a) 
Forty-eight hours after injection of 2 nmol of PEGylated chimera, survivin mRNA 
expression was reduced by approximately 42.48% when compared to saline 
control. (b) Touchdown PCR amplification of reverse transcribed total proteins 
extracted from HT-29 tumours using GeneRacer 5’ primers and survivin gene 
sequence specific primer, resulting in amplification of the expected band at ~726 
bp. (c) Nested PCR reactions using the amplicons from the touchdown PCR with 
GeneRacer nested 5’ primer and survivin gene specific nested primer. (d) After 
transforming competent E. coli cells with the nested PCR product using the 
pCRTM4-TOPO cloning vectors, plasmids were extracted and subjected to EcoRI 
digestion, resulting in the expected bands of ~159 bp and ~4000 bp. (e) The same 
E. coli colonies from which the plasmids were extracted were subjected to PCR 
amplification using M13 primers, resulting in the expected band of 310 bp 
containing the 141 bp insert (nested PCR product). (f) A representative graph of 
DNA sequencing. Purified plasmids (200 ng – 800 ng) were prepared with 10 pmol 
of M13 reverse primer and were sent to the Australian Genome Research Facility 
(AGRF) for sequencing. Sequencing of the 5’RACE-PCR products demonstrated 
that Ago2-mediated cleavage occurs between bases 10 and 11, relative to the 5’ end 
of the guide strand of the survivin siRNA portion of the chimera. 
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4.4. PEGylated chimera treatment sensitizes HT-29 tumour cells to 5-
fluorouracil 
Having established the chimera’s capacity to accumulate in EpCAM-expressing 
tumours and target survivin expression, the effects of combined chimera and 5-
fluorouracil treatments in HT-29 tumour-bearing mice was examined. Mice bearing 
HT-29 xenograft tumours were treated with three intravenous injections of 2 
nmol/mouse of either chimera or control chimera (on days 1, 3, and 5) with or 
without 30 mg/kg of 5-fluorouracil (on days 3, 5, and 7). 
Given that survivin is a key member of the antiapoptotic gene family, the effects of 
combined chimera and 5-fluorouracil treatments on apoptosis on HT-29 tumour 
cells were examined with TUNEL assay using formalin fixed cells prepared from 
dissociated cells of in vivo-treated tumours (Figure 4-9a). The combinatorial 
treatment of chimera and 5-fluorouracil greatly enhanced the sensitivity to 5-
fluorouracil and resulted in increased apoptosis (20.88% ± 3.32), whilst single 
treatment with 5-fluorouracil-alone or chimera-alone induced limited apoptosis in 
tumours by 7.23% ± 2.038 and 9.132% ± 0.5787, respectively (Figure 4-9b). 
Additionally, the control group treated with control chimera and 5-fluorouracil 
combination showed limited apoptosis similar to 5-fluorouracil-alone or chimera-
alone treatments (3.975% ± 3.213) (Figure 4-9b). This study suggests that survivin 
expression in HT-29 tumours provided an intrinsic mechanism underlying 
resistance towards 5-fluorouracil, and the combinatorial treatment of chimera and 
5-fluorouracil reversed such resistance and enhanced apoptosis. Furthermore, this 
observation is consistent with the reported relationship between survivin expression 
and poor colon cancer prognosis in patients [216, 448, 449]. 
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Figure 4-9. Combined chimera and 5-fluorouracil treatments induce enhanced 
HT-29 tumour apoptosis in comparison with 5-fluorouracil-alone treatment. 
(a) Representative images of TUNEL apoptosis assay on dissociated HT-29 
xenograft tumours. NOD/SCID mice bearing HT-29 tumours (60 mm3) were 
injected intravenously with 2 nmol/mouse of PEGylated chimera or control 
chimera with or without 30 mg/kg of 5-fluorouracil every other day over 5 days. 
Two days after the final injection, the tumours were extracted and dissociated by 
collagenase digestion. The apoptotic rate was measured via TUNEL assay. (b) 
Percentage of apoptotic cells in treated tumours as determined by TUNEL assay. 
Data shown are mean ± SD, n = 3 – 5. ****, p < 0.0001. Scale bar = 100 μm. 
4.5. Chimera treatment increases 5-fluorouracil sensitivity of cancer stem cells 
in HT-29 xenograft tumours 
According to the cancer stem cell theory, these cells are largely responsible for 
tumour progression and drug resistance, and are therefore critical targets for an 
effective cancer cure [38]. Furthermore, conventional anticancer chemotherapeutic 
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drugs, such as 5-fluorouracil, are largely ineffective in eliminating cancer stem cells 
[394, 395]. The markedly increased apoptosis in HT-29 tumours treated by chimera 
and 5-fluorouracil as opposed to 5-fluorouracil-only or other controls (Figure 4-9), 
along with the previous observation of 5-fluorouracil sensitization of HT-29 cancer 
stem cells after chimera treatment in in vitro and ex vivo studies (Chapter 3), has 
led to the hypothesis that chimera-mediated survivin silencing in vivo would result 
in overcoming the intrinsic chemoresistance of colon cancer stem cells. 
To test this hypothesis, a number of experiments were carried out to evaluate the 
functional properties of cancer stem cells. Firstly, a tumoursphere assay was 
performed using single cell suspension from dissociated in vivo-treated HT-29 
tumours. Following treatments using 5-fluorouracil, chimera, combination of 
chimera and 5-fluorouracil, and combination of control chimera and 5-fluorouracil, 
tumours were extracted 48 hours after final treatment and dissociated by 
collagenase digestion. Single cell suspensions were prepared and seeded in serum-
free stem cell medium in ultra-low attachment 96-well round-bottom plates. The 
chimera treatment resulted in enhanced sensitivity of cancer stem cells to 5-
fluorouracil as evidenced by the reduced cancer stem cell frequency compared to 
saline treatment (Table 4-1). Cells prepared from tumours that underwent in vivo 
combinatorial treatment of chimera and 5-fluorouracil showed reduced 
tumoursphere formation by 5.22 fold compared to that of saline control. 
Furthermore, 5-fluorouracil-alone treatment did not lead to a significant reduction 
of tumoursphere frequency compared to saline control (1.28 fold difference). 
Similarly, no significant differences in tumoursphere formation was observed in 
tumour cells that underwent in vivo treatments of chimera-alone or combination of 
control chimera and 5-fluorouracil treatment. These results suggest that neither 
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chimera nor 5-fluorouracil individual treatments were sufficient in supressing the 
self-renewal capacities of cancer stem cells in HT-29 tumours.  In contrast, the 
combinatorial treatment of chimera and 5-fluorouracil was capable of sensitizing 
the HT-29 cancer stem cells to 5-fluorouracil. 
Table 4-1. Tumoursphere limiting dilution assay prepared from in vivo treated 
tumours. Single cell suspension from in vivo-treated tumours were cultured in 
DMEM/F-12 media supplemented with 1x B27, 20 ng/mL EGF, 10 ng/mL FGF 
and 4 ng/mL insulin in ultralow attachment round bottom 96-well plates at 5% CO2 
and 37 ιC. Cells were plated at limiting dilutions and counted 5 days after seeding. 
Data was analysed using the ELDA [366]. 
 
Secondly, although tumoursphere formation assay can provide valuable 
information on the self-renewal capacity and changes to the cancer stem cells 
population, it remains a surrogate for the gold standard in vivo limiting dilution 
assay [450]. To provide strong evidence that the combinatorial treatment of chimera 
and 5-fluorouracil can eliminate cancer stem cells in vivo, the single cell suspension 
collected from tumours of in vivo-treated mice (5-fluorouracil-only, chimera-only, 
chimera with 5-fluorouracil, and control chimera with 5-fluorouracil) were 
transplanted subcutaneously into the left flanks of NOD/SCID mice for in vivo 
limiting dilution assay. As shown in Table 4-2, the tumour formation and latency 
observed from transplanting 1 x 105, 1 x 104, and 1 x 103 cells/mouse were 
essentially similar for all treatment groups, including 5-fluorouracil-alone and the 
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combinatorial chimera and 5-fluorouracil treatment. However, a stark contrast in 
tumour formation between the combinatorial chimera and 5-fluorouracil treatment 
and 5-fluorouracil-only treatment was observed with the 1 x 102 cells/mouse 
transplants. Moreover, in a four-month observation period, only 1 in 4 mice in the 
combinatorial chimera and 5-fluorouracil treatment group formed tumours as 
opposed to the saline control, chimera-only treatment, and 5-fluorouracil-only 
treatment, in which all transplanted mice formed tumours. Surprisingly, the tumour 
formation capacity in the control chimera and 5-fluorouracil treatment group was 
identical to that of the chimera and 5-fluorouracil treatment group. The only 
difference between the two groups was the extended latency in tumour formation 
in mice that received 1 x 102 cells injection, where the chimera and 5-fluorouracil 
treatment grew tumours approximately 55 days later than the mice with the control 
chimera and 5-fluorouracil treatment (Table 4-2). These data suggests that while 
the combinatorial chimera and 5-fluorouracil treatment did not significantly reduce 
tumour formation capacity, the treatment was successful in increasing the tumour-
free period. 
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Table 4-2. Tumour-forming assay from in vivo-treated tumours. Single cell 
suspension from in vivo-treated tumours were injected subcutaneously into the left 
flank of NOD/SCID mice to monitor tumour formation capacity. 
 
4.6. Chimera and 5-fluorouracil treatment transiently improves the survival 
of HT-29 xenograft tumour-bearing mice 
Following the impact of the combinatorial chimera and 5-fluorouracil treatment in 
extending tumour-free time, the efficacy of the treatment in extending the overall 
survival of HT-29 tumour-bearing mice was assessed. Once tumours reached 60 
mm3 in volume, the tumour-bearing mice were randomly divided into five groups 
and treated with 2 nmol/mouse of chimera or control chimera (on days 1, 3, and 5) 
with or without 30 mg/kg of 5-fluorouracil (on days 3, 5, 7, 9, and 11) with a two-
day interval to allow the knockdown of survivin before the administration of 5-
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fluorouracil. Saline and chimera-only treated mice showed no significant difference 
in either tumour growth nor survival rate (Figure 4-10). Treatment with 5-
fluorouracil-only or the combinatorial control chimera and 5-fluorouracil elicited a 
moderate response observed by slower tumour growth and improved survival rate 
compared with saline and chimera-only treatments (Figure 4-10a & b). Treatment 
with the combinatorial chimera and 5-fluorouracil showed a markedly retarded 
tumour growth and improved survival rate at the initial stages of the treatment. 
However, approximately 10 days after the final chimera treatment, tumour growth 
rate was similar to 5-fluorouracil-only treatment group and eventually reached the 
designated animal ethics end point (tumour length exceeding 13 mm and/or 
lesions). 
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Figure 4-10. Combined chimera and 5-fluorouracil treatments transiently 
improves therapeutic outcome in HT-29 tumour-bearing mice. (a) tumour-
bearing mice (60 mm3) underwent various treatments as indicated in the figure. The 
combination treatment of chimera and 5-fluorouracil reduced the tumour growth 
rate at the initial stages. However, the tumour growth rate increased after ~10 days 
of the final chimera treatment. (b) The survival rate of the treated mice was 
observed over the course of the treatments. Similar to (a), the combination 
treatment of chimera and 5-fluorouracil improved the survival rate of mice until 
~10 days after the final chimera injection, leading similar survival rates of 5-
fluorouracil-only and control chimera + 5-fluorouracil treatments. Data shown are 
mean ± SD, n = 4 – 5. P > 0.05. 
 
Although previous in vitro, ex vivo, and some of the in vivo experiments showed 
promising results for the combinatorial treatment of chimera and 5-fluorouracil in 
enhancing apoptosis, reducing self-renewal, and reducing tumourigenicity of 
cancer stem cells ex vivo (chapter 3), the systemic treatment of tumour-bearing 
mice with chimera and 5-fluorouracil resulted in limited improvement on tumour 
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growth and survival. While there was indeed an improved response within the first 
28 days of the combinatorial chimera and 5-fluorouracil treatment, where tumour 
growth rate was slow and survival was high, the effect did not last long and the 
mice eventually reached their experimental endpoints. It is likely that limited in 
vivo survivin silencing capacity of the chimera (Figure 48a) and the limited number 
of chimera injections (3 in total) may have been insufficient to maintain the desired 
results of reduced tumour growth and improved survival. Despite that, earlier 
results of successful siRNA delivery, enhanced apoptosis, and reduced self-renewal 
support the aim of cancer stem cell targeted therapies, and suggest that we may be 
on a correct path towards the development of an effective anticancer therapy. 
4.7. Chimera demonstrates a good safety profile 
To determine the potential acute side effects of the chimera on the overall state of 
health of the treated animals, a complete blood count assay was performed on 
immunocompetent Balb/c mice that had been treated with 2 nmol/mouse of chimera 
24 hours prior to the experiment. Whole blood cell profiling was done with an 
automated blood cell analyser, and a blood smear was also prepared to assess the 
subtypes of white blood cells via microscopy. As illustrated in table 4-3, the saline 
treatment group showed no detectable abnormalities in blood cells, which suggests 
that the mice used in these experiments were in good health. Similar to the saline 
treatment group, both chimera and control chimera treatments showed no 
significant abnormalities. The results obtained from this broad screening test 
suggest that the chimera did not elicit any gross or acute adverse effects on the 
general wellbeing of the mice. 
 
 
121 
 
Table 4-3: Chimera treatment does not induce abnormal hemogram in Balb/c 
mice. 
 
HGB: haemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular 
haemoglobin; MCHC: mean cell haemoglobin concentration; WBC: white blood 
cell; RBC: red blood cell; HCT: haematocrit. 
4.8. Chimera treatment does not evoke the innate immune response 
One major concern regarding PEGylated chimera in in vivo treatment is the 
activation of the innate immune response which may lead to cellular toxicity and 
confound the in vivo therapeutic potential [451]. To test its ability to activate Toll-
like receptor (TLR) 7 and 8, an in vitro assay using human peripheral blood 
mononuclear cells (PMBCs) and their ability to secrete interferon (IFN)-α and 
tumour necrosis factor (TNF)-α was carried out [452]. High doses of the chimera 
(750 nmol/L), either chimera-alone or duplexed with the cationic liposome N-[1-
(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP) 
targeting endosomal TLR7/8, had failed to induce significant levels of IFN-α and 
 
 
122 
 
TNF-α in PBMCs, while  the known TLR 7 and 8 single strand RNA ligand (ssRNA 
positive control) elicited a potent production of IFN-α and TNF-α, which suggested 
the lack of immunostimulatory activity of the chimera in vitro (Figure 4-11a) [417, 
453].  Subsequently, the in vivo innate immune response was also studied by 
injecting 2 nmol/mouse of chimera intravenously in immunocompetent Balb/c 
mice, with the RIG-I and TLR3 ligand polyinosinic:polycytidylic acid (poly I:C) 
as positive controls [452]. In sharp contrast to poly I:C, which induced a rapid and 
sustained induction of IFN- α and TNF- α, the PEGylated chimera showed no 
detectable cytokine production (Figure 4-11b). 
To address the potential activation of intracellular RIG-I like pathways which may 
not necessarily lead to detectable circulating cytokines, the induction of the RIG-I 
target, interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) [454], in 
the lung and liver of Balb/c mice injected with 2 nmol of PEGylated chimera was 
tested. Following the administration of the chimera, no detectable cytokine 
production was observed in both organs, while poly I:C led to a 100-fold increase 
in IFIT1 expression (Figure 4-11c) [452] . These data demonstrate that the 
PEGylated chimera does not illicit an immune response, which is a major concern 
associated with oligonucleotide-based treatments [455], and also indicates that the 
suppression of tumour growth by chimera and 5-fluorouracil co-treatments is not 
immune-mediated. 
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Figure 4-11. PEGylated chimera does not trigger innate immune response. (a) 
Chimera treatment did not stimulate human peripheral blood mononuclear cells 
(PBMCs) in vitro. Human PBMCs were incubated with 750 nmol/L of chimera, 
negative control chimera or indicated controls overnight. The IFN-α and TNF-α 
from the culture media was measured by ELISA. (b) Chimera did not elicit 
inflammatory responses in Balb/c mice. After treatment with a single intravenous 
injection of 2 nmol/mouse chimera or 200 ng/mouse Poly I:C, the blood was 
collected after 4 hours or 24 hours of treatment. Levels of IFN-α and TNF-α in the 
serum was determined by ELISA. (c) Chimera treatment in Balb/c mice for 24 
hours did not induce elevation of IFIT1 mRNA in the liver and lungs as determined 
by qRT-PCR. Data shown are mean ± SEM, n=6. **, P < 0.001; compared with 
saline control. 
4.9. Chimera treatment does not cause intestinal pathological abnormalities. 
The PEGylated chimera previously displayed accumulation in the intestine of mice 
(Figure 4-6). The potential side effects of this accumulation were tested by 
pathological examination. With comparison to saline control, the PEGylated 
chimera showed no signs of morphological or pathological abnormalities on the 
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intestines in both acute and chronic toxicity experiments (Figure 4-12). 
Theoretically, the potential side effects from PEGylated chimera on intestines may 
arise from survivin silencing in healthy intestine tissues, which may potentially lead 
to survivin-related functional abnormalities, or from toxicities induced from the 
materials that make up the chimera itself. Given that survivin expression is either 
undetectable or present as very low levels in both human and mouse normal 
intestines [441, 444], and that survivin addiction mechanism is specifically shown 
in tumours and not in normal tissues [218], it is more likely that any potential side 
effects may be restricted to the chimera itself. The materials that make up the 
chimera (oligonucleotides, PEG, FITC, biotin) are generally biocompatible and 
safe, excluding the possibility of triggering a sequence-dependent innate immune 
response by oligonucleotides [451]. Given that no gross morphological 
abnormalities and immunogenicity were detected, the chimera can be considered 
safe for clinical applications. 
 
Figure 4-12. Chimera treatment does not induce pathological abnormality in 
intestine tissues. Representative images of mice intestine treated with chimera. 
Balb/c mice were intravenously injected with 2 nmol/mouse of PEGylated chimera 
on days a, 3, and 5. The intestines were extracted on day 7 (acute) and 3 months 
after final injection (chronic). HE stain was conducted and pathological 
examination was carried out by a qualified pathologist via microscopy. 
4.10. Conclusion 
In summary, the data from the study in this chapter suggest that PEGylated chimera 
not only targets tumours in xenograft mice, but is also retained in the tumour for an 
extended period of time (Figure 4-2 & Figure 4-6). The 5’ RACE assay confirmed 
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that survivin mRNA silencing was targeted by the siRNA portion of the chimera, 
and the combinatorial treatment of chimera and 5-fluorouracil resulted in not only 
enhanced apoptosis, but also reduced the capacity for self-renewal in vivo, a key 
property of cancer stem cells. Surprisingly, the gold standard for cancer stem cell 
assessment (in vivo limiting dilution assay) demonstrated that the treatment 
regimen used was not capable of reducing the frequency of tumour formation, but 
only in extending the tumour-period by approximately 55 days (Table 4-2). This is 
reflective of the improved response of tumour bearing mice within 28 days of 
receiving chimera and 5-fluorouracil treatment via the tail vein, and the eventual 
poor response afterwards (Figure 4-10). This could be attributed to multiple factors. 
Firstly, chimera treatment was limited to 3 injections in contrast to the 5 injections 
of 5-fluorouracil; secondly, chemoresistance observed in cancer stem cells was not 
mediated exclusively by enhanced survivin expression, and therefore targeting a 
single protein may not be efficient for cancer treatment; and thirdly, with the 
exception of survivin’s antiapoptotic property, targeting survivin in vivo may have 
unintended consequences that may enhance chemoresistance, which will be 
addressed  in Chapter 5. 
As drug-delivery vehicles, the major advantage of using aptamers for in vivo siRNA 
delivery is the lack of immunogenicity, which was demonstrated here in both in 
vitro and in vivo experiments. Additionally, it was confirmed that the chimera-
mediated gene silencing was not a result of immune-associated off-target effects. 
The overall safety of the chimera was further supported by a complete blood count 
(CBC) assay and a histopathological examination on mice intestines in addition to 
the cytokines studies. The simple and biocompatible structure of the chimera 
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contributes to the lack of any detrimental effects in a series of preclinical safety 
studies, and future tests in non-human primates may pave the way to clinical trials. 
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Chapter 5 
Role of autophagy in protecting colon cancer stem cells 
5.1. Introduction 
Increasing evidence in recent years has strongly suggested the close association of 
autophagy with tumour biology, starting with its role as a tumour suppressor in the 
early stages of tumour development [456, 457]. In cancer cells however, autophagy 
has often been found to play contradictory roles when induced by anticancer 
therapies. In one instance, induced autophagy can promote cancer cell death, either 
through apoptosis or other mechanisms, including autophagic cell death or non-
lysosomal vesiculate cell death [458]. In contrast, autophagy can also play a critical 
role for survival and is therefore a protective mechanism against anticancer 
therapies by recycling proteins and cellular components, as well as providing 
energy and nutrients from the degradation of damaged proteins and organelles [306, 
457]. The contradictory roles of autophagy in cancer cells appear to be context-
driven [459], and its effect in cancer cells largely depends on the type of cells and 
type of treatments [357, 460-463]. The answer to how autophagy can either protect 
or kill cancer cells in response to chemotherapy can be delivered by identifying 
what autophagy degrades under such circumstances [459]. This may be the key to 
predicting the outcome of chemotherapy-induced autophagy and may provide a 
way to decide which tumours should or shouldn’t be treated with autophagy 
inhibitors [459]. Meanwhile, it is important to identify and document the role of 
autophagy in different types of tumour cells and how autophagy was induced. Thus, 
there has been in increasing interest in the exploration of autophagy as a new 
therapeutic strategy in anticancer therapy. 
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In colon cancer, autophagy has been shown to be associated with chemoresistance, 
and its inhibition enhanced cytotoxic effects of chemotherapeutic drugs, especially 
5-fluorouracil [329-331, 464]. Furthermore, induced autophagy-mediated survival 
is closely associated with colon cancer stem cells [313, 314], as it was shown that 
cancer stem cells use autophagy as a mechanism of chemoresistance and the 
maintenance of stemness and tumourigenicity [83, 312]. In this chapter, the effects 
of 5-fluorouracil was tested on HT-29 cells to examine its autophagic response. 
Furthermore, the role of autophagy as a protective mechanism for cancer stem cells 
was examined by tumoursphere assay to examine its effect on self-renewal 
capacities. The experimental strategy involved the inhibition of autophagy through 
the application of 3-methyladenine (3-MA), a popular and established autophagy 
inhibitor that functions by inhibiting the activity of PI3-Kinase to block the 
formation of autophagosomes and autophagic vacuoles [465]. In addition, 
autophagy was also inhibited by silencing Autophagy related 5 (ATG5) expression 
using dicer substrate siRNA (d-siRNA), as ATG5 that is essential for 
autophagosome formation [466]. And finally, the effect of down-regulation of 
survivin with or without 5-fluorouracil treatment on autophagy was explored. 
5.2. Establishing a strategy for detecting autophagic activity 
In order to study the autophagic state of cells, it is critical to understand that 
autophagy is a highly dynamic process with varying turnover rates, therefore direct 
detection of certain autophagic markers may lead to inaccurate interpretation [467, 
468]. Under physiological conditions, there is a constant autophagic flux/flow. The 
initiation of autophagy involves the formation of phagophores and expands to 
autophagosomes. The autophagosomes are then fused with lysosomes, thus 
forming autolysosomes and their degradation along with their encapsulated 
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contents (Figure 5-1a). In this process, the number of autophagosome formation 
reflects the state of autophagy, in which an increase in autophagosomes correlate 
with increased autophagic activity. However, this direct observation neglects the 
fact that autophagosomes are subject to degradation upon fusion with the lysosome 
(autophagosome turnover). In this case, as autophagy becomes more active, so does 
the degradation of autophagosomes.  Therefore, the level of certain autophagic 
markers or the number of autophagosomes may not accurately correlate with the 
extent of autophagy [469-472]. 
 
Figure 5-1. Schematic representation of autophagy. (a) Under normal 
conditions, cells undergo normal autophagic flux starting with the formation of 
autophagosomes and ending with lysosomal degradation. (b) Autophagosomes 
remain intact when lysosomal degradation is blocked, thus the rate of 
autophagosome accumulation reflects the autophagic activity of cells. Ideally, 
autophagic activity is best monitored by comparing samples under (a) and (b) 
conditions. 
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Besides microscopy, autophagosome formation can be evaluated through the 
detection of the ubiquitin-like protein microtubule-associated protein 1 light chain 
3 (LC-3). LC3 is initially synthesized in an unprocessed form (pro-LC3), and is 
then converted into a proteolytically processed form (LC3-I). Upon autophagy 
activation, LC3-I conjugates to phosphatidylethanolamine to form LC3-
phosphatidylethanolamine conjugate (LC3-II), which is then recruited to 
autophagosomal membranes [465]. Once fused with the lysosomes, the 
autophagosome content and intra-autophagosomal components are degraded by 
lysosomal hydrolases [473, 474]. The association of LC3 with autophagosome 
formation makes it possible to detect autophagic activity in cells, either by Western 
blot analysis (LC3-I, approximately 18 kDa; LC3-II, approximately 16 kDa), or by 
fluorescence microscopy using LC3-GFP expression or fluorescently-labelled 
antibodies. As a result, LC3 has become and remains one of the most widely used 
markers for autophagy-related studies. However, it is important to note that LC3 
levels do not necessarily change in a predictable manner, especially if lysosomal 
degradation was rapid, leading to lower levels of detectable LC3-II and thus lower 
LC3-I/LC3-II ratio. Furthermore, these observable patterns may not only vary 
between different cell types, but is also related to the type of stress involved. For 
example, cells of neuronal origin, such as the neuroblastoma cell line SH-SY5Y, 
can initiate autophagy under nutrient starvation. Therefore, it is expected to have a 
high LC3-I/LC3-II ratio, yet it is common for it to display a slight increase of LC3-
II despite the clear reduction of LC3-I [475]. This is likely related to the high basal 
autophagic flux of the cells, which is suggested by an increase of LC3-II when 
lysosomal degradation was blocked with NH4Cl [476, 477]. When the same cell 
line was subjected to a different type of stress with the mitochondrial uncoupler 
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CCCP, a well-known inducer of mitophagy, the cells displayed a strong increase in 
LC3-II [476, 477]. In MEF cells, a short period of starvation increased the LC3-
I/LC3-II ratio significantly [468]. In contrast, a long period of starvation resulted 
in the disappearance of both LC3-I and LC3-II. This is because LC3-II is present 
on both the inner and outer membrane of autophagosomes, where the inner LC3-II 
is degraded by autolysosome while the outer LC3-II is deconjugated by ATG4 and 
returns to the cytosol [478]. Following treatment with lysosome inhibitors E64d 
and pepstatin, LC3-II was detectable as its degradation was inhibited. 
These findings collectively indicate that neither the consumption of LC3-I, nor the 
evaluation of LC3-II levels without inhibiting lysosome degradation, necessarily 
gives a reliable reading on autophagy, and neither measurement provides a wide 
view of autophagic flux. Moreover, LC3-I may be less sensitive for detection by 
certain types of antibodies, and their sensitivities vary between different cell lines. 
Additionally, LC3-I is more labile than LC3-II because it is more sensitive to 
freeze/thaw cycles and to degradation in SDS-based buffers, a common reagent 
used in polyacrylamide gels for Western blot analysis [467]. The dynamic nature 
of autophagic flux (autophagosome formation and degradation) can be more 
accurately represented by differences in the amount of LC3-II between samples in 
the presence and absence of lysosome inhibitors, such as vinblastine, bafilomycin 
A1, E-64d, pepstatin A, or chloroquine [467, 468]. After blocking lysosome 
degradation, the accumulation of LC3-II at a higher than the cell’s basal flux is a 
clear indication of enhanced autophagic flux (Figure 5-1b). Therefore, in this 
chapter autophagy is primarily detected by the turnover rate of LC3-II by Western 
analysis using samples with and without chloroquine treatment, which inhibits 
lysosomal degradation of autophagosomes [467, 468]. 
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Prior to testing this strategy of autophagy evaluation, the LC3 antibody (Nanotools 
#0231-100/LC3-5F10) was tested to confirm its efficacy in detecting LC3-I and 
LC3-II in Western analysis. When tested on HT-29 cell lysates, LC3-II was clearly 
detected but not LC3-I (Figure 5-2a & b). To confirm if the antibody itself was 
inefficient at detecting LC3-I in HT-29 cells, it was additionally tested on HEK-
293T cell lysate and LC3-I/II positive controls (LC3-I and LC3-II enriched 
fractions from PC3 cells; Nanotools #1041 & #1042, respectively). within 
comparison to HT-29, the LC3 antibody was capable of detecting LC3-I in HEK-
293T (Figure 5-2a). Similarly, the antibody was capable of detecting each of the 
LC3-I and LC3-II positive controls (Figure 5-2b), thus indicating that LC3-I in HT-
29 cells could not be efficiently detected by the LC3 antibody. Fortunately, 
observation of LC3-II accumulation by inhibiting lysosomal degradation is 
sufficient for evaluating autophagy. To test this strategy for autophagy evaluation, 
the effects of 5-fluorouracil in inducing autophagy was tested on HT-29 cell lysates. 
Two groups of cells were treated with 2 μM of 5-fluorouracil for 5 days, similar to 
the ex vivo treatment strategy described in Chapter 3.7. Prior to total protein 
extraction, one of the sample groups was treated with 50 μM of chloroquine for 4 
hours in order to block the fusion of lysosomes with autophagosomes (Figure 5-
2c). Without the use of lysosomal inhibitors, treatment with 2 μM 5-fluorouracil 
showed an irregular and inconsistent LC3-II levels, which was not reliable for 
determining the autophagic state of the cells (Figure 5-2d). However, evaluating 
LC3-II levels with and without the use of chloroquine resulted in a clear indication 
of enhanced LC3-II turnover rate by approximately 3-fold, compared to saline 
control, thus suggesting enhanced autophagy (Figure 5-2e). These results are 
consistent with the literature in which autophagy induced by 5-fluorouracil protects 
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the cells from death [464].  Furthermore, the data provides a mechanism underlying 
the results reported in Chapters 3 and 4 in which treatment with 5-fluorouracil alone 
was incapable of reducing self-renewal and tumourigenicity of HT-29 cells in vivo, 
ex vivo, and in vivo.  
 
Figure 5-2. The efficacy of LC3 antibody and its use for the evaluation of 
autophagy. (a) The LC3 antibody could detect LC3-II in HT-29 cells, but not LC3-
I. In contrast, LC3-I was detectable in HEK-293T cells, but not LC3-II. (b) The 
LC3 antibody was tested on LC3-I and LC3-II controls, further suggesting that 
LC3-I in HT-29 cells could not be detected. (c) Representative western blot of LC3-
II on HT-29 cells. The addition of chloroquine treatment enhanced the LC3-II 
signal. (d) Evaluation of autophagy solely by measuring LC3-II levels without 
lysosomal inhibition produced an unreliable result. (e) LC3-II turnover rate was 
evaluated by comparing LC3-II levels with and without blocking lysosomal 
degradation, which revealed that 2 μM 5-fluorouracil treatment induced autophagy 
in HT-29 cells. Data shown are mean ± SD, n = 3. *; p < 0.05. 
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5.3. Autophagy plays a protective role in colon cancer stem cells 
To test the role of autophagy in protecting colon cancer stem cells, autophagy 
inhibitors were used with HT-29 cells in ultra-low attachment plates for 
tumoursphere assay with or without 5-fluorouracil. 3-MA is an established 
autophagy inhibitor that operates by inhibiting the class III PI3K to block the 
production of phosphatidylinositol 3-phosphate (PI3P) [465], an essential 
component for the initiation of autophagy via recruitment of ATG proteins at the 
isolation membrane or phagophore [479, 480]. HT-29 cells were grown on adherent 
culture and then collected to prepare single cell suspension. The cells were then 
plated on ultra-low attachment 96-well plates with 10 or 20 μM 5-fluorouracil, 5 
mM 3-MA, or combination of 5-fluorouracil and 3-MA. After 5 days of incubation, 
treatment with 3-MA alone did not lead to decreased sphere formation (Figure 5-
3). Similarly, treatment with 10 μM 5-fluorouracil-alone did not lead to any 
changes in sphere formation either.  Only when combined with 5 mM 3-MA did 5-
fluorouracil lead to a significant decrease in tumourspheres, by approximately 2-
fold, compared to 5-fluorouracil, 3-MA, and saline treated cells. A similar 
reduction in tumourpsheres was obtained with 20 μM 5-fluorouracil and 5 mM 3-
MA combinatorial treatment when compared with saline-treated cells, yet the 
reduction of tumoursphere was not statistically significant compared to 20 μM 5-
fluorouracil-treated cells (figure 5-3). These data indicate that autophagy 
potentially plays a role in cancer stem cell drug resistance as the combinatorial 
treatment of 5-fluorouracil with autophagy inhibition greatly reduced HT-29 self-
renewal. 
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Figure 5-3. Autophagy plays a role in cancer stem cell resistance. HT-29 cells 
were cultured in tumoursphere media to evaluate self-renewal after treatment with 
3-MA and 5-fluorouracil. Treatment with 5-fluorouracil did not reduce sphere 
formation capacity at either doses of 10 and 20 μM. However, combined treatment 
of the drug with 3-MA significantly reduced sphere-forming capacity of HT-29 
cells. Data shown are mean ± SD, n = 3. *; p < 0.05. 
 
To further confirm the role of autophagy in chemoresistance, anti-ATG5 siRNA 
was used to specifically inhibit autophagy as ATG5 is a key molecule involved in 
autophagic vacuole formation [481, 482]. The siRNA used was derived from a 
previously published 21-mer which was confirmed to have a high knockdown 
efficiency [483], and was extended to 27-mer dicer substrate siRNA (d-siRNA) for 
this study to enhance the silencing efficiency [251, 401]. The silencing efficacy of 
the ATG5 d-siRNA was tested on HT-29 cells. Following incubation for 72 hours 
with 20 nM of d-siRNA, a 75% reduction in ATG5 protein was achieved (Figure 
5-4a). To confirm the role of autophagy in maintaining cancer stem cells, HT-29 
cells were plated in 6-well plates and treated with 20 nM ATG5 d-siRNA using 
Lipofectamine 2000®. Following 72 hours of incubation, cells were collected and 
plated on ultra-low attachment 96-well plated for tumoursphere assay with or 
without 2 μM 5-fluorouracil. Following five days of incubation, there was no 
significant reduction in tumourspheres in cells treated with 5-fluorouracil-alone 
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compared with those treated with saline. Interestingly, ATG5 knockdown alone 
resulted in a significant reduction in tumourspheres from 27.0% ± 6.15 (saline 
control) to 2.26% ± 1.03. Moreover, the addition of 2 μM 5-fluorouracil to ATG5-
deficient cells significantly inhibited tumoursphere formation to 0.687% ± 0.0869 
(Figure 5-4b). 
 
Figure 5-4. Inhibiting autophagy by silencing ATG5 reduced the sphere-
forming capacity HT-29 cells. (a) The efficacy of ATG5 d-siRNA was evaluated 
on HT-29 cells, resulting in efficient ATG5 knockdown by >70%. (b) Following 
ATG5 knockdown, HT-29 cells were incubated in tumoursphere culture to evaluate 
their self-renewal capacities. ATG5 knockdown on its own reduced tumoursphere 
formation significantly. Moreover, tumourspheres were greatly reduced when 
combined with 2 μM 5-fluorouracil. Data shown are mean ± SD, n = 3. **; p < 
0.01. 
 
Autophagy has been reported to be a survival mechanism in many types of cancer 
cells, the results collected so far suggest that autophagy plays a significant role in 
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protecting colon cancer stem cells against the chemotherapeutic drug 5-fluorouracil 
as observed with 3-MA treatment in combination with 5-fluorouracil (Figure 5-3). 
Additionally, autophagy by itself may potentially be critical for cancer stem cell 
survival as observed with ATG5 knockdown (Figure 5-4). In contrast, treatment 
with 3-MA alone did not reduce tumoursphere formation unless it was coupled with 
5-fluorouracil. Although 3-MA is an established autophagy inhibitor, its effects 
have largely been conducted on cells under nutrient-deprived culture for relatively 
short periods of time or had been isolated from starved animals [465, 484-486]. The 
effect of 3-MA on autophagy induced by other stimuli in a nutrient-containing 
media for a relatively prolonged duration of time have yet to be evaluated [484]. 
ATG5 however operates by conjugating with ATG12 to generate an E3 ubiquitin 
ligase-like enzyme which is required for autophagy [487]. Furthermore, ATG5 is 
critical for cell survival, and mice born deficient in ATG5 gene die on the first day 
after birth [488]. 
5.4. Autophagy induction is inhibited after combinatorial treatment of 
chimera and 5-fluorouracil  
Earlier results in chapters 3 and 4 suggest that the combinatorial treatment of 
chimera and 5-fluorouracil was effective in killing colon cancer stem cells, yet 
individual treatments of either chimera or 5-fluorouracil showed no signs of cancer 
stem cell elimination. To determine if chimera treatment played a role in 
attenuating autophagy-mediated survival in HT-29 cancer stem cells, two groups 
of HT-29 cells were treated with 20 nM of chimera or 20 nM control chimera for 
24 hours, followed by treatment with 2 μM 5-fluorouracil for 5 days, a similar 
treatment strategy used for the ex vivo tumour formation assay (Chapter 3.7). 
Following 5 days of incubation, 50 μM of chloroquine was added to one of the 
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treatment groups for 4 hours to inhibit lysosome degradation of autophagosomes, 
and then the total protein was extracted for Western analysis of LC3-II.  As shown 
in Figure 5-5, the treatment with 5-fluorouracil-only led to increased LC3-II 
turnover rate. Similarly, knocking down survivin via treatment with chimera alone 
induced LC3-II accumulation as well, suggesting the survivin inhibition induced 
autophagic flux in HT-29 cells. This finding is consistent with the literature in 
which the use of survivin inhibitors, YM-155, induced autophagy [358, 359]. 
However, the induced autophagy mediated by YM-155 resulted in a pro-cell death 
response, while the induced autophagy as a result of survivin knockdown presented 
in this study showed no effect in terms of self-renewal and tumourigenicity 
compared with saline control (chapter 3 and 4). Interestingly, the combination of 
chimera and 5-fluorouracil reduced the LC3-II turnover rate compared with 
chimera-only treatment (Figure 5-5). This result suggests that chimera treatment 
may have prevented 5-fluorouracil-induced autophagy and in turn, led to a 
reduction in self-renewal (Figure 3-8) and tumourigenicity (Table 3-2). It is unclear 
how the combination treatment reduced LC3-II turnover whereas the individual 
treatment of either chimera or 5-fluorouracil enhanced autophagic flux, which may 
reflect the dynamic nature of autophagy and its contextual-dependent cellular 
functions. 
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Figure 5-5. Evaluating the chimera’s impact on autophagy. The aptamer-
survivin siRNA chimera was tested on HT-29 cells with or without 2 μM 5-
fluorouracil to determine its impact on autophagy. Each individual treatment of 
chimera and 5-fluorouracil induced LC3-II turnover, but adding 5-fluorouracil 24 
hours after chimera treatment prevented the LC3-II turnover from increasing as 
observed with the individual treatments. 
 
The treatment with chimera control resulted in an increase in LC3-II turnover, and 
a lower turnover rate when combined with 5-fluorouracil (Figure 5-5), although 
this was not statistically significant. This may potentially be due to the binding of 
EpCAM via the aptamer portion of the chimera control, suggesting that blocking 
of the EpCAM surface receptor may modulate autophagy. The effect of aptamers 
that bind to different cancer stem cell markers, such as EpCAM, CD133, and CD44, 
on autophagy will be determined in future studies. 
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5.5. Conclusion 
Autophagy is a conserved cellular process that can function as a tumour suppression 
mechanism in healthy cells and as an adaptive stress response in tumour cells to 
maintain survival under stressful conditions, including stresses caused by DNA 
damaging drugs [489]. Although autophagy in tumour cells displayed both pro-
death and pro-survival in different settings, increasing evidence suggest stress-
induced autophagy in tumour cells predominantly act as a cytoprotective 
mechanism, and its inhibition can enhance the efficacy of diverse anticancer 
therapies [329-331, 464]. With autophagy being viewed as a protective mechanism 
for cancer cells, it became a target for therapeutic purposes to enhance the efficacy 
of anticancer drugs. 
As shown in Chapter 3, treatment with the 5-fluorouracil alone did not lead to 
significant reduction in self-renewal in vitro, nor did it reduce the tumourigenic 
potential of HT-29 cells ex vivo. Moreover, in vivo treatment of tumour-bearing 
mice with 5-fluorouracil did not lead to significant improvement in survival 
(Chapter 4). In this chapter, drug-induced autophagy in HT-29 cells was found to 
promote cancer stem cell survival, and the inhibition of autophagy by either 3-MA 
or ATG5 d-siRNA reversed chemoresistance towards 5-fluorouracil and resulted 
in a significant reduction of cancer stem cells. 
While survivin has many functions, including protection from apoptosis [490, 491] 
and forming the chromosome passenger complex [492, 493], its knockdown in HT-
29 cells was found to induce autophagy evident by increased LC3-II turnover rate. 
This finding is in agreement with the effects of the survivin inhibitor YM-155 in 
inducing autophagy in breast and prostate cancer cells in vitro [358, 359]. Wang 
and colleagues found that YM-155 induced autophagy and apoptosis in prostate 
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cancer cells [359]. Similarly, Cheung and colleagues found that survivin inhibition 
with YM-155 in breast cancer cells induced autophagy-dependent DNA damage 
and cell death [358]. The results presented in our study showed that survivin 
knockdown in colorectal cancer cells induced autophagy. However, the autophagy 
in this setting maintained chemoresistance towards 5-fluorouracil. This further 
demonstrates the unpredictable outcome of autophagy in cancer cells as autophagy 
may react differently in different cell types and towards different treatments. 
However, autophagy induced by survivin inhibition remains a very common 
phenomenon as more and more reports demonstrate that survivin plays a role in 
regulating autophagy [359, 494-496].  
This raises the concern of using survivin inhibitors as a therapeutic tool as enhanced 
autophagy may protect tumour cells and cancer stem cells altogether. Furthermore, 
it was reported that induced autophagy in tumour cells displayed physical 
interaction between ATG5 and survivin, which may have caused mitotic defects as 
survivin contributes to chromatin-associated spindle formation [492]. In addition, 
a fraction of cells that survive may be aneuploid that are potentially very dangerous, 
which at least partially explains why autophagy can have tumour promoting 
activities [362].  
Although treatment of cells with either survivin siRNA or 5-fluorouracil enhanced 
autophagy, it was a surprise to find that combinatorial treatment inhibited 
autophagic activity as evident by the reduced LC3-II turnover. In theory, 
suppressing the antiapoptotic effect of survivin while preventing enhanced 
autophagic flux would result in the desired antitumour effect, and our data, at least 
partially, demonstrated this phenomenon. It is as yet unknown how autophagic 
activity was prevented as a result of survivin silencing and 5-fluorouracil treatment, 
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but these data suggest that inhibiting survivin alone may risk inducing autophagy 
that prevents tumour cells from being killed by chemotherapy drugs [357]. 
Therefore, inhibition of autophagy could be new avenue to combat 
chemoresistance. In addition, the use of cancer stem cell-targeting aptamers, such 
as the EpCAM aptamer used in this project, could facilitate novel approaches for 
specific autophagy modulation in cancer stem cells while sparing normal and 
healthy cells. 
  
 
 
143 
 
Chapter 6 
Conclusions and future perspective 
6.1. General conclusions 
Although the cancer stem cell model is still under debate especially in regards to 
their origin and frequency in tumours [205], it remains under attention for its critical 
role in treatment failure and cancer relapse [497]. The lack of specific targeting 
strategies against cancer stem cells is at least partially responsible for the short 
survival period experienced by many cancer patients [205]. A novel strategy for 
specific targeting to cancer stem cells for the delivery of siRNA has been 
established by directly conjugating a survivin-specific siRNA to an RNA aptamer 
which can specifically bind to the epithelial cell adhesion molecule (EpCAM). 
There are at least two factors that need to be considered for an effective siRNA 
delivery to cancer stem cells. The first is that the targeted gene has to be critical for 
the survival of cancer stem cells, and the second is that the siRNA should be 
delivered to cancer stem cells in vivo with sufficient quantity and retention time for 
an effective gene silencing. By silencing survivin expression in cancer stem cells, 
we can increase their sensitivities towards traditional anticancer drugs and improve 
the therapeutic outcome in the clinic. 
The general conclusions of this work are described below: 
1) A cancer stem cell targeting system has been successfully used to deliver 
survivin siRNA to EpCAM-expressing colorectal cancer cells, which is 
sufficiently internalized and integrated into the endogenous RNAi 
machinery. 
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2) Aptamer-guided siRNA delivery successfully targeted the cancer stem cells 
in vitro and supressed their stem cell functionalities when combined with 
chemotherapeutic drugs. 
3) The addition of polyethylene glycol to the chimera improved its systemic 
circulation and tumour retention time. 
4) Aptamer-guided siRNA delivery effectively targeted the putative cancer 
stem cells, overcame the intrinsic chemoresistance, and prevented tumour 
initiation, thereby functionally impairing tumourigenicity of colon cancer 
stem cells. 
5) The combined treatment of survivin siRNA chimera and 5-fluorouracil 
significantly suppressed tumour growth in xenograft models and improved 
overall survival by enhancing tumour apoptosis. 
6) Treatments with either survivin siRNA chimera or 5-fluorouracil induced 
autophagy in tumour cells. 
7) Combinatorial treatment with 5-fluorouracil following survivin siRNA 
chimera treatment suppressed autophagy induction, which in turn 
contributed to the successful overcoming of the intrinsic chemoresistance 
of colon cancer stem cells. 
6.2. Future perspective 
In this study, an aptamer-siRNA chimera was used to specifically target colorectal 
cancer stem cells and impair their tumourigenic capacities, which translated into 
reduced self-renewal, reduced tumour growth rate, and improved survival of 
tumour-bearing mice. Targeting survivin expression in cancer cells remains a major 
therapeutic target for anticancer therapies. Indeed, a wide variety of survivin 
inhibition strategies have been developed and showed promising results in vitro and 
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in animal models, including targeting transcription factors, antisense 
oligonucleotides, targeting signal transduction pathways, intracellular binding to 
survivin, and induction of specific cytotoxic killer cells [498]. However, translation 
into a clinical setting has met with limited success. The introduction of YM-115 
into clinical trials for the treatment of various solid tumours was met with a variety 
of adverse effects, but were yet mostly tolerable. Such effects included fevers, acute 
renal failure, urine microalbumin and increased urinary protein, and frequent 
decreases in hemoglobin/anemia [219, 220]. Nevertheless, clinical trials 
demonstrated partial responses in a very limited number of patients to YM-155-
based treatments [220-222], and only one patient showed complete remission 
[222]. Our results show that mono-treatment of survivin inhibition had no effect on 
tumourigenicity or self-renewal, which is consistent with clinical trial results 
demonstrating survivin inhibition is ineffective as a single-agent treatment, and 
should therefore be included in a combination treatment [222]. While targeting the 
antiapoptotic function of survivin in tumours shows promising results, it may also 
alter their critical function in regulating mitosis as survivin contributes to 
chromosome alignment, spindle formation, and microtubule attachment [499], thus 
may show unwanted complications. Such complications include Aurora B 
mislocation that leads to loss of chromosome alignment and disruption of 
cytokinesis in the absence of cell death [500], and mitotic catastrophe was also 
observed in cells with knocked-down survivin expression [501]. 
Our results suggest that autophagy plays an important role in cancer stem cell 
resistance, but more importantly, this study highlighted the potential pitfall of using 
different types of anticancer treatments in inducing autophagy. While conventional 
anticancer treatments with chemotherapeutics and irradiation have been confirmed 
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to induce autophagy [336, 502-506], so does inhibition of survivin [358-361], 
which supports our finding of enhanced autophagic flux as a result of chimera 
mono-treatment. In addition to autophagy’s role in increased survival and drug 
resistance of tumour cells, increased autophagy also enhances ATG5 expression 
and promotes its physical interaction with survivin, thus interfering with survivin 
and Aurora B in chromosome alignment and segregation during mitosis [362], 
which in turn may lead to tumour-promoting activities and the prevalence of 
genetically diverse and dangerous aneuploid cells [363, 364]. 
The results from this work help to mitigate a couple of challenges in developing 
effective anti-cancer stem cell therapies: First, aptamers proved to be an efficient 
siRNA delivery tool for in vivo therapeutics, demonstrating efficient gene silencing 
efficacy and safety. Furthermore, the chimera had no detrimental effect on the 
general well-being of mice and showed no detectable immune response. Second, 
targeting cancer stem cell-relevant signalling pathways is complicated. While 
silencing survivin did reduce its antiapoptotic properties, it may also inhibit its 
other function in regulating mitosis and may result in more complications and 
induced autophagic flux that may enhance drug resistance [362]. 
Therefore, the results from this study open up new and practical avenues to 
overcome drug resistance in cancer therapy to achieve long-term remission in a 
clinical setting. By delivering siRNA via cancer-targeting aptamers, we can reverse 
the inherent resistance in tumour cells and increase the treatment efficacy with great 
potential to minimize dose-limiting toxicities which is a major problem associated 
with current cancer chemotherapy. Additionally, this study reveals the role of 
autophagy in cancer stem cell survival, and given that autophagy is a conserved 
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cellular process that reacts to varying from of stresses, it is important to monitor 
autophagy when testing new experimental drugs. 
Both the chimera and the therapeutic drugs used in this system target the bulk 
cancer cells and the cancer stem cells altogether, and the success of this project will 
bring us a few steps closer towards to not only an effective anticancer treatment 
strategy, but also a deeper understanding on autophagy. As autophagy has shown 
to be critical for survival, its inhibition may potentially turn a wide variety of 
anticancer drugs into cancer stem cell killers. 
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